

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 12
JAN'97-DEC'97**



APPROVED DRUG PRODUCTS

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

17TH EDITION

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES**

1997

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

Cumulative Supplement 12

DECEMBER 1997

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Court Order Affecting Uruguay Round Agreements Act-Extended Patents	iv
1.3 Applicant Name Changes	v
1.4 Acyclovir 200 mg Tablet-Reference Listed Drug	vi
1.5 Follitropin Alfa and Beta	vii
1.6 Availability of the Publication and Updating Procedures	vii
1.7 Report of Counts for the Prescription Drug Product List.....	viii
 2.0 DRUG PRODUCT LISTS.....	
2.1 Prescription Drug Product List.....	1
2.2 OTC Drug Product List	85
2.3 Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	89
2.4 Orphan Product Designations and Approvals List	90
2.5 Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	102
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Terms.....	103
B. Patent and Exclusivity Lists.....	107

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

17TH EDITION

**CUMULATIVE SUPPLEMENT 12
DECEMBER 1997**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 17th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 17th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 18th Edition.

1.2 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

As a result of the April 4, 1996, decision of the United States Court of Appeals for the Federal Circuit in Merck, et al. v. Kessler, patent expiration dates for certain patents subject to patent term extensions under the Uruguay Round Agreements Act and to the patent term extension provisions at 35 U.S.C. ' 156 may be changed. FDA has published a notice in the March 14, 1997, *Federal Register* advising NDA and NADA applicants that patent expiration dates changed by the Merck decision must be submitted within 60 days. Because there may be changes in listed patents as a result of the Merck decision, users of this publication should consult the most recent

supplement, and are encouraged to confirm that patent information upon which they intend to rely is current. (See the *Patent and Exclusivity Addendum* to the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 17th Edition that explains the background information on this court decision).

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)

NEW APPLICANT NAME (NEW ABBREVIATED NAME)

CIBA GEIGY CORP
(CIBA GEIGY)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

CIBA GEIGY CORP PHARMACEUTICALS DIV
(CIBA GEIGY)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

CIBA PHARMACEUTICAL CO
DIV CIBA GEIGY CORP
(CIBA)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

CIBA SELF MEDICATION INC
DIV CIBA GEIGY CORP
(CIBA)

NOVARTIS CONSUMER HEALTH INC
(NOVARTIS)

CIBA VISION CORP
(CIBA)

CIBA VISION CORPORATION A
NOVARTIS COMPANY
(CIBA)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

CIBA VISION OPHTHALMICS
DIV CIBA VISION CORP
(CIBA)

CIBA VISION CORPORATION A
NOVARTIS COMPANY
(CIBA)

FERRING LABORATORIES INC
(FERRING)

FERRING PHARMACEUTICALS INC
(FERRING)

GEIGY PHARMACEUTICALS
DIV CIBA GEIGY CORP
(GEIGY)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

LEMMON CO SUB TAG PHARMACEUTICAL INC
(LEMMON)

BIOCRAFT LABORATORIES INC
(BIOCRAFT)

THEN CHANGED TO
TEVA PHARMACEUTICALS USA
(TEVA)

REXAR PHARMACAL
(REXAR)

SHIRE RICHWOOD INC
(SHIRE RICHWOOD)

RICHWOOD PHARMACEUTICAL CO INC
(RICHWOOD PHARM)

SHIRE RICHWOOD INC
(SHIRE RICHWOOD)

SANDOZ CONSUMER HEALTH
CARE GROUP DIV SANDOZ PHARMACEUTICALS
(SANDOZ)

NOVARTIS CONSUMER HEALTH INC
(NOVARTIS)

SANDOZ PHARMACEUTICALS
CORP DIV SANDOZ INC
(SANDOZ)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

SANDOZ RESEARCH INSTITUTE INC
(SANDOZ)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

SANOFI WINTHROP INC
(SANOFI WINTHROP)

SANOFI PHARMACEUTICAL INC
(SANOFI)

SURVIVAL TECHNOLOGY INC
(SURVIVAL TECH)

MERIDIAN MEDICAL TECHNOLOGIES INC
(MERIDIAN MEDCL TECHN)

1.4 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acyclovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit

an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.5 FOLLITROPIN ALFA AND BETA

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

1.6 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; Prescription and OTC Drug Product Patent and Exclusivity Data; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaced the Agency's electronic bulletin board. To access the CDER Home Page, use this Uniform Resource Locator (URL): <http://www.fda.gov/cder>. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

1.7 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1996) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 1996*</u>	<u>JUN 1997</u>	<u>SEP 1997</u>	<u>DEC 1997</u>
DRUG PRODUCTS LISTED	9392	9533	9501	9624
SINGLE SOURCE	2383 (25.4%)	2388 (25.0%)	2420 (25.5%)	2462 (25.6%)
MULTISOURCE	6905 (73.5%)	7031 (73.8%)	6970 (73.8%)	7052 (73.3%)
THERAPEUTICALLY EQUIVALENT	6463 (68.8%)	6626 (69.5%)	6587 (69.3%)	6673 (69.3%)
NOT THERAPEUTICALLY EQUIVALENT	442 (4.7%)	405 (4.3%)	383 (4.0%)	379 (4.0%)
EXCEPTIONS ¹	104 (1.1%)	114 (1.2%)	111 (1.2%)	110 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	--	8	14	14
NUMBER OF APPLICANTS	650	682	701	511

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

*Exceptions were originally included in the total count of the Multisource Drug Products. Beginning with December 1996, exceptions were no longer included in the Multisource Drug Products total count, but included in the total count of the Drug Products Listed.

PRESCRIPTION DRUG PRODUCT LIST
17TH EDITION
RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'97 - DEC'97

1

ACARBOSE

TABLET; ORAL
PRECOSE
BAYER

25MG

N20482 004
MAY 29, 1997
N20482 004
MAY 29, 1997

@

25MG

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL
BUCET

AB MALLINCKRODT 650MG; 50MG

N88991 001
JUN 28, 1985

BUTALBITAL AND ACETAMINOPHEN

AB GRAHAM DM 650MG; 50MG

N88991 001
JUN 28, 1985

CONTEN

AB GRAHAM DM 650MG; 50MG

N89405 001
MAY 15, 1990

TENCON

AB MALLINCKRODT 650MG; 50MG

N89405 001
MAY 15, 1990

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN, CAFFEINE

AB GRAHAM DM 325MG; 50MG; 40MG

N88743 001
JUL 18, 1985

AB 325MG; 50MG; 40MG

N88765 001
MAR 27, 1985

AB 325MG; 50MG; 40MG

N89023 001
JUN 19, 1985

AB 325MG; 50MG; 40MG

N89067 001
APR 19, 1985

AB 325MG; 50MG; 40MG

N89102 001
JUN 19, 1985

@ 325MG; 50MG; 40MG

N88743 001
JUL 18, 1985

@ 325MG; 50MG; 40MG

N88765 001
MAR 27, 1985

@ 325MG; 50MG; 40MG

N89067 001
APR 19, 1985

FEMCET

AB MALLINCKRODT 325MG; 50MG; 40MG

N89102 001
JUN 19, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
TRIAD

AB MALLINCKRODT 325MG; 50MG; 40MG

N89023 001
JUN 19, 1985

TABLET; ORAL

REPAN

AB GRAHAM DM 325MG; 50MG; 40MG

N87804 001
JAN 24, 1985

AB MALLINCKRODT 325MG; 50MG; 40MG

N87804 001
JAN 24, 1985

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AA MIKART 356.4MG; 30MG; 16MG N40109 001
AUG 26, 1997

DHC PLUS

AA + PURDUE FREDERICK 356.4MG; 30MG; 16MG N88584 001
MAR 04, 1986

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA DURAMED 300MG; 15MG N40223 001
NOV 18, 1997

AA 300MG; 30MG

N40223 002
NOV 18, 1997

AA 300MG; 60MG

N40223 003
NOV 18, 1997

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

AA + GRAHAM DM 500MG; 5MG N87336 001
JUL 08, 1982

AA 500MG; 5MG

N88956 001
JUL 19, 1985

HYDROCET

AA GRAHAM DM 500MG; 5MG

N89006 001
AUG 09, 1985

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCET

AA MALLINCKRODT 500MG; 5MG

N89006 001
AUG 09, 1985LORCET-HD

AA + MALLINCKRODT 500MG; 5MG

N87336 001
JUL 08, 1982ZYDONE

AA MALLINCKRODT 500MG; 5MG

N88956 001
JUL 19, 1985

TABLET; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

AA GRAHAM DM 500MG; 5MG

N87722 001
JUL 09, 1982HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ BARR 500MG; 5MG

N88577 001
DEC 21, 1984

AA EON 500MG; 5MG

N40149 001
JAN 27, 1997

AA 750MG; 7.5MG

N40149 002
JAN 27, 1997

AA HALSEY 500MG; 5MG

N40236 001
SEP 25, 1997

AA 650MG; 7.5MG

N40240 002
NOV 26, 1997

AA 650MG; 10MG

N40240 001
NOV 26, 1997

AA 750MG; 7.5MG

N40236 002
SEP 25, 1997

AA PEACHTREE 500MG; 10MG

N40210 001
AUG 13, 1997

AA VINTAGE PHARMS 500MG; 2.5MG

N40144 002
APR 25, 1997

AA 650MG; 7.5MG

N40155 001
APR 14, 1997

AA WATSON LABS 500MG; 10MG

N40148 002
FEB 14, 1997HYDROCODONE BITARTRATE W/ ACETAMINOPHEN

AA BARR 500MG; 5MG

N88577 001
DEC 21, 1984LORTAB

AA * GRAHAM DM 500MG; 10MG

N40100 001
JAN 26, 1996

AA MALLINCKRODT 500MG; 5MG

N87722 001
JUL 09, 1982ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

LORTAB

AA + UCB 500MG; 10MG

N40100 001
JAN 26, 1996
N40099 001
JUN 25, 1997

325MG; 5MG

NORCO

+ WATSON LABS 325MG; 10MG

N40148 001
FEB 14, 1997ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

AA ROYCE LABS 500MG; 5MG

N40234 001
OCT 30, 1997

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA ROYCE LABS 325MG; 5MG

N40171 001
OCT 30, 1997PERCOCET

AA * DUPONT MERCK 325MG; 5MG

N85106 002
N85106 002

AA + ENDO PHARMS 325MG; 5MG

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB VINTAGE PHARMS 650MG; 100MG

N74843 001
FEB 12, 1997ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

AB TARO 125MG

N40195 001
MAY 28, 1997

AB 250MG

N40195 002
MAY 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

<u>AP</u>	ABBOTT	<u>EQ 500MG BASE/VIAL</u>
<u>AP</u>	SANOFI WINTHROP	<u>EQ 500MG BASE/VIAL</u>

N40108 001
OCT 30, 1995
N40108 001
OCT 30, 1995

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; AURICULAR (OTIC)

TRIDESILON

© BAYER

2%;0.05%

N17914 001

SOLUTION/DROPS; OTIC

TRIDESILON

BAYER

2%;0.05%

N17914 001

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

<u>AB</u>	AESGEN	<u>200MG</u>
<u>AB</u>	APOTHECON	<u>200MG</u>
<u>AB</u>	COPLEY PHARM	<u>200MG</u>
<u>AB</u>	ESI LEDERLE	<u>200MG</u>
<u>AB</u>	LEK PHARM	<u>200MG</u>
<u>AB</u>	LEMMON	<u>200MG</u>
<u>AB</u>	MYLAN	<u>200MG</u>
<u>AB</u>	NOVOPHARM	<u>200MG</u>
<u>AB</u>	PUREPAC PHARM	<u>200MG</u>
<u>AB</u>	ROXANE	<u>200MG</u>
<u>AB</u>	TEVA	<u>200MG</u>
<u>AB</u>	ZENITH GOLDLINE	<u>200MG</u>

N74833 001
APR 22, 1997
N74889 001
OCT 31, 1997
N74914 001
NOV 26, 1997
N74872 001
APR 22, 1997
N74750 001
APR 22, 1997
N74828 001
APR 22, 1997
N74727 001
APR 22, 1997
N74578 001
APR 22, 1997
N74906 001
AUG 26, 1997
N74570 002
APR 22, 1997
N74828 001
APR 22, 1997
N74674 001
APR 22, 1997

ACYCLOVIR

CAPSULE; ORAL

ZOVIRAX

<u>AB</u>	+ GLAXO WELLCOME	<u>200MG</u>
-----------	------------------	--------------

N18828 001
JAN 25, 1985

SUSPENSION; ORAL

ACYCLOVIR

ALPHARMA

200MG/5ML

N74738 001
APR 28, 1997

ZOVIRAX

<u>AB</u>	+ GLAXO WELLCOME	<u>200MG/5ML</u>
-----------	------------------	------------------

N19909 001
DEC 22, 1989

TABLET; ORAL

ACYCLOVIR

AESGEN

400MG

N74946 001
NOV 19, 1997

<u>AB</u>		<u>800MG</u>
-----------	--	--------------

N74946 002
NOV 19, 1997

<u>AB</u>	APOTHECON	<u>400MG</u>
-----------	-----------	--------------

N74891 001
OCT 31, 1997

<u>AB</u>		<u>800MG</u>
-----------	--	--------------

N74891 002
OCT 31, 1997

<u>AB</u>	ESI LEDERLE	<u>400MG</u>
-----------	-------------	--------------

N74834 001
APR 24, 1997

<u>AB</u>		<u>800MG</u>
-----------	--	--------------

N74834 002
APR 24, 1997

<u>AB</u>	LEK PHARM	<u>400MG</u>
-----------	-----------	--------------

N74658 001
APR 22, 1997

<u>AB</u>		<u>800MG</u>
-----------	--	--------------

N74658 002
APR 22, 1997

<u>AB</u>	NOVOPHARM	<u>400MG</u>
-----------	-----------	--------------

N74556 002
APR 22, 1997

<u>AB</u>		<u>800MG</u>
-----------	--	--------------

N74556 003
APR 22, 1997

+		200MG
---	--	-------

N74556 001
APR 22, 1997

<u>AB</u>	PUREPAC PHARM	<u>400MG</u>
-----------	---------------	--------------

N74870 001
JUN 05, 1997

<u>AB</u>		<u>800MG</u>
-----------	--	--------------

N74870 002
JUN 05, 1997

<u>AB</u>	ZENITH GOLDLINE	<u>400MG</u>
-----------	-----------------	--------------

N74836 001
APR 22, 1997

<u>AB</u>		<u>800MG</u>
-----------	--	--------------

N74836 002
APR 22, 1997

ZOVIRAX

<u>AB</u>	GLAXO WELLCOME	<u>400MG</u>
-----------	----------------	--------------

N20089 001
APR 30, 1991

<u>ACYCLOVIR</u>				> ADD >	<u>ALATROFLOXACIN MESYLATE</u>		
TABLET; ORAL				> ADD >	INJECTABLE; INJECTION		
<u>ZOVIRAX</u>				> ADD >	TROVAN PRESERVATIVE FREE		
AB	+	GLAXO WELLCOME	800MG	N20089 002	PFIZER	EQ 200MG BASE/VIAL	N20760 001
				APR 30, 1991			DEC 18, 1997
<u>ACYCLOVIR SODIUM</u>				> ADD >	+	EQ 300MG BASE/VIAL	N20760 002
				> ADD >			DEC 18, 1997
INJECTABLE; INJECTION				> ADD >	<u>ALBUMIN HUMAN</u>		
> ADD >		ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE		> ADD >	INJECTABLE; INJECTION		
> ADD >		+ ESI LEDERLE	EQ 500MG BASE/VIAL	N74885 001	OPTISON		
> ADD >			EQ 1GM BASE/VIAL	DEC 19, 1997	+ MOLECULAR BIOSYSTEMS 10MG/ML		N20899 001
> ADD >				N74885 002			DEC 31, 1997
				DEC 19, 1997			
AP		<u>ACYCLOVIR SODIUM</u>	<u>EQ 500MG BASE/VIAL</u>	N74663 001			
		ABBOTT		APR 22, 1997	<u>ALBUTEROL</u>		
AP			<u>EQ 500MG BASE/VIAL</u>	N74758 001	AEROSOL, METERED; INHALATION		
				APR 22, 1997	<u>ALBUTEROL</u>		
AP			<u>EQ 1GM BASE/VIAL</u>	N74663 002	AB	ALPHARMA	0.09MG/INH
				APR 22, 1997			N73045 001
AP			<u>EQ 1GM BASE/VIAL</u>	N74758 002	> DLT >	AB	ARMSTRONG PHARMS
				APR 22, 1997	> DLT >		0.09MG/INH
AP	BEDFORD		<u>EQ 500MG BASE/VIAL</u>	N74596 002	> ADD >	AB	MEDEVA
				APR 22, 1997	> ADD >		0.09MG/INH
AP			<u>EQ 1GM BASE/VIAL</u>	N74596 001			N72273 001
				APR 22, 1997			AUG 14, 1996
AP	ESI LEDERLE		<u>EQ 500MG BASE/VIAL</u>	N74913 001			
				OCT 15, 1997	<u>ALBUTEROL SULFATE</u>		
AP			<u>EQ 1GM BASE/VIAL</u>	N74913 002	SOLUTION; INHALATION		
				OCT 15, 1997	<u>ALBUTEROL SULFATE</u>		
	+	FAULDING	EQ 25MG BASE/ML	N74720 001	AN	NEPHRON	EQ 0.083% BASE
AP			<u>EQ 500MG BASE/VIAL</u>	N74969 001			N74880 001
				APR 22, 1997			SEP 17, 1997
AP			<u>EQ 1GM BASE/VIAL</u>	N74969 002			
				AUG 26, 1997	<u>ALENDRONATE SODIUM</u>		
AP			<u>EQ 500MG BASE/VIAL</u>	N74663 001	TABLET; ORAL		
				APR 22, 1997	FOSAMAX		
AP			<u>EQ 1GM BASE/VIAL</u>	N74663 002	MERCK	EQ 5MG BASE	N20560 003
				APR 22, 1997			APR 25, 1997
AP		<u>ZOVIRAX</u>	<u>EQ 500MG BASE/VIAL</u>	N18603 001			
	+	GLAXO WELLCOME		OCT 22, 1982			
AP	+		<u>EQ 1GM BASE/VIAL</u>	N18603 002			
				JUN 29, 1989			

ALLOPURINOLTABLET; ORAL
LOPURIN

> <u>ADD</u> >	<u>AB</u>	<u>BASF</u>	<u>100MG</u>
> <u>ADD</u> >			
> <u>ADD</u> >	<u>AB</u>		<u>300MG</u>
> <u>ADD</u> >			
> <u>DLT</u> >	<u>AB</u>	<u>KNOLL PHARM</u>	<u>100MG</u>
> <u>DLT</u> >			
> <u>DLT</u> >	<u>AB</u>		<u>300MG</u>
> <u>DLT</u> >			

N71586 001
APR 02, 1987
N71587 001
APR 02, 1987
N71586 001
APR 02, 1987
N71587 001
APR 02, 1987

ALPRAZOLAMTABLET; ORAL
ALPRAZOLAM
ROYCE LABS

<u>AB</u>	<u>0.25MG</u>
<u>AB</u>	<u>0.5MG</u>
<u>AB</u>	<u>1MG</u>

N74479 001
JAN 21, 1997
N74479 002
JAN 21, 1997
N74479 003
JAN 21, 1997

ALPROSTADILINJECTABLE; INJECTION
CAVERJECT

<u>AP</u>	<u>PHARMACIA AND UPJOHN</u>	<u>0.005MG/VIAL</u>
<u>AP</u>		<u>0.01MG/VIAL</u>
<u>AP</u>		<u>0.02MG/VIAL</u>
<u>AP</u> +		<u>0.04MG/VIAL</u>
		0.005MG/ML
		0.01MG/ML
		0.02MG/ML
<u>AP</u>	<u>EDEX</u>	<u>0.005MG/VIAL</u>
<u>AP</u>	<u>SCHWARZ PHARMA</u>	<u>0.01MG/VIAL</u>

N20379 003
JUN 27, 1996
N20379 001
JUL 06, 1995
N20379 002
JUL 06, 1995
N20379 004
MAY 19, 1997
N20755 001
OCT 31, 1997
N20755 002
OCT 01, 1997
N20755 003
OCT 01, 1997
N20649 001
JUN 12, 1997
N20649 002
JUN 12, 1997

ALPROSTADILINJECTABLE; INJECTION
EDEX

<u>AP</u>	<u>SCHWARZ PHARMA</u>	<u>0.02MG/VIAL</u>
<u>AP</u> +		<u>0.04MG/VIAL</u>

N20649 003
JUN 12, 1997
N20649 004
JUN 12, 1997

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

<u>AB</u>	<u>SYNADINE</u>	<u>100MG</u>
	<u>SOLVAY</u>	
@		100MG

N71000 001
SEP 04, 1986
N71000 001
SEP 04, 1986

TABLET; ORAL
SYMMETREL
@ DUPONT MERCK
@ ENDO PHARMS

100MG
100MG

N18101 001
N18101 001

AMIKACIN SULFATE

INJECTABLE; INJECTION

<u>AP</u>	<u>AMIKACIN SULFATE</u>	<u>EQ 250MG BASE/ML</u>
	<u>ABBOTT</u>	
<u>AP</u>		<u>EQ 250MG BASE/ML</u>
<u>AP</u>	<u>ELKINS SINN</u>	<u>EQ 50MG BASE/ML</u>
@		EQ 50MG BASE/ML
<u>AP</u>	<u>SANOFI WINTHROP</u>	<u>EQ 250MG BASE/ML</u>
<u>AP</u>		<u>EQ 250MG BASE/ML</u>

N64098 001
JUN 26, 1995
N64099 001
JUN 20, 1995
N63274 001
MAY 18, 1992
N63274 001
MAY 18, 1992
N64098 001
JUN 26, 1995
N64099 001
JUN 20, 1995

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC
CONTAINER
ABBOTT

EQ 500MG BASE/100ML

N64146 001
APR 02, 1997

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN II 5%

ABBOTT

5%

N19438 002

APR 03, 1986

©

5%

N19438 002

APR 03, 1986

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;
POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM
CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM
IN PLASTIC CONTAINER

ABBOTT

3.5%;36.8MG/100ML;25GM/100ML;
51MG/100ML;22.4MG/100ML;261MG/100ML;
205MG/100ML

N19714 001

SEP 12, 1988

©

3.5%;36.8MG/100ML;25GM/100ML;
51MG/100ML;22.4MG/100ML;261MG/100ML;
205MG/100ML

N19714 001

SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/
CALCIUM IN PLASTIC CONTAINER

ABBOTT

4.25%;36.8MG/100ML;20GM/100ML;
51MG/100ML;22.4MG/100ML;261MG/100ML;
205MG/100ML

N19714 002

SEP 12, 1988

©

4.25%;36.8MG/100ML;20GM/100ML;
51MG/100ML;22.4MG/100ML;261MG/100ML;
205MG/100ML

N19714 002

SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/
CALCIUM IN PLASTIC CONTAINER

ABBOTT

4.25%;36.8MG/100ML;25GM/100ML;
51MG/100ML;22.4MG/100ML;261MG/100ML;
205MG/100ML

N19714 004

SEP 12, 1988

©

4.25%;36.8MG/100ML;25GM/100ML;
51MG/100ML;22.4MG/100ML;261MG/100ML;
205MG/100ML

N19714 004

SEP 12, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;
POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM
CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM
IN PLASTIC CONTAINER

ABBOTT

5%;36.8MG/100ML;25GM/100ML;

51MG/100ML;22.4MG/100ML;261MG/100ML;

205MG/100ML

N19683 004

NOV 07, 1988

5%;36.8MG/100ML;25GM/100ML;

51MG/100ML;22.4MG/100ML;261MG/100ML;

205MG/100ML

N19714 003

SEP 12, 1988

©

5%;36.8MG/100ML;25GM/100ML;

51MG/100ML;22.4MG/100ML;261MG/100ML;

205MG/100ML

N19683 004

NOV 07, 1988

©

5%;36.8MG/100ML;25GM/100ML;

51MG/100ML;22.4MG/100ML;261MG/100ML;

205MG/100ML

N19714 003

SEP 12, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;
POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/
CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

2.75%;33MG/100ML;10GM/100ML;

51MG/100ML;261MG/100ML;217MG/100ML;

112MG/100ML

N20678 002

MAR 26, 1997

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/
CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

2.75%;33MG/100ML;25GM/100ML;

51MG/100ML;261MG/100ML;217MG/100ML;

112MG/100ML

N20678 005

MAR 26, 1997

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/
CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

2.75%;33MG/100ML;5GM/100ML;

51MG/100ML;261MG/100ML;217MG/100ML;

112MG/100ML

N20678 001

MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;
POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/
CALCIUM IN PLASTIC CONTAINER+ BAXTER HLTHCARE 4.25%;33MG/100ML;10GM/100ML;
51MG/100ML;261MG/100ML;297MG/100ML;
77MG/100ML N20678 009
MAR 26, 1997CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/
CALCIUM IN PLASTIC CONTAINER+ BAXTER HLTHCARE 4.25%;33MG/100ML;20GM/100ML;
51MG/100ML;261MG/100ML;297MG/100ML;
77MG/100ML N20678 011
MAR 26, 1997CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/
CALCIUM IN PLASTIC CONTAINER+ BAXTER HLTHCARE 4.25%;33MG/100ML;25GM/100ML;
51MG/100ML;261MG/100ML;297MG/100ML;
77MG/100ML N20678 012
MAR 26, 1997CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/
CALCIUM IN PLASTIC CONTAINER+ BAXTER HLTHCARE 4.25%;33MG/100ML;5GM/100ML;
51MG/100ML;261MG/100ML;297MG/100ML;
77MG/100ML N20678 008
MAR 26, 1997CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/
CALCIUM IN PLASTIC CONTAINER+ BAXTER HLTHCARE 5%;33MG/100ML;10GM/100ML;51MG/100ML;
261MG/100ML;340MG/100ML;
59MG/100ML N20678 016
MAR 26, 1997CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/
CALCIUM IN PLASTIC CONTAINER+ BAXTER HLTHCARE 5%;33MG/100ML;15GM/100ML;51MG/100ML;
261MG/100ML;340MG/100ML;
59MG/100ML N20678 017
MAR 26, 1997CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/
CALCIUM IN PLASTIC CONTAINER+ BAXTER HLTHCARE 5%;33MG/100ML;20GM/100ML;51MG/100ML;
261MG/100ML;340MG/100ML;
59MG/100ML N20678 018
MAR 26, 1997AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;
POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/
CALCIUM IN PLASTIC CONTAINER+ BAXTER HLTHCARE 5%;33MG/100ML;25GM/100ML;51MG/100ML;
261MG/100ML;340MG/100ML;
59MG/100ML N20678 019
MAR 26, 1997CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/
CALCIUM IN PLASTIC CONTAINER+ BAXTER HLTHCARE 5%;33MG/100ML;35GM/100ML;51MG/100ML;
261MG/100ML;340MG/100ML;
59MG/100ML N20678 021
MAR 26, 1997AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT 3.5%;25GM/100ML N19505 002
NOV 07, 19863.5%;25GM/100ML N19713 006
SEP 09, 1988@ 3.5%;25GM/100ML N19505 002
NOV 07, 1986@ 3.5%;25GM/100ML N19713 006
SEP 09, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT 3.5%;5GM/100ML N19506 001
NOV 07, 19863.5%;5GM/100ML N19713 002
SEP 09, 1988@ 3.5%;5GM/100ML N19506 001
NOV 07, 1986@ 3.5%;5GM/100ML N19713 002
SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT 4.25%;10GM/100ML N19713 001
SEP 09, 1988@ 4.25%;10GM/100ML N19713 001
SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

ABBOTT 4.25%;20GM/100ML N19713 004
SEP 09, 1988@ 4.25%;20GM/100ML N19713 004
SEP 09, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT 4.25%;25GM/100ML N19504 002

NOV 07, 1986

4.25%;25GM/100ML N19713 005

SEP 09, 1988

@ 4.25%;25GM/100ML N19504 002

NOV 07, 1986

@ 4.25%;25GM/100ML N19713 005

SEP 09, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT 5%;25GM/100ML N19713 003

SEP 09, 1988

@ 5%;25GM/100ML N19713 003

SEP 09, 1988

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC

CONTAINER BAXTER HLTHCARE 2.75%;10% N20734 002

SEP 29, 1997

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC

CONTAINER BAXTER HLTHCARE 2.75%;25GM/100ML N20734 005

SEP 29, 1997

CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC

CONTAINER BAXTER HLTHCARE 2.75%;5GM/100ML N20734 001

SEP 29, 1997

CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC

CONTAINER BAXTER HLTHCARE 4.25%;10GM/100ML N20734 008

SEP 29, 1997

CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC

CONTAINER BAXTER HLTHCARE 4.25%;20GM/100ML N20734 010

SEP 29, 1997

CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC

CONTAINER BAXTER HLTHCARE 4.25%;25GM/100ML N20734 011

SEP 29, 1997

CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC

CONTAINER BAXTER HLTHCARE 4.25%;5GM/100ML N20734 007

SEP 29, 1997

CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC

CONTAINER BAXTER HLTHCARE 5%;10GM/100ML N20734 014

SEP 29, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC

CONTAINER BAXTER HLTHCARE 5%;15GM/100ML N20734 015

SEP 29, 1997

CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC

CONTAINER BAXTER HLTHCARE 5%;20GM/100ML N20734 016

SEP 29, 1997

CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC

CONTAINER BAXTER HLTHCARE 5%;25GM/100ML N20734 017

SEP 29, 1997

CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC

CONTAINER BAXTER HLTHCARE 5%;35GM/100ML N20734 018

SEP 29, 1997

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE;
POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM
CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN

DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT 4.25%;10GM/100ML;51MG/100ML;

176.5MG/100ML;22.4MG/100ML;

104.5MG/100ML;205MG/100ML N19682 003

NOV 01, 1988

4.25%;10GM/100ML;51MG/100ML;

176.5MG/100ML;22.4MG/100ML;

104.5MG/100ML;205MG/100ML N19712 002

SEP 08, 1988

@ 4.25%;10GM/100ML;51MG/100ML;

176.5MG/100ML;22.4MG/100ML;

104.5MG/100ML;205MG/100ML N19682 003

NOV 01, 1988

@ 4.25%;10GM/100ML;51MG/100ML;

176.5MG/100ML;22.4MG/100ML;

104.5MG/100ML;205MG/100ML N19712 002

SEP 08, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE;
SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABEOTT
1.5%; 5GM/100ML; 30MG/100ML;
97MG/100ML; 120MG/100ML;
49.3MG/100ML N19712 001
SEP 08, 1988

@ 3.5%; 5GM/100ML; 30MG/100ML;
97MG/100ML; 120MG/100ML;
49.3MG/100ML N19712 001
SEP 08, 1988

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLIN

AP * SEARLE 25MG/ML N87243 001
MAY 24, 1982
@ 25MG/ML N87243 001
MAY 24, 1982

AMINOPHYLLINE

AP ELKINS SINN 25MG/ML N87239 001
AP + 25MG/ML N87239 001
AP PHARMA SERVE NY 25MG/ML N87387 001
JUN 03, 1983
@ 25MG/ML N87387 001
JUN 03, 1983

TABLET; ORAL

AMINOPHYLLINE

BD HALSEY 100MG N84674 001
@ 100MG N84674 001

TABLET, EXTENDED RELEASE; ORAL

PHYLOCONTIN

* PURDUE FREDERICK 225MG N86760 001
@ 225MG N86760 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

BP HALSEY 10MG N85923 001
BP 50MG N85925 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

BP HALSEY 75MG N85926 001
MAY 20, 1983
BP 100MG N85927 001
MAY 20, 1983
@ 10MG N85923 001
@ 50MG N85925 001
@ 75MG N85926 001
MAY 20, 1983
@ 100MG N85927 001
MAY 20, 1983

AMITRIPTYLINE HYDROCHLORIDE

AB VINTAGE PHARMS 10MG N40218 001
SEP 11, 1997
AB 25MG N40218 002
SEP 11, 1997
AB 50MG N40218 003
SEP 11, 1997
AB 75MG N40218 004
SEP 11, 1997
AB 100MG N40218 005
SEP 11, 1997
AB 150MG N40218 006
SEP 11, 1997

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

LIMBITROL

AB ICN EQ 12.5MG BASE; 5MG N16949 001
AB ROCHE EQ 12.5MG BASE; 5MG N16949 001
AB + ICN EQ 25MG BASE; 10MG N16949 002
AB * ROCHE EQ 25MG BASE; 10MG N16949 002

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAPON-A

BP SCHERING 10MG; 4MG N14713 002
@ 10MG; 4MG N14713 002
PERPHENAZINE AND AMITRIPTYLINE HCL
@ ZENITH GOLDLINE 10MG; 2MG N70935 001
SEP 11, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

@ ZENITH GOLDLINE 10MG;4MG

@ 25MG;2MG

@ 25MG;4MG

@ 50MG;4MG

AB ZENITH LABS 10MG;2MG

AB 10MG;4MG

AB 25MG;2MG

AB 25MG;4MG

AB 50MG;4MG

> DLT > TRIAVIL 2-10

> DLT > AB LOTUS BIOCHEM 10MG;2MG

> ADD > @ 10MG;2MG

> DLT > TRIAVIL 2-25

> DLT > AB LOTUS BIOCHEM 25MG;2MG

> ADD > @ 25MG;2MG

> DLT > TRIAVIL 4-10

> DLT > AB LOTUS BIOCHEM 10MG;4MG

> ADD > @ 10MG;4MG

> DLT > TRIAVIL 4-25

> DLT > AB LOTUS BIOCHEM 25MG;4MG

> ADD > @ 25MG;4MG

> DLT > TRIAVIL 4-50

> DLT > AB LOTUS BIOCHEM 50MG;4MG

> ADD > @ 50MG;4MG

N70937 001

SEP 11, 1986

N70936 001

SEP 11, 1986

N70938 001

SEP 11, 1986

N70939 001

SEP 12, 1986

N70935 001

SEP 11, 1986

N70937 001

SEP 11, 1986

N70936 001

SEP 11, 1986

N70938 001

SEP 11, 1986

N70939 001

SEP 12, 1986

N14715 004

N14715 004

N14715 002

N14715 002

N14715 003

N14715 003

N14715 005

N14715 005

N14715 006

N14715 006

AMOXICILLIN

CAPSULE; ORAL

AMOXIL

@ SMITHKLINE BEECHAM 250MG

@ 500MG

N50459 001

N50459 002

POWDER FOR RECONSTITUTION; ORAL

AMOXIL

AB * SMITHKLINE BEECHAM 125MG/5ML

AB 125MG/5ML

AB + 125MG/5ML

AB * 250MG/5ML

AB 50MG/ML

AB + 250MG/5ML

AB 50MG/ML

AB + 50MG/ML

AB @ 125MG/5ML

AB @ 250MG/5ML

AB @ 50MG/ML

LAROTID

AB SMITHKLINE BEECHAM 50MG/ML

@ 50MG/ML

N50460 001

N62226 001

N62226 001

N50460 002

N50460 005

N62226 002

N62226 002

N62226 005

N62226 005

N50460 001

N50460 002

N50460 005

N50460 006

N50460 006

> ADD > AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

> ADD > CAPSULE, TABLET, CAPSULE, EXTENDED RELEASE; ORAL

> ADD > PREVPAC

> ADD > + TAP HOLDINGS 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,

> ADD > 30MG N50757 001

> ADD > DEC 02, 1997

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINESACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

ADDERALL 10

RICHWOOD PHARM 2.5MG;2.5MG;2.5MG;2.5MG N11522 007

FEB 13, 1996

SHIRE RICHWOOD 2.5MG;2.5MG;2.5MG;2.5MG N11522 007

FEB 13, 1996

ADDERALL 20

* RICHWOOD PHARM 5MG,5MG,5MG,5MG N11522 008

FEB 13, 1996

AMOXICILLIN

CAPSULE; ORAL

AMOXIL

AB * SMITHKLINE BEECHAM 250MG

AB 250MG

AB + 250MG

AB * 500MG

AB 500MG

AB + 500MG

N50459 001

N62216 001

N62216 001

N50459 002

N62216 002

N62216 004

N62216 004

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE
SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL			
ADDERALL 20			
SHIRE RICHWOOD	5MG;5MG;5MG;5MG	N11522 008	
		FEB 13, 1996	
ADDERALL 30			
+ SHIRE RICHWOOD	7.5MG;7.5MG;7.5MG;7.5MG	N11522 010	
		MAY 12, 1997	
ADDERALL 5			
SHIRE RICHWOOD	1.25MG;1.25MG;1.25MG; 1.25MG	N11522 009	
		MAY 12, 1997	

AMPHOTERICIN B

INJECTABLE; INJECTION			
<u>AMPHOTERICIN B</u>			
AP	ABBOTT	50MG/VIAL	N64141 001
			DEC 23, 1996
AP	SANOPI WINTHROP	50MG/VIAL	N64141 001
			DEC 23, 1996
INJECTABLE, LIPOSOMAL; INJECTION			
AMBISOME			
+ FUJISAWA	50MG/VIAL	N50740 001	
		AUG 11, 1997	
<u>GINTMENT; TOPICAL</u>			
FUNGIZONE			
* APOTHECON	3%	N50313 001	
@	3%	N50313 001	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION			
UNASYN			
> ADD >	+ PFIZER	EQ 10GM BASE/VIAL;	
> ADD >		EQ 5GM BASE/VIAL	N50608 005
> ADD >			DEC 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL		
<u>AMPICILLIN TRIHYDRATE</u>		
@ ZENITH GOLDLINE	EQ 250MG BASE	N60765 001

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL		
<u>AMPICILLIN TRIHYDRATE</u>		
@ ZENITH GOLDLINE	EQ 500MG BASE	N60765 002
AB		N60765 001
AB	EQ 250MG BASE	N60765 002
	EQ 500MG BASE	

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL		
AGRYLIN		
ROBERTS LABS	EQ 0.5MG BASE	N20333 001
		MAR 14, 1997
+	EQ 1MG BASE	N20333 002
		MAR 14, 1997

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL		
VALPIN 50		
@ DUPONT MERCK	50MG	N13428 001
@ ENDO PHARMS	50MG	N13428 001

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION		
GENESA		
+ GENSIA	0.05MG/ML	N20420 001
		SEP 12, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION		
NORMIFLO		
+ WYETH AYERST	5,000 UNITS/0.5ML	N20227 002
		MAY 23, 1997
+	10,000 UNITS/0.5ML	N20227 001
		MAY 23, 1997

ASPIRIN; BUTALBITALTABLET; ORAL
AXOTAL

* SAVAGE LABS	650MG;50MG	N88305 001
		OCT 13, 1983
@	650MG;50MG	N88305 001
		OCT 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL COMPOUND

@ ZENITH GOLDLINE 325MG;50MG;40MG

N85441 002
OCT 31, 1984

AB ZENITH LABS 325MG;50MG;40MG

N85441 002
OCT 31, 1984ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

@ PAR PHARM 385MG;30MG;25MG

N71642 001
JUN 23, 1987

ORPHENGESIC FORTE

@ PAR PHARM 770MG;60MG;50MG

N71643 001
JUN 23, 1987ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE COMPOUND 65

@ ZENITH GOLDLINE 389MG;32.4MG;65MG

N83077 002
DEC 07, 1984

AA ZENITH LABS 389MG;32.4MG;65MG

N83077 002
DEC 07, 1984ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB AMIDE PHARM 325MG;200MG

N40252 001
DEC 10, 1997> ADD >
> ADD >ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODOXY

AA HALSEY

325MG;4.5MG;0.38MG

N87464 001

@

325MG;4.5MG;0.38MG

JUL 01, 1982
N87464 001
JUL 01, 1982

PERCODAN

AA * DUPONT MERCK

325MG;4.5MG;0.38MG

N07337 006

AA + ENDO PHARMS

325MG;4.5MG;0.38MG

N07337 006

PERCODAN-DEMI

AA * DUPONT MERCK

325MG;2.25MG;0.19MG

N07337 005

AA + ENDO PHARMS

325MG;2.25MG;0.19MG

N07337 005

ATENOLOL

TABLET; ORAL

ATENOLOL

AB MUTUAL PHARM

25MG

N74499 001

AB SIDMAK LABS NJ

25MG

JUL 30, 1997
N74101 001

AB

50MG

JUL 17, 1997
N74101 002

AB

100MG

JUL 17, 1997
N74101 003

JUL 17, 1997

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB SIDMAK LABS NJ

50MG;25MG

N74107 001

AB

100MG;25MG

SEP 24, 1997
N74107 002

SEP 24, 1997

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP ABBOTT

10MG/ML

N74633 001

AP BEDFORD

10MG/ML

DEC 23, 1996
N74901 001

JUL 18, 1997

ATRACURIUM BESYLATEINJECTABLE; INJECTION
ATRACURIUM BESYLATE

<u>AP</u>	ESI LEDERLE	<u>10MG/ML</u>	N74824 001 SEP 30, 1997
<u>AP</u>	FAULDING	<u>10MG/ML</u>	N74740 001 MAR 28, 1997
<u>AP</u>	GENSIA	<u>10MG/ML</u>	N74784 001 JUN 11, 1997
<u>AP</u>	OHMEDA	<u>10MG/ML</u>	N74753 001 JAN 23, 1997
<u>ATRACURIUM BESYLATE PRESERVATIVE FREE</u>			
<u>AP</u>	ABBOTT	<u>10MG/ML</u>	N74633 001 DEC 23, 1996
<u>AP</u>		<u>10MG/ML</u>	N74639 001 MAR 25, 1997
<u>AP</u>	BEDFORD	<u>10MG/ML</u>	N74900 001 JUL 18, 1997
<u>AP</u>	ESI LEDERLE	<u>10MG/ML</u>	N74825 001 SEP 30, 1997
<u>AP</u>	FAULDING	<u>10MG/ML</u>	N74741 001 MAR 28, 1997
<u>AP</u>	OHMEDA	<u>10MG/ML</u>	N74768 001 JAN 23, 1997
<u>TRACRIUM</u>			
<u>AP</u>	* GLAXO WELLCOME	<u>10MG/ML</u>	N18831 001 NOV 23, 1983
<u>AP</u>	+	<u>10MG/ML</u>	N18831 002 JUN 20, 1985
<u>TRACRIUM PRESERVATIVE FREE</u>			
<u>AP</u>	+	<u>10MG/ML</u>	N18831 001 NOV 23, 1983

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDETABLET; ORAL

<u>AA</u>	<u>DIPHENOXYLATE HCL AND ATROPINE SULFATE</u>		
	ROXANE	<u>0.025MG; 2.5MG</u>	N86057 001
@		<u>0.025MG; 2.5MG</u>	N86057 001
<u>AA</u>	<u>DIPHENOXYLATE HCL W/ ATROPINE SULFATE</u>		
	ICN	<u>0.025MG; 2.5MG</u>	N87195 001
@		<u>0.025MG; 2.5MG</u>	FEB 16, 1982
			N87195 001
			FEB 16, 1982
<u>AA</u>	<u>KV PHARM</u>	<u>0.025MG; 2.5MG</u>	N85659 001
@		<u>0.025MG; 2.5MG</u>	N85659 001
@	ZENITH GOLDLINE	<u>0.025MG; 2.5MG</u>	N86727 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDETABLET; ORAL

<u>AA</u>	<u>DIPHENOXYLATE HCL W/ ATROPINE SULFATE</u>		
	ZENITH LABS	<u>0.025MG; 2.5MG</u>	N86727 001

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDEINJECTABLE; INJECTION
ATROPINE AND DEMEROL

+	ABBOTT	0.4MG/ML; 50MG/ML	N87853 001
+		0.4MG/ML; 75MG/ML	NOV 26, 1982
+		0.4MG/ML; 100MG/ML	N87847 001
+		0.4MG/ML; 100MG/ML	NOV 26, 1982
*	STERLING WINTHROP	0.4MG/ML; 50MG/ML	N87848 001
*		0.4MG/ML; 50MG/ML	NOV 26, 1982
*		0.4MG/ML; 75MG/ML	N87853 001
*		0.4MG/ML; 75MG/ML	NOV 26, 1982
*		0.4MG/ML; 100MG/ML	N87847 001
*		0.4MG/ML; 100MG/ML	NOV 26, 1982
*		0.4MG/ML; 100MG/ML	N87848 001
*		0.4MG/ML; 100MG/ML	NOV 26, 1982

AURANOFINCAPSULE; ORAL

	RIDAURO		
+	CONNECTICS	3MG	N18689 001
+			MAY 24, 1985
*	SMITHKLINE BEECHAM	3MG	N18689 001
*			MAY 24, 1985

AZITHROMYCIN DIHYDRATEINJECTABLE; INJECTION

	ZITHROMAX		
+	PFIZER	EQ 500MG BASE/VIAL	N50733 001
+			JAN 30, 1997

AZLOCILLIN SODIUMINJECTABLE; INJECTION

	AZLIN		
*	BAYER	EQ 2GM BASE/VIAL	N50562 001
*			SEP 03, 1982

AZLOCILLIN SODIUMINJECTABLE; INJECTIONAZLIN

* BAYER	EQ 3GM BASE/VIAL	N50562 002	
		SEP 03, 1982	
*	EQ 4GM BASE/VIAL	N50562 003	
		SEP 03, 1982	
@	EQ 2GM BASE/VIAL	N50562 001	
		SEP 03, 1982	
@	EQ 3GM BASE/VIAL	N50562 002	
		SEP 03, 1982	
@	EQ 4GM BASE/VIAL	N50562 003	
		SEP 03, 1982	

BACITRACININJECTABLE; INJECTIONBACIIM

AP	PHARMA TEK	50,000 UNITS/VIAL	N64153 001
			MAY 09, 1997

BACITRACIN

AP	+ PHARMACIA AND UPJOHN	50,000 UNITS/VIAL	N60733 002
----	------------------------	-------------------	------------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATEointment; TOPICAL
CORTISPORIN

* GLAXO WELLCOME	400 UNITS/GM; 1%; EQ 3.5MG BASE/GM;		
	5,000 UNITS/GM	N50168 002	
		MAY 04, 1984	
+ MONARCH PHARMS	400 UNITS/GM; 1%; EQ 3.5MG BASE/GM;		
	5,000 UNITS/GM	N50168 002	
		MAY 04, 1984	

BECLOMETHASONE DIPROPIONATE MONOHYDRATESPRAY, METERED; NASAL
BECONASE AQ

BN	GLAXO WELLCOME	EQ 0.042MG DIPROP/SPRAY	N19389 001
			JUL 27, 1987
BN	+	EQ 0.042MG DIPROP/SPRAY	N19389 001
			JUL 27, 1987

BENZQUINAMIDE HYDROCHLORIDESUPPOSITORY; RECTALEMETE-CON

* ROERIG	EQ 100MG BASE	N16818 006
@	EQ 100MG BASE	N16818 006

BETAMETHASONE DIPROPIONATECREAM; TOPICALBETAMETHASONE DIPROPIONATE

AB	CLAY PARK	EQ 0.05% BASE	N74579 001
			NOV 26, 1997

LOTION; TOPICALBETAMETHASONE DIPROPIONATE

@ ALPHARMA	EQ 0.05% BASE	N71085 001	
		FEB 03, 1987	
AB	NMC	EQ 0.05% BASE	N71085 001
			FEB 03, 1987

BETAMETHASONE VALERATECREAM; TOPICALBETAMETHASONE VALERATE

AB	FOUGERA	EQ 0.1% BASE	N18861 001
			AUG 31, 1983
AB	+	EQ 0.1% BASE	N18861 001
			AUG 31, 1983

VALISONE

AB	* SCHERING	EQ 0.1% BASE	N16322 001
		EQ 0.01% BASE	N16322 002
@		EQ 0.01% BASE	N16322 002
@		EQ 0.1% BASE	N16322 001

LOTION; TOPICALBETAMETHASONE VALERATE

AB	FOUGERA	EQ 0.1% BASE	N18866 001
			AUG 31, 1983
AB	+	EQ 0.1% BASE	N18866 001
			AUG 31, 1983

VALISONE

AB	* SCHERING	EQ 0.1% BASE	N16932 001
@		EQ 0.1% BASE	N16932 001

ointment; TOPICALBETAMETHASONE VALERATE

AB	FOUGERA	EQ 0.1% BASE	N18865 001
			AUG 31, 1983

BETAMETHASONE VALERATE

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

AB	+	FOUGERA	EQ 0.1% BASE	N18865 001
				AUG 31, 1983
		<u>VALISONE</u>		
AP	*	SCHERING	EQ 0.1% BASE	N16740 001
		@	EQ 0.1% BASE	N16740 001

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

+	ALCON	EQ 0.25% BASE;1.75%	N20619 001
			APR 17, 1997

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

	@	ZENITH GOLDLINE	25MG	N84689 001
AA		ZENITH LABS	25MG	N84689 001

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE

AP	+	BRISTOL MYERS SQUIBB	EQ 30 UNITS BASE/VIAL	N50443 002
				SEP 07, 1995

BLEOMYCIN SULFATE

AP		PHARMACIA AND UPJOHN	EQ 30 UNITS BASE/VIAL	N64084 002
				JUN 01, 1996
			EQ 30 UNITS BASE/VIAL	N64084 002
				JUN 01, 1996

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	*	BAXTER HLTHCARE	200MG/100ML	N19837 002
				APR 12, 1989
AP	*		400MG/100ML	N19837 001
				APR 12, 1989

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	200MG/100ML	N19837 002
			APR 12, 1989
@		400MG/100ML	N19837 001
			APR 12, 1989

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

+	ALLERGAN	0.5%	N20490 001
			MAR 13, 1997

BROMFENAC SODIUM

CAPSULE; ORAL

DURACT

+	WYETH AYERST	EQ 25MG BASE	N20535 001
			JUL 15, 1997

BROMPHENIRAMINE MALEATE

TABLET; ORAL

BROMPHENIRAMINE MALEATE

@	ZENITH GOLDLINE	4MG	N84351 001
@	ZENITH LABS	4MG	N84351 001

BUDESONIDE

AEROSOL, METERED; NASAL

RHINOCORT

*	ASTRA	0.05MG/INH	N20233 001
			FEB 14, 1994
+		0.032MG/INH	N20233 001
			FEB 14, 1994

POWDER, METERED; INHALATION

PULMICORT

+	ASTRA	0.16MG/INH	N20441 002
			JUN 24, 1997
@		0.32MG/INH	N20441 003
			JUN 24, 1997

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP	ABBOTT	0.25MG/ML
AP		0.25MG/ML
AP	GENSIA	0.25MG/ML
AP	SANOFI WINTHROP	0.25MG/ML

N74160 001
OCT 30, 1997
N74332 001
OCT 31, 1994
N74613 001
NOV 18, 1997
N74332 001
OCT 31, 1994

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HCL

AP	ABBOTT	EQ 0.3MG BASE/ML
AP	SANOFI WINTHROP	EQ 0.3MG BASE/ML

N74137 001
JUN 03, 1996
N74137 001
JUN 03, 1996

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN

+	GLAXO WELLCOME	100MG
+		150MG

ZYBAN

GLAXO WELLCOME

		100MG
		150MG
+		100MG
+		150MG

N20358 002
OCT 04, 1996
N20358 003
OCT 04, 1996

N20711 002
MAY 14, 1997
N20711 003
MAY 14, 1997
N20711 002
MAY 14, 1997
N20711 003
MAY 14, 1997

BUTABARBITAL SODIUM

TABLET; ORAL

SODIUM BUTABARBITAL

@	ZENITH GOLDLINE	15MG
@		30MG

N83484 001
N84040 001

BUTABARBITAL SODIUM

TABLET; ORAL

SODIUM BUTABARBITAL

@	ZENITH LABS	15MG
@		30MG

N83484 001
N84040 001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT ONE

+ SYNTEX 2%

N19881 001
FEB 07, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	ABBOTT	1MG/ML
AP		1MG/ML
AP		2MG/ML
AP		2MG/ML

N74620 001
JAN 22, 1997
N74626 001
JAN 23, 1997
N74620 002
JAN 22, 1997
N74626 002
JAN 23, 1997

	STADOL	
AP	+ APOTHECON	2MG/ML
	STADOL PRESERVATIVE FREE	
AP	+ APOTHECON	1MG/ML
AP	+	2MG/ML

N17857 004

N17857 001
N17857 002

CALCIPOTRIENE

SOLUTION; TOPICAL

DOVONEX

+ BRISTOL MYERS SQUIBB 0.005%

N20611 001
MAR 03, 1997

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE;
SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC
CONTAINER

MCGAW

4MG/100ML; 4GM/100ML; 6MG/100ML;
120MG/100ML; 62MG/100ML N19634 002
FEB 24, 1988

@

4MG/100ML; 4GM/100ML; 6MG/100ML;
120MG/100ML; 62MG/100ML N19634 002
FEB 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP MCGAW

20MG/100ML; 5GM/100ML; 30MG/100ML;
600MG/100ML; 310MG/100ML N17510 001
20MG/100ML; 5GM/100ML; 30MG/100ML;
600MG/100ML; 310MG/100ML N17510 001

@

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM
ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

MCGAW

35MG/100ML; 30MG/100ML; 74MG/100ML;
640MG/100ML; 500MG/100ML;
74MG/100ML N18899 001
OCT 31, 1983

@

35MG/100ML; 30MG/100ML; 74MG/100ML;
640MG/100ML; 500MG/100ML;
74MG/100ML N18899 001
OCT 31, 1983

SOLUTION; IRRIGATION

BSS

+ ALCON

0.48MG/ML; 0.3MG/ML; 0.75MG/ML;
3.9MG/ML; 6.4MG/ML;
1.7MG/ML N20742 001
DEC 10, 1997

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM
LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP MCGAW

20MG/100ML; 30MG/100ML; 600MG/100ML;
310MG/100ML N18023 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM
LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

@ MCGAW

20MG/100ML; 30MG/100ML; 600MG/100ML;
310MG/100ML N18023 001

CAPTOPRIL

TABLET; ORAL

CAPOTEN

AB * BRISTOL MYERS SQUIBB 25MG N18343 002
AB 25MG N18343 002

CAPTOPRIL

AB EGIS PHARMS 12.5MG N74748 004

AB 25MG MAY 29, 1997 N74748 002

AB 50MG MAY 29, 1997 N74748 001

AB 100MG MAY 29, 1997 N74748 003

AB ENDO LABS 12.5MG N74418 001

AB 12.5MG FEB 13, 1996 N74418 001

AB 25MG FEB 13, 1996 N74418 002

AB 25MG FEB 13, 1996 N74418 002

AB 50MG FEB 13, 1996 N74418 003

AB 50MG FEB 13, 1996 N74418 003

AB 100MG FEB 13, 1996 N74418 004

AB 100MG FEB 13, 1996 N74418 004

AB PUREPAC PHARM 12.5MG N74640 001

AB 25MG MAR 31, 1997 N74640 002

AB 50MG MAR 31, 1997 N74640 003

AB 100MG MAR 31, 1997 N74640 004

MAR 31, 1997

> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >
> ADD >

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

CAPTOPRILTABLET; ORAL
CAPTOPRIL

<u>AB</u>	STASON	<u>12.5MG</u>
<u>AB</u>		<u>25MG</u>
<u>AB</u>		<u>50MG</u>
<u>AB</u>		<u>100MG</u>
<u>AB</u>	WOCKHARDT	<u>12.5MG</u>
<u>AB</u>		<u>25MG</u>
<u>AB</u>		<u>50MG</u>
<u>AB</u>		<u>100MG</u>

CAPTOPRIL; HYDROCHLOROTHIAZIDETABLET; ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE

N74677 004	> ADD >	<u>AB</u>	LEMMON	<u>25MG;15MG</u>	N74827 001
MAY 30, 1997	> ADD >				DEC 29, 1997
N74677 002	> ADD >	<u>AB</u>		<u>25MG;25MG</u>	N74827 002
MAY 30, 1997	> ADD >				DEC 29, 1997
N74677 001	> ADD >	<u>AB</u>		<u>50MG;15MG</u>	N74827 004
MAY 30, 1997	> ADD >				DEC 29, 1997
N74677 003	> ADD >	<u>AB</u>		<u>50MG;25MG</u>	N74827 003
MAY 30, 1997	> ADD >				DEC 29, 1997
N74532 001	> ADD >	<u>AB</u>	MYLAN	<u>25MG;15MG</u>	N74896 001
MAR 28, 1997	> ADD >				DEC 29, 1997
N74532 002	> ADD >	<u>AB</u>		<u>25MG;25MG</u>	N74896 002
MAR 28, 1997	> ADD >				DEC 29, 1997
N74532 003	> ADD >	<u>AB</u>		<u>50MG;15MG</u>	N74896 004
MAR 28, 1997	> ADD >				DEC 29, 1997
N74532 004	> ADD >	<u>AB</u>		<u>50MG;25MG</u>	N74896 003
MAR 28, 1997	> ADD >				DEC 29, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDETABLET; ORAL
CAPOZIDE 25/15

> ADD >	<u>AB</u>	SQUIBB	<u>25MG;15MG</u>
> ADD >			
> ADD >	<u>AB</u>	+ SQUIBB	<u>25MG;25MG</u>
> ADD >			
> ADD >	<u>AB</u>	+ SQUIBB	<u>50MG;15MG</u>
> ADD >			
> ADD >	<u>AB</u>	SQUIBB	<u>50MG;25MG</u>
> ADD >			
> ADD >	<u>AB</u>	<u>CAPTOPRIL AND HYDROCHLOROTHIAZIDE</u>	<u>50MG;25MG</u>
> ADD >		DANBURY PHARMA	
> ADD >	<u>AB</u>	ENDO LABS	<u>25MG;15MG</u>
> ADD >			
> ADD >	<u>AB</u>		<u>25MG;25MG</u>
> ADD >			
> ADD >	<u>AB</u>		<u>50MG;15MG</u>
> ADD >			
> ADD >	<u>AB</u>		<u>50MG;25MG</u>
> ADD >			

N18709 001	
OCT 12, 1984	
N18709 002	
OCT 12, 1984	
N18709 004	
OCT 12, 1984	
N18709 003	
OCT 12, 1984	
N74832 001	
DEC 29, 1997	
N74788 001	
DEC 29, 1997	
N74788 002	
DEC 29, 1997	
N74788 004	
DEC 29, 1997	
N74788 003	
DEC 29, 1997	

CARBAMAZEPINECAPSULE, EXTENDED RELEASE; ORAL
CARBATROL

+ ATHENA	200MG	N20712 001
		SEP 30, 1997
+	300MG	N20712 002
		SEP 30, 1997

TABLET; ORAL

<u>AB</u>	<u>EPITOL</u>	<u>200MG</u>	N70541 001
	LEMMON		SEP 17, 1986
<u>AB</u>	TEVA	<u>200MG</u>	N70541 001
			SEP 17, 1986

TABLET, CHEWABLE; ORAL

<u>AB</u>	<u>EPITOL</u>	<u>100MG</u>	N73524 001
	LEMMON		JUL 29, 1992
<u>AB</u>	TEVA	<u>100MG</u>	N73524 001
			JUL 29, 1992

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	<u>LEMMON</u>	<u>10MG;100MG</u>	<u>N73618 001</u>
			<u>AUG 28, 1992</u>
<u>AB</u>		<u>25MG;100MG</u>	<u>N73589 001</u>
			<u>AUG 28, 1992</u>
<u>AB</u>		<u>25MG;250MG</u>	<u>N73607 001</u>
			<u>AUG 28, 1992</u>
<u>AB</u>	TEVA	<u>10MG;100MG</u>	<u>N73618 001</u>
			<u>AUG 28, 1992</u>
<u>AB</u>		<u>25MG;100MG</u>	<u>N73589 001</u>
			<u>AUG 28, 1992</u>
<u>AB</u>		<u>25MG;250MG</u>	<u>N73607 001</u>
			<u>AUG 28, 1992</u>

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

<u>AA</u>	AMIDE PHARM	<u>350MG</u>	<u>N40188 001</u>
			<u>MAR 07, 1997</u>
<u>AA</u>	VINTAGE PHARMS	<u>350MG</u>	<u>N40245 001</u>
			<u>SEP 08, 1997</u>

CARVEDILOL

TABLET; ORAL

COREG

SMITHKLINE BEECHAM	3.125MG	<u>N20297 004</u>
		<u>MAY 29, 1997</u>

CEFACTOR

CAPSULE; ORAL

CEFACTOR

<u>AB</u>	RANBAXY	<u>EQ 250MG BASE</u>	<u>N64156 001</u>
			<u>AUG 28, 1997</u>
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N64156 002</u>
			<u>AUG 28, 1997</u>

POWDER FOR RECONSTITUTION; ORAL

CEFACTOR

<u>AB</u>	RANBAXY	<u>EQ 125MG BASE/5ML</u>	<u>N64166 001</u>
			<u>OCT 02, 1997</u>

CEFACTOR

POWDER FOR RECONSTITUTION; ORAL

CEFACTOR

<u>AB</u>	RANBAXY	<u>EQ 187MG BASE/5ML</u>	<u>N64165 001</u>
			<u>OCT 02, 1997</u>
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>N64164 001</u>
			<u>OCT 02, 1997</u>
<u>AB</u>		<u>EQ 375MG BASE/5ML</u>	<u>N64155 001</u>
			<u>OCT 02, 1997</u>

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

<u>AP</u>	<u>LEMMON</u>	<u>EQ 250MG BASE/VIAL</u>	<u>N63016 001</u>
			<u>MAR 14, 1989</u>
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>N63016 002</u>
			<u>MAR 14, 1989</u>
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>N63016 003</u>
			<u>MAR 14, 1989</u>
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>N63018 001</u>
			<u>MAR 05, 1990</u>
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>N63018 002</u>
			<u>MAR 05, 1990</u>
<u>AP</u>	TEVA	<u>EQ 250MG BASE/VIAL</u>	<u>N63016 001</u>
			<u>MAR 14, 1989</u>
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>N63016 002</u>
			<u>MAR 14, 1989</u>
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>N63016 003</u>
			<u>MAR 14, 1989</u>
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>N63018 001</u>
			<u>MAR 05, 1990</u>
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>N63018 002</u>
			<u>MAR 05, 1990</u>

> ADD >

CEFDINIR

> ADD >

CAPSULE; ORAL

> ADD >

OMNICEF

> ADD >

+ PARKE DAVIS 300MG

> ADD >

N50739 001
DEC 04, 1997

> ADD >

POWDER FOR RECONSTITUTION; ORAL

> ADD >

OMNICEF

> ADD >

+ PARKE DAVIS 125MG/5ML

> ADD >

N50749 001
DEC 04, 1997

CEFPODOXIME PROXETILGRANULE, FOR RECONSTITUTION; ORAL
VANTIN

> <u>ADD</u> >	PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML	N50675 001
> <u>ADD</u> >			AUG 07, 1992
> <u>ADD</u> >	+	EQ 100MG BASE/5ML	N50675 002
> <u>ADD</u> >			AUG 07, 1992
> <u>DLT</u> >	UPJOHN	EQ 50MG BASE/5ML	N50675 001
> <u>DLT</u> >			AUG 07, 1992
> <u>DLT</u> >	*	EQ 100MG BASE/5ML	N50675 002
> <u>DLT</u> >			AUG 07, 1992

CEFTRIAZONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION

ROCEPHIN KIT

+	ROCHE	EQ 1GM BASE/VIAL,N/A;N/A,	
		1%	N50585 006
			MAY 08, 1996
+		EQ 500MG BASE/VIAL,N/A;N/A,	
		1%	N50585 007
			MAY 08, 1996

CEFUROXIME AXETIL

POWDER FOR RECONSTITUTION; ORAL

CEFTIN

*	GLAXO WELLCOME	EQ 125MG BASE/5ML	N50672 001
			JUN 30, 1994
		EQ 125MG BASE/5ML	N50672 001
			JUN 30, 1994
+		EQ 250MG BASE/5ML	N50672 002
			APR 29, 1997

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM

<u>AB</u>	HANFORD GC	EQ 750MG BASE/VIAL	N64125 001
			MAY 30, 1997
<u>AP</u>		EQ 1.5GM BASE/VIAL	N64125 002
			MAY 30, 1997
<u>AP</u>		EQ 7.5GM BASE/VIAL	N64124 001
			MAY 30, 1997

CEFUROXIME SODIUM

INJECTABLE; INJECTION

KEFUROX

<u>AB</u>	LILLY	EQ 750MG BASE/VIAL	N62591 001
			JAN 10, 1986
<u>AB</u>		EQ 750MG BASE/VIAL	N62592 001
			JAN 10, 1986
<u>AP</u>		EQ 750MG BASE/VIAL	N62591 001
			JAN 10, 1986
<u>AP</u>		EQ 750MG BASE/VIAL	N62592 001
			JAN 10, 1986
	<u>ZINACEF</u>		
<u>AB</u>	+ GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558 002
<u>AP</u>	*	EQ 750MG BASE/VIAL	OCT 19, 1983
			N50558 002
			OCT 19, 1983

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

<u>AB</u>	APOTHECON	EQ 250MG BASE	N62973 001
			NOV 08, 1988
<u>AB</u>		EQ 500MG BASE	N62974 001
			NOV 23, 1988
@		EQ 250MG BASE	N62973 001
@		EQ 500MG BASE	NOV 08, 1988
			N62974 001
			NOV 23, 1988
<u>AB</u>	PUREPAC PHARM	EQ 250MG BASE	N62809 001
			APR 22, 1987
<u>AB</u>		EQ 500MG BASE	N62809 002
			APR 22, 1987
@		EQ 250MG BASE	N62809 001
@		EQ 500MG BASE	APR 22, 1987
			N62809 002
			APR 22, 1987

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

APOTHECON

EQ 1GM BASE/VIAL	N62724 001
	DEC 23, 1986
EQ 2GM BASE/VIAL	N62724 002
	DEC 23, 1986

CEPHAPIRIN SODIUMINJECTABLE; INJECTION
CEFADYL

@ APOTHECON

EQ 1GM BASE/VIAL

N62724 001

DEC 23, 1986

@

EQ 2GM BASE/VIAL

N62724 002

DEC 23, 1986

CEPHRADINE

CAPSULE; ORAL

CEPHRADINE

@ ZENITH GOLDLINE

250MG

N62762 001

MAR 06, 1987

@

500MG

N62762 002

MAR 06, 1987

AB ZENITH LABS250MGN62762 001MAR 06, 1987AB500MGN62762 002MAR 06, 1987CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

@ BAYER

0.05MG

N20740 001

JUN 26, 1997

@

0.1MG

N20740 002

JUN 26, 1997

0.2MG

N20740 003

JUN 26, 1997

+

0.3MG

N20740 004

JUN 26, 1997

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

OPHTHOCORT

* PARKE DAVIS

10MG/GM; 5MG/GM;

10,000 UNITS/GM

N50201 002

@

10MG/GM; 5MG/GM;

10,000 UNITS/GM

N50201 002

> ADD >> ADD >> ADD >> DLT >> DLT >> DLT >> DLT >> DLT >> ADD >> DLT >CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

CHLOROMYCETIN PALMITATE

PARKE DAVIS

EQ 150MG BASE/5ML

N62301 001

@

EQ 150MG BASE/5ML

N62301 001

CHLORDIAZEPOXIDE

CAPSULE; EXTENDED RELEASE; ORAL

LIBRELEAS

@ ICN

30MG

N17813 001

SEP 12, 1983

> ADD >> ADD >> DLT >> DLT >

@ ROCHE

30MG

N17813 001

SEP 12, 1983

TABLET; ORAL

LIBRITABS

ROCHE

5MG

N85482 001

10MG

N85481 001

25MG

N85488 001

+

5MG

N85482 001

@

10MG

N85481 001

@

25MG

N85488 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

@ ZENITH GOLDLINE

5MG

N83741 001

@

10MG

N83742 001

@

25MG

N83570 001

ABZENITH LABS5MGN83741 001AB10MGN83742 001AB25MGN83570 001

LIBRIUM

@ ICN

5MG

N12249 002

@

10MG

N12249 001

@

25MG

N12249 003

@ ROCHE

5MG

N12249 002

@

10MG

N12249 001

@

25MG

N12249 003

INJECTABLE; INJECTION

LIBRIUM

+ ICN

100MG/AMP

N12301 001

* ROCHE

100MG/AMP

N12301 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	LEMMON	0.12%
AT	TEVA	0.12%

N74522 001
DEC 15, 1995
N74522 001
DEC 15, 1995

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NESACAINE-MPF

AP	* ASTRA	2%
AP	+	2%
AP	*	3%
AP	+	3%
	@	2%
	@	3%

N09435 003
N09435 006
MAY 02, 1996
N09435 004
N09435 007
MAY 02, 1996
N09435 003
N09435 004

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

AA	KV PHARM	4MG
	@	4MG
	@ ZENITH GOLDLINE	4MG
	@ ZENITH LABS	4MG
AA	KLOROMIN	4MG
	HALSEY	4MG
	@	4MG

N87164 001
N87164 001
N80779 001
N80779 001
N83629 001
N83629 001

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HCL

	@ ZENITH GOLDLINE	10MG
	@	25MG
	@	50MG
	@	100MG
	@	200MG
BP	ZENITH LABS	10MG
BP		25MG
BP		50MG

N83549 001
N83549 002
N83549 003
N83574 001
N83575 001
N83549 001
N83549 002
N83549 003

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HCL

BP	ZENITH LABS	100MG
BP		200MG

N83574 001
N83575 001

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ ZENITH GOLDLINE 100MG

AB	ZENITH LABS	250MG
AB		100MG

N88840 001
OCT 25, 1984
N87353 001
N88840 001
OCT 25, 1984
N87353 001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

@ LEMMON 50MG

AB	PUREPAC PHARM	25MG
AB		50MG

@ 25MG

@ 50MG

@ TEVA 50MG

AB	ZENITH GOLDLINE	25MG
AB		50MG

@ 25MG

@ 50MG

AB	ZENITH LABS	25MG
AB		50MG
AB		50MG

@ 25MG

N88651 001
MAY 30, 1985
N88139 001
JUL 16, 1986
N88140 001
AUG 11, 1983
N88139 001
JUL 16, 1986
N88140 001
AUG 11, 1983
N88651 001
MAY 30, 1985
N88164 001
JAN 09, 1984
N87176 001
N87555 001
N87947 001
FEB 27, 1984
N88164 001
JAN 09, 1984
N87176 001
N87947 001
FEB 27, 1984
N87555 001

CHLORTHALIDONE

TABLET; ORAL			
THALITONE			
BX	HORUS THERAP	25MG	N88051 001
			NOV 12, 1982
	*	15MG	N19574 001
			DEC 20, 1988
BX	MONARCH PHARMS	25MG	N19574 002
			FEB 12, 1992
	+	15MG	N19574 001
			DEC 20, 1988
	@	25MG	N88051 001
			NOV 12, 1982

CHLORZOXAZONE

TABLET; ORAL			
CHLORZOXAZONE			
AA	LEMMON	500MG	N89859 001
			MAY 04, 1988
AA	TEVA	500MG	N89859 001
			MAY 04, 1988
PARAFLEX			
AA	* JOHNSON RW	250MG	N11300 003
	@	250MG	N11300 003

CHOLESTYRAMINE

POWDER; ORAL			
CHOLESTYRAMINE			
AB	BAKER NORTON	EQ 4GM RESIN/PACKET	N74771 001
			JUL 09, 1997
AB		EQ 4GM RESIN/SCOOPFUL	N74771 002
			JUL 09, 1997

CICLOPIROX

GEL; TOPICAL			
LOPROX			
+	HOECHST MARION RSSL	0.77%	N20519 001
			JUL 21, 1997

CIMETIDINE

TABLET; ORAL			
CIMETIDINE			
AB	ENDO LABS	200MG	N74281 001
			MAY 17, 1994
AB		300MG	N74281 002
			MAY 17, 1994
AB		400MG	N74281 003
			MAY 17, 1994
AB		800MG	N74329 001
			MAY 17, 1994
AB	ENDO PHARMS	200MG	N74281 001
			MAY 17, 1994
AB		300MG	N74281 002
			MAY 17, 1994
AB		400MG	N74281 003
			MAY 17, 1994
AB		800MG	N74329 001
			MAY 17, 1994
AB	LEMMON	200MG	N74365 001
			FEB 28, 1995
AB		300MG	N74365 002
			FEB 28, 1995
AB		400MG	N74365 003
			FEB 28, 1995
AB		800MG	N74365 004
			FEB 28, 1995
AB	SIDMAK LABS NJ	200MG	N74568 001
			FEB 27, 1997
AB		300MG	N74568 002
			FEB 27, 1997
AB		400MG	N74568 003
			FEB 27, 1997
AB		800MG	N74566 001
			FEB 27, 1997
AB	TEVA	200MG	N74365 001
			FEB 28, 1995
AB		300MG	N74365 002
			FEB 28, 1995
AB		400MG	N74365 003
			FEB 28, 1995
AB		800MG	N74365 004
			FEB 28, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HCL

<u>AP</u>	ABBOTT	<u>EQ 300MG BASE/2ML</u>	N74296 001 MAR 28, 1997
<u>AP</u>		<u>EQ 300MG BASE/2ML</u>	N74412 001 MAR 28, 1997
<u>AP</u>	ENDO LABS	<u>EQ 300MG BASE/2ML</u>	N74005 001 AUG 31, 1994
<u>AP</u>	ENDO PHARMS	<u>EQ 300MG BASE/2ML</u>	N74005 001 AUG 31, 1994
<u>AP</u>	GENSIA	<u>EQ 300MG BASE/2ML</u>	N74252 001 NOV 26, 1997
<u>AP</u>	SANOFI	<u>EQ 300MG BASE/2ML</u>	N74296 001 MAR 28, 1997
<u>AP</u>		<u>EQ 300MG BASE/2ML</u>	N74412 001 MAR 28, 1997

SOLUTION; ORAL

CIMETIDINE HCL

<u>AA</u>	ENDO LABS	<u>EQ 300MG BASE/5ML</u>	N74251 001 DEC 22, 1994
<u>AA</u>	ENDO PHARMS	<u>EQ 300MG BASE/5ML</u>	N74251 001 DEC 22, 1994
<u>AA</u>	HI TECH PHARMA	<u>EQ 300MG BASE/5ML</u>	N74664 001 OCT 28, 1997
<u>AA</u>	MORTON GROVE	<u>EQ 300MG BASE/5ML</u>	N74757 001 OCT 17, 1997
<u>AA</u>	PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	N74553 001 JAN 27, 1997
<u>AA</u>	ROXANE	<u>EQ 300MG BASE/5ML</u>	N74541 001 AUG 05, 1997

CIPROFLOXACIN

POWDER FOR RECONSTITUTION; ORAL

CIPRO

	BAYER	250MG/5ML	N20780 001 SEP 26, 1997
+		500MG/5ML	N20780 002 SEP 26, 1997

CISAPRIDE MONOHYDRATE

TABLET; ORAL

PROPULSID QUICKSOLV

+ JANSSEN

EQ 20MG BASE

N20767 001
NOV 07, 1997CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATEAA LEMMONEQ 0.5MG BASE/5MLN73399 001
JUN 30, 1994> ADD >
> ADD >AA SILARXEQ 0.5MG BASE/5MLN74884 001
DEC 17, 1997AA TEVAEQ 0.5MG BASE/5MLN73399 001
JUN 30, 1994

TABLET; ORAL

CLEMASTINE FUMARATEAB LEMMON2.68MGN73283 001
JAN 11, 1992

@

1.34MGN73282 001
JAN 11, 1992AB TEVA2.68MGN73283 001
JAN 31, 1992

@

1.34MGN73282 001
JAN 31, 1992CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATEAP QUAD PHARMSEQ 150MG BASE/MLN62795 001
DEC 21, 1987

@

EQ 150MG BASE/ML

N62795 001
DEC 21, 1987

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATEAT FOUGERAEQ 1% BASEN64159 001
JUN 05, 1997AT LEMMONEQ 1% BASEN62930 001
JUN 28, 1989AT MORTON GROVEEQ 1% BASEN63304 001
JUL 15, 1997

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT TEVA EQ 1% BASE

N62930 001
JUN 28, 1989CLOBETASOL PROPIONATE

CREAM; TOPICAL

CORMAX

AB HEALTHPOINT 0.05%

N74220 001
MAY 16, 1997

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB STIEFEL 0.05%

N75027 001
OCT 31, 1997TEMOVATE

AB + GLAXO WELLCOME 0.05%

N20337 001
APR 29, 1994CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM* CTR LABS 0.1%
+ EM INDS 0.1%N17765 001
N17765 001CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HCL

AB INVAMED 25MG

N74953 001
JUN 25, 1997

AB 50MG

N74953 002
JUN 25, 1997

AB 75MG

N74953 003
JUN 25, 1997

> DLT > AB LEMMON 25MG

N74958 001
AUG 26, 1997

> DLT > AB 50MG

N74958 002
AUG 26, 1997

> DLT > AB 75MG

N74958 003
AUG 26, 1997

> DLT > AB

> DLT > AB

> DLT > AB

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HCL

AB NOVOPHARM 25MG

N74849 001

AB 50MG

APR 04, 1997

AB 75MG

N74849 002

> ADD > AB TEVA 25MG

APR 04, 1997

> ADD > AB 50MG

N74849 003

> ADD > AB 50MG

APR 04, 1997

> ADD > AB 75MG

N74958 001

> ADD > AB 75MG

AUG 26, 1997

> ADD > AB 75MG

N74958 002

> ADD > AB 75MG

AUG 26, 1997

> ADD > AB 75MG

N74958 003

> ADD > AB 75MG

AUG 26, 1997

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB ALPHAPHARM 0.5MG

N74940 001

AB 1MG

OCT 30, 1997

AB 2MG

N74940 002

AB EON 0.5MG

OCT 30, 1997

AB 1MG

N74940 003

AB 2MG

OCT 30, 1997

AB INVAMED 0.5MG

N74979 001

AB 1MG

AUG 29, 1997

AB 2MG

N74979 002

AB WATSON LABS 0.5MG

AUG 29, 1997

> ADD > AB 0.5MG

N74979 003

> ADD > AB 1MG

AUG 29, 1997

> ADD > AB 2MG

N74925 001

> ADD > AB 2MG

SEP 30, 1997

> ADD > AB 2MG

N74925 002

> ADD > AB 2MG

SEP 30, 1997

> ADD > AB 2MG

N74925 003

> ADD > AB 2MG

SEP 30, 1997

> ADD > AB 2MG

N74964 001

> ADD > AB 2MG

DEC 30, 1997

> ADD > AB 2MG

N74964 002

> ADD > AB 2MG

DEC 30, 1997

> ADD > AB 2MG

N74964 003

> ADD > AB 2MG

DEC 30, 1997

KLONOPIN

+ ROCHE 0.125MG

N17533 005

APR 09, 1997

CLONAZEPAM

TABLET; ORAL			
KLONOPIN			
	ROCHE	0.25MG	N17533 006
			APR 09, 1997
> ADD >	KLONOPIN RAPIDLY DISINTEGRATING		
> ADD >	+ ROCHE	0.125MG	N20813 001
> ADD >			DEC 23, 1997
> ADD >		0.25MG	N20813 002
> ADD >			DEC 23, 1997
> ADD >		0.5MG	N20813 003
> ADD >			DEC 23, 1997
> ADD >		1MG	N20813 004
> ADD >			DEC 23, 1997
> ADD >	+	2MG	N20813 005
> ADD >			DEC 23, 1997

CLOPIDOGREL BISULFATE

TABLET; ORAL		
PLAVIX		
	+ SANOFI	EQ 75MG BASE

	N20839 001
	NOV 17, 1997

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL			
<u>CLORAZEPATE DIPOTASSIUM</u>			
AB	PUREPAC PHARM	7.5MG	N71925 001
			APR 25, 1988
AB		15MG	N71926 001
			APR 25, 1988
	@	7.5MG	N71925 001
			APR 25, 1988
	@	15MG	N71926 001
			APR 25, 1988

TABLET; ORAL			
<u>CLORAZEPATE DIPOTASSIUM</u>			
AB	PUREPAC PHARM	3.75MG	N72330 001
			AUG 08, 1988
AB		7.5MG	N72331 001
			AUG 08, 1988
AB		15MG	N72332 001
			AUG 08, 1988

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL			
<u>CLORAZEPATE DIPOTASSIUM</u>			
	@ PUREPAC PHARM	3.75MG	N72330 001
			AUG 08, 1988
	@	7.5MG	N72331 001
			AUG 08, 1988
	@	15MG	N72332 001
			AUG 08, 1988

CLOZAPINE

TABLET; ORAL			
<u>CLOZAPINE</u>			
AB	ZENITH GOLDLINE	25MG	N74949 001
			NOV 26, 1997
AB		100MG	N74949 002
			NOV 26, 1997

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL			
<u>PROMETHAZINE HCL AND CODEINE PHOSPHATE</u>			
AA	HALSEY	10MG/5ML; 6.25MG/5ML	N88739 001
			DEC 23, 1988
	@	10MG/5ML; 6.25MG/5ML	N88739 001
			DEC 23, 1988
AA	HI TECH PHARMA	10MG/5ML; 6.25MG/5ML	N40151 001
			AUG 26, 1997

CORTICOTROPIN

INJECTABLE; INJECTION			
<u>ACTHAR</u>			
AP	Rhone-Poulenc Rorer	40 UNITS/VIAL	N07504 003
		25 UNITS/VIAL	N07504 002
	@	25 UNITS/VIAL	N07504 002
	@	40 UNITS/VIAL	N07504 003
AP	<u>CORTICOTROPIN</u>	40 UNITS/VIAL	N88772 001
	STERIS		NOV 21, 1984
	+	40 UNITS/VIAL	N88772 001
			NOV 21, 1984

CORTISONE ACETATE

TABLET; ORAL			
CORTISONE ACETATE			
BP	PUREPAC PHARM	25MG	N80493 001
@		25MG	N80493 001
@	ZENITH GOLDLINE	25MG	N80630 001
@		25MG	N83536 001
@	ZENITH LABS	25MG	N80630 001
@		25MG	N83536 001

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION			
INTAL			
*	FISONS	0.8MG/INH	N18887 001
			DEC 05, 1985
+	RHONE POULENC RORER	0.8MG/INH	N18887 001
			DEC 05, 1985

CAPSULE; INHALATION			
INTAL			
*	FISONS	20MG	N16990 001
+	RHONE POULENC RORER	20MG	N16990 001

SOLUTION; INHALATION			
INTAL			
AN	* FISONS	10MG/ML	N18596 001
			MAY 28, 1982
AN	+ RHONE POULENC RORER	10MG/ML	N18596 001
			MAY 28, 1982

SOLUTION/DROPS; OPHTHALMIC			
OPTICROM			
@	FISONS	4%	N18155 001
			OCT 03, 1984
@	RHONE POULENC RORER	4%	N18155 001
			OCT 03, 1984

SPRAY, METERED; NASAL			
NASALCROM			
*	FISONS	5.2MG/SPRAY	N18306 001
			MAR 18, 1983

CYANOCOBALAMIN

INJECTABLE; INJECTION			
COBAVITE			
AP	STERIS	0.1MG/ML	N83013 001
AP		1MG/ML	N83064 001
@		0.1MG/ML	N83013 001
@		1MG/ML	N83064 001
CYANOCOBALAMIN			
AP	SOLOPAK	1MG/ML	N87551 001
			FEB 29, 1984
@		1MG/ML	N87551 001
			FEB 29, 1984
AP	STERIS	0.1MG/ML	N83120 001
@		0.1MG/ML	N83120 001

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A			
DICOPAC KIT			
	MEDI PHYSICS	N/A;N/A;N/A	N17406 001
	NYCOMED AMERSHAM	N/A;N/A;N/A	N17406 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC			
AK-PENTOLATE			
AT	AKORN	1%	N85555 001
@		1%	N85555 001
AKPENTOLATE			
AT	AKORN	1%	N40164 001
			JAN 13, 1997
AT		2%	N40165 001
			JAN 13, 1997
CYCLOGYL			
AT	+ ALCON	2%	N84108 001

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION			
CYCLOPHOSPHAMIDE			
AP	ASTA	100MG/VIAL	N88371 001
			JUL 03, 1986
AP		200MG/VIAL	N88372 001
			JUL 03, 1986

CYCLOPHOSPHAMIDEINJECTABLE; INJECTION
CYCLOPHOSPHAMIDE

AP	ASTA	500MG/VIAL	N88373 001
			JUL 03, 1986
AP		1GM/VIAL	N88374 001
			SEP 24, 1986
AP	ELKINS SINN	100MG/VIAL	N88371 001
			JUL 03, 1986
AP		200MG/VIAL	N88372 001
			JUL 03, 1986
AP		500MG/VIAL	N88373 001
			JUL 03, 1986
AP		1GM/VIAL	N88374 001
			SEP 24, 1986
<u>CYTOXAN</u>			
AP	* BRISTOL MYERS SQUIRE	100MG/VIAL	N12142 001
AP	+	200MG/VIAL	N12142 002
AP	+	500MG/VIAL	N12142 003
AP	+	1GM/VIAL	N12142 004
			AUG 30, 1982
AP	*	2GM/VIAL	N12142 005
			AUG 30, 1982
	@	100MG/VIAL	N12142 001
	@	200MG/VIAL	N12142 002
	@	500MG/VIAL	N12142 003
	@	1GM/VIAL	N12142 004
			AUG 30, 1982
	@	2GM/VIAL	N12142 005
			AUG 30, 1982

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HCL

AA	HALSEY	4MG	N89057 001
			JUL 03, 1986
	@	4MG	N89057 001
			JUL 03, 1986

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

AP	RHONE POULENC RORER	EQ 20MG BASE/VIAL	N61876 001
	@	EQ 20MG BASE/VIAL	N61876 001

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

AP	* WYETH AYERST	EQ 20MG BASE/VIAL	N50484 001
	@	EQ 20MG BASE/VIAL	N50484 001
AP	DAUNORUBICIN HCL	EQ 20MG BASE/VIAL	N64103 001
	BEDFORD		FEB 03, 1995
	+	EQ 20MG BASE/VIAL	N64103 001
			FEB 03, 1995

DELAVIDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

+ PHARMACIA AND UPJOHN 100MG

N20705 001
APR 04, 1997

DESERPIDINE

TABLET; ORAL

HARMONYL

* ABBOTT

@

0.25MG

0.25MG

N10796 002

N10796 002

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HCL

AB	SIDMAK LABS NJ	100MG	N71803 001
			MAY 29, 1997
AB		150MG	N71804 001
			MAY 29, 1997

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

AP	+ RHONE POULENC RORER	0.004MG/ML	N18938 001
			MAR 30, 1984

DESMOPRESSIN ACETATE

AP	GENSIA	0.004MG/ML	N74888 001
			OCT 15, 1997

DESMOPRESSIN ACETATESPRAY, METERED; NASAL
DDAVP

* RHONE-POULENC RORER	0.01MG/SPRAY	N17922 002
		FEB 06, 1989
@	0.01MG/SPRAY	N17922 002
		FEB 06, 1989
+	0.01MG/SPRAY	N17922 003
		AUG 07, 1996

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	ALPHARMA	0.5MG/5ML	N88997 001
			OCT 10, 1986
@		0.5MG/5ML	N88997 001
			OCT 10, 1986

GEL, TOPICAL

DECADERM

* MERCK SHARP DOHME	0.1%	N13538 001
@	0.1%	N13538 001

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXASPORIN

AT	BAUSCH AND LOMB	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N64063 001
			JUL 25, 1994

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	BAUSCH AND LOMB	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N64063 001
			JUL 25, 1994

DEXAMETHASONE SODIUM PHOSPHATE

CREAM, TOPICAL

DECADRON

* MERCK SHARP DOHME	EQ 0.1% PHOSPHATE	N11983 002
@	EQ 0.1% PHOSPHATE	N11983 002

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	STERIS	EQ 4MG PHOSPHATE/ML	N84355 001
----	--------	---------------------	------------

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

@	STERIS	EQ 4MG PHOSPHATE/ML	N84355 001
---	--------	---------------------	------------

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

> DLT >			
> DLT >	AA	REXAR	5MG
> DLT >			10MG
> ADD >			
> ADD >	AA	DEXTROSTAT	5MG
> ADD >		SHIRE RICHWOOD	10MG
> ADD >		+	

N84051 001

N84051 002

N84051 001

N84051 002

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC

CONTAINER			
MCGAW	5GM/100ML; 37MG/100ML	N19699 001	
			SEP 29, 1989
@	5GM/100ML; 37MG/100ML	N19699 001	
			SEP 29, 1989

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC

CONTAINER			
AP	MCGAW	5GM/100ML; 75MG/100ML	N19699 002
			SEP 29, 1989
@		5GM/100ML; 75MG/100ML	N19699 002
			SEP 29, 1989

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC

CONTAINER			
MCGAW	5GM/100ML; 110MG/100ML	N19699 003	
			SEP 29, 1989
@		5GM/100ML; 110MG/100ML	N19699 003
			SEP 29, 1989

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC

CONTAINER			
MCGAW	5GM/100ML; 220MG/100ML	N19699 005	
			SEP 29, 1989
@		5GM/100ML; 220MG/100ML	N19699 005
			SEP 29, 1989

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE0.075% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML; 75MG/100ML; 200MG/100ML	N18268 009
@		5GM/100ML; 75MG/100ML; 200MG/100ML	N18268 009

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE0.15% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML; 150MG/100ML; 200MG/100ML	N18268 004
@		5GM/100ML; 150MG/100ML; 200MG/100ML	N18268 004

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE0.224% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML; 220MG/100ML; 200MG/100ML	N18268 005
@		5GM/100ML; 220MG/100ML; 200MG/100ML	N18268 005

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE0.3% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML; 300MG/100ML; 200MG/100ML	N18268 006
@		5GM/100ML; 300MG/100ML; 200MG/100ML	N18268 006

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE0.075% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML; 75MG/100ML; 330MG/100ML	N18268 011
@		5GM/100ML; 75MG/100ML; 330MG/100ML	N18268 011

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE0.15% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML; 150MG/100ML; 330MG/100ML	N18268 012
@		5GM/100ML; 150MG/100ML; 330MG/100ML	N18268 012

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE0.22% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML; 220MG/100ML; 330MG/100ML	N18268 013
			JAN 18, 1986

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE0.22% IN PLASTIC CONTAINER

@	MCGAW	5GM/100ML; 220MG/100ML; 330MG/100ML	N18268 013
			JAN 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE0.30% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML; 300MG/100ML; 330MG/100ML	N18268 014
@		5GM/100ML; 300MG/100ML; 330MG/100ML	N18268 014

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE0.075%

AP	MCGAW	5GM/100ML; 75MG/100ML; 450MG/100ML	N18268 010
@		5GM/100ML; 75MG/100ML; 450MG/100ML	N18268 010

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE0.15% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML; 150MG/100ML; 450MG/100ML	N18268 001
@		5GM/100ML; 150MG/100ML; 450MG/100ML	N18268 001

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE0.22% IN PLASTIC CONTAINER

	MCGAW	5GM/100ML; 220MG/100ML; 450MG/100ML	N18268 002
@		5GM/100ML; 220MG/100ML; 450MG/100ML	N18268 002

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE0.3% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML; 300MG/100ML; 450MG/100ML	N18268 003
@		5GM/100ML; 300MG/100ML; 450MG/100ML	N18268 003

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	MCGAW	10GM/100ML; 900MG/100ML	N18047 001
@		10GM/100ML; 900MG/100ML	N18047 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML; 900MG/100ML	N18026 001
----	-------	------------------------	------------

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ MCGAW 5GM/100ML;900MG/100ML N18026 001

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLONIN

KNOLL PHARM

1MG

N12302 005

2MG

N12302 002

4MG

N12302 004

*

1MG

N12302 005

@

2MG

N12302 002

@

4MG

N12302 004

DIAZEPAM

GEL; RECTAL

DIASTAT

+ ATHENA

2.5MG/0.5ML

N20648 001

JUL 29, 1997

5MG/ML

N20648 002

JUL 29, 1997

10MG/2ML

N20648 003

JUL 29, 1997

15MG/3ML

N20648 004

JUL 29, 1997

+

20MG/4ML

N20648 005

JUL 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

AP ABBOTT

5MG/ML

N72079 001

DEC 20, 1988

AP STERIS

5MG/ML

N70912 001

AUG 28, 1986

@

5MG/ML

N70912 001

AUG 28, 1986

AP STERLING WINTHROP

5MG/ML

N72079 001

DEC 20, 1988

TABLET; ORAL

DIAZEPAM

AB HALSEY

2MG

N70987 001

AUG 15, 1986

DIAZEPAM

TABLET; ORAL

DIAZEPAM

AB HALSEY

5MG

N70996 001

AUG 15, 1986

AB

10MG

N70956 001

AUG 15, 1986

@

2MG

N70987 001

AUG 15, 1986

@

5MG

N70996 001

AUG 15, 1986

@

10MG

N70956 001

AUG 15, 1986

AB ZENITH GOLDLINE

10MG

N70362 001

SEP 04, 1985

@

2MG

N70360 001

SEP 04, 1985

@

5MG

N70361 001

SEP 04, 1985

@

10MG

N70362 001

SEP 04, 1985

@ ZENITH LABS

2MG

N70360 001

SEP 04, 1985

@

5MG

N70361 001

SEP 04, 1985

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB COPLEY PHARM

25MG

N74459 001

JUN 25, 1997

AB

50MG

N74459 002

JUN 25, 1997

AB

75MG

N74459 003

JUN 25, 1997

> ADD >

DICLOFENAC SODIUM; MISOPROSTOL

> ADD >

TABLET, DELAYED RELEASE; ORAL

> ADD >

ARTHROTEC

> ADD >

+ SEARLE

50MG;0.2MG

N20607 001

> ADD >

+

75MG;0.2MG

N20607 002

> ADD >

DEC 24, 1997

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL
DICYCLOMINE HCL
AB WEST WARD 10MG N40204 001
 FEB 28, 1997

SYRUP; ORAL
BENTYL
AA * HOECHST MARION RSSL 10MG/5ML N07961 002
 OCT 15, 1984
 + 10MG/5ML N07961 002
 OCT 15, 1984

DICYCLOMINE HCL
AA ALPHARMA 10MG/5ML N84479 001
 @ 10MG/5ML N84479 001

DIETHYLSTILBESTROL

TABLET; ORAL
DIETHYLSTILBESTROL
 LILLY 1MG N04041 004
 * 5MG N04041 005
 @ 1MG N04041 004
 @ 5MG N04041 005

STILBESTROL
TABLCAPS 0.5MG N83004 001
 @ 0.5MG N83004 001

STILBESTROL TAB
 SMITH MILLER PATCH 25MG N06194 001

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL
AB DANBURY PHARMA 250MG N74400 001
 JUL 17, 1997
AB 500MG N74400 002
 JUL 17, 1997

DIGOXIN

INJECTABLE; INJECTION
DIGOXIN
AP ABBOTT 0.25MG/ML N40093 001
 MAY 16, 1996

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN
AP SANOFI WINTHROP 0.25MG/ML N40093 001
 MAY 16, 1996

DIGOXIN PEDIATRIC
AP ABBOTT 0.1MG/ML N40092 001
 APR 25, 1996

AP SANOFI WINTHROP 0.1MG/ML N40092 001
 APR 25, 1996

TABLET; ORAL

LANOXIN
 @ GLAXO WELLCOME 0.0625MG N20405 001
 SEP 30, 1997
 0.125MG N20405 002
 SEP 30, 1997
 @ 0.1875MG N20405 003
 SEP 30, 1997
 + 0.25MG N20405 004
 SEP 30, 1997
 @ 0.375MG N20405 005
 SEP 30, 1997
 @ 0.5MG N20405 006
 SEP 30, 1997

DIHYDROERGOTAMINE MESYLATE

> ADD >
 > ADD >
 > ADD >
 > ADD >

SPRAY, METERED; NASAL
 MIGRANAL
 + NOVARTIS 0.5MG/INH N20148 001
 DEC 08, 1997

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR
AB * HOECHST MARION RSSL 60MG N19471 001
 JAN 23, 1989
AB1 + 60MG N19471 001
 JAN 23, 1989
AB * 90MG N19471 002
 JAN 23, 1989
AB1 + 90MG N19471 002
 JAN 23, 1989

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM SRAB * HOECHST MARION RESE 120MG

N19471 003

JAN 23, 1989

AB1 + 120MG

N19471 003

JAN 23, 1989

DILACOR XRAB2 + WATSON LABS 120MG

N20092 001

MAY 29, 1992

AB2 + 180MG

N20092 002

MAY 29, 1992

AB2 + 240MG

N20092 003

MAY 29, 1992

DILTIAZEM HCLAB2 ANDRX 120MG

N74852 001

OCT 10, 1997

AB2 180MG

N74852 002

OCT 10, 1997

AB2 240MG

N74852 003

OCT 10, 1997

AB MYLAN 60MG

N74910 001

MAY 02, 1997

AB1 60MG

N74910 001

MAY 02, 1997

AB 90MG

N74910 002

MAY 02, 1997

AB1 90MG

N74910 002

MAY 02, 1997

AB 120MG

N74910 003

MAY 02, 1997

AB1 120MG

N74910 003

MAY 02, 1997

AB PROGRAPHARM 60MG

N74079 001

NOV 30, 1993

AB 90MG

N74079 002

NOV 30, 1993

AB 120MG

N74079 003

NOV 30, 1993

AB1 TEVA 60MG

N74079 001

NOV 30, 1993

AB1 90MG

N74079 002

NOV 30, 1993

AB1 120MG

N74079 003

NOV 30, 1993

INJECTABLE; INJECTION

CARDIZEMAP + HOECHST MARION RSSL 100MG/VIAL

N20792 001

SEP 05, 1997

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HCLAP GENSLA 5MG/ML

N74894 001

AUG 26, 1997

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATEAP ELKINS SINN 50MG/ML
@ 50MG/ML

N84767 001

N84767 001

DIMERCAPROL

INJECTABLE; INJECTION

BAL

+ AKORN 10%

N05939 001

* BECTON DICKINSON 10%

N05939 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCLAA EON 25MG

N80845 002

AA 50MG

N80845 001

@ 25MG

N80845 002

@ 50MG

N80845 001

@ ZENITH GOLDLINE 25MG

N80762 001

@ 50MG

N80762 002

AA ZENITH LABS 25MG

N80762 001

AA 50MG

N80762 002

ELIXIR; ORAL

DIPHENHYDRAMINE HCLAA BONDY 12.5MG/5ML
@ 12.5MG/5ML

N83674 001

N83674 001

INJECTABLE; INJECTION

BENADRYLAP + PARKE DAVIS 10MG/ML

N06146 001

AP * 50MG/ML

N09486 001

@ 10MG/ML

N06146 001

BENADRYL PRESERVATIVE FREEAP + PARKE DAVIS 50MG/ML

N09486 001

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

AP	FUJISAWA	50MG/ML	N80586 002
AP	INTL MEDICATION	50MG/ML	N84094 001
AP	STERIS	10MG/ML	N80873 001
AP		10MG/ML	N83533 001
	+	10MG/ML	N80873 001
	@	10MG/ML	N83533 001
	<u>DIPHENHYDRAMINE HCL PRESERVATIVE FREE</u>		
AP	FUJISAWA	50MG/ML	N80586 002
AP	INTL MEDICATION	50MG/ML	N84094 001
AP	STERIS	50MG/ML	N80873 003

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

> ADD >	AP	ABBOTT	5MG/ML	N74601 001
> ADD >				DEC 19, 1997
	AP	GENSIA	5MG/ML	N74952 001
				NOV 26, 1997

TABLET; ORAL

DIPYRIDAMOLE

AB	CHELSEA LABS	50MG	N87160 001
			JUN 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

@ LILLY

+

250MG

250MG

N50678 001
JUN 19, 1995
N50678 001
JUN 19, 1995

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

AP	ABBOTT	EQ 12.5MG BASE/ML	N74292 001
			FEB 16, 1995
AP	SANOFI WINTHROP	EQ 12.5MG BASE/ML	N74292 001
			FEB 16, 1995

DOLASETRON MESYLATE MONOHYDRATE

INJECTABLE; INJECTION

ANZEMET

+ HOECHST MARION RSSL EQ 20MG BASE/ML

N20624 001
SEP 11, 1997

TABLET; ORAL

ANZEMET

+ HOECHST MARION RSSL EQ 50MG BASE

N20623 001
SEP 11, 1997

EQ 100MG BASE

N20623 002
SEP 11, 1997

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

PRIZER

EQ 1MG BASE

N19668 001
NOV 02, 1990

+

EQ 8MG BASE

N19668 004
NOV 02, 1990

+

EQ 1MG BASE

N19668 001
NOV 02, 1990

EQ 8MG BASE

N19668 004
NOV 02, 1990

DOXEPIIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIIN HCL

PUREPAC PHARM

EQ 10MG BASE

N73054 001
DEC 28, 1990

> DLT > AB

> DLT > AB

EQ 25MG BASE

N72109 001
DEC 28, 1990

> DLT > AB

> DLT > AB

EQ 50MG BASE

N73055 001
DEC 28, 1990

> DLT > AB

> DLT > AB

EQ 100MG BASE

N72110 001
SEP 08, 1988

> ADD > @

> ADD > @

EQ 10MG BASE

N73054 001
DEC 28, 1990

> ADD > @

> ADD > @

EQ 25MG BASE

N72109 001
DEC 28, 1990

> ADD > @

> ADD > @

EQ 50MG BASE

N73055 001
DEC 28, 1990

> ADD > @

EQ 100MG BASE

N72110 001
SEP 08, 1988

DOXYCYCLINE HYCLATECAPSULE, ORAL
DOXYCYCLINE HYCLATE

> DLT >	AB	PURSPAC PHARM	EQ 50MG BASE	N62479 001
> DLT >				DEC 23, 1983
> DLT >	AB		EQ 100MG BASE	N62479 002
> DLT >				DEC 23, 1983
> ADD >	@		EQ 50MG BASE	N62479 001
> ADD >				DEC 23, 1983
> ADD >	@		EQ 100MG BASE	N62479 002
> ADD >				DEC 23, 1983

CAPSULE, COATED PELLETS; ORAL

DORYX

AB	PARKE DAVIS	EQ 100MG BASE	N62653 001
			OCT 10, 1985
AB	WARNER CHILCOTT	EQ 100MG BASE	N62653 001
			OCT 30, 1985

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

AP	ABBOTT	2.5MG/ML	N72272 001
			AUG 31, 1995
AP	SANOFI SINTHROP	2.5MG/ML	N72272 001
			AUG 31, 1995

ECONAZOLE NITRATECREAM; TOPICAL
SPECTAZOLE

+ J AND J 1%

* JOHNSON RW 1%

N18751 001
DEC 23, 1982
N18751 001
DEC 23, 1982

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

TENSILON

> ADD >	AP	+ ICN	10MG/ML	N07959 001
> DLT >	AP	* ROCHE	10MG/ML	N07959 001
> ADD >	AP	+ ICN	10MG/ML	N07959 002

EDROPHONIUM CHLORIDEINJECTABLE; INJECTION
TENSILON PRESERVATIVE FREE

> DLT >	AP	* ROCHE	10MG/ML	N07959 002
> ADD >				
> ADD >		EMEDASTINE DIFUMARATE		
> ADD >		SOLUTION/DROPS; OPHTHALMIC		
> ADD >		EMADINE		
> ADD >		+ ALCON	0.05%	N20706 001
> ADD >				DEC 29, 1997

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HCL W/ EPINEPHRINE

AP	CARLISLE	0.01MG/ML; 2%	N84720 001
AP		0.02MG/ML; 2%	N84732 001
	@	0.01MG/ML; 2%	N84720 001
	@	0.02MG/ML; 2%	N84732 001

> ADD > EPROSARTAN MESYLATE

> ADD > TABLET; ORAL

> ADD > TEVETEN

> ADD > SMITHKLINE BEECHAM EQ 300MG BASE

> ADD > N20738 004

> ADD > + EQ 400MG BASE

> ADD > N20738 005

> ADD > DEC 22, 1997

ERGOLOID MESYLATES

TABLET; SUBLINGUAL

HYDROGENATED ERGOT ALKALOIDS

@ ZENITH GOLDLINE 0.5MG

@ ZENITH LABS 0.5MG

N87186 001

N87186 001

ERYTHROMYCIN

GEL; TOPICAL

ERYTHROMYCIN

AT ALTANA 2%

N64184 001

SEP 30, 1997

ERYTHROMYCIN

SOLUTION; TOPICAL

ERYTHROMYCINAT ALTANA 2%AT STIEFEL 2%ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL

ERYTHROMYCIN ESTOLATEAB @ ZENITH GOLDLINE EQ 250MG BASE
ZENITH LABS EQ 250MG BASEESTAZOLAM

TABLET; ORAL

ESTAZOLAMAB ROYCE LABS 1MGAB 2MGAB TEVA 1MGAB 2MGAB ZENITH GOLDLINE 1MGAB 2MGPROSOMAB ABBOTT 1MGAB + 2MGESTRADIOL

TABLET; ORAL

ESTRADIOLAB BARR 0.5MGAB 1MG

N64187 001

SEP 30, 1997

N64127 001

FEB 14, 1997

N62237 001

N62237 001

N74818 001

AUG 19, 1997

N74818 002

AUG 19, 1997

N74921 001

JUL 10, 1997

N74921 002

JUL 10, 1997

N74826 001

JUL 03, 1997

N74826 002

JUL 03, 1997

N19080 001

DEC 26, 1990

N19080 002

DEC 26, 1990

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> DLT >

> ADD >

> DLT >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

ESTRADIOL

TABLET; ORAL

ESTRADIOLAB BARR 2MGAB DURAMED 0.5MGAB 1MGAB 2MG

1.5MG

N40197 003

OCT 22, 1997

N40212 001

DEC 29, 1997

N40212 002

DEC 29, 1997

N40212 004

DEC 29, 1997

N40212 003

DEC 29, 1997

ESTROGENS, ESTERIFIED

TABLET; ORAL

ESTRATABBS SOLVAY 1.25MGBS @ 1.25MGMENESTBS SMITHKLINE BEECHAM 1.25MGBS 1.25MG

N83856 001

N83856 001

N84950 001

N84950 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

+ WYETH AYERST

0.02MG; 0.1MG

N20683 001

MAR 27, 1997

TRIPHASIL-21AB + WYETH AYERST0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG,0.125MG

N19192 001

NOV 01, 1984

TRIVORA-21AB SEARLE0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG,0.125MG

N74538 001

DEC 18, 1997

TABLET; ORAL-28

ALESSE

WYETH AYERST

0.02MG; 0.1MG

N20683 002

MAR 27, 1997

TRIPHASIL-28AB WYETH AYERST0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG,0.125MG

N19190 001

NOV 01, 1984

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28
TRIVORA-28
 > ADD > AB SEARLE 0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG,
 > ADD > 0.125MG N74538 002
 > ADD > DEC 18, 1997

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
GENCEPT 0.5/35-21
 > ADD > AB BARR 0.035MG; 0.5MG N72692 001
 > ADD > FEB 28, 1992
 > DLT > AB GENCON 0.035MG; 0.5MG N72692 001
 > DLT > FEB 28, 1992
GENCEPT 1/35-21
 > ADD > AB BARR 0.035MG; 1MG N72693 001
 > ADD > FEB 28, 1992
 > DLT > AB GENCON 0.035MG; 1MG N72693 001
 > DLT > FEB 28, 1992
GENCEPT 10/11-21
 > ADD > AB BARR 0.035MG, 0.035MG; 0.5MG, 1MG N72694 001
 > ADD > FEB 28, 1992
 > DLT > AB GENCON 0.035MG, 0.035MG; 0.5MG, 1MG N72694 001
 > DLT > FEB 28, 1992

TABLET; ORAL-28
GENCEPT 0.5/35-28
 > ADD > AB BARR 0.035MG; 0.5MG N72695 001
 > ADD > FEB 28, 1992
 > DLT > AB GENCON 0.035MG; 0.5MG N72695 001
 > DLT > FEB 28, 1992
GENCEPT 1/35-28
 > ADD > AB BARR 0.035MG; 1MG N72696 001
 > ADD > FEB 28, 1992
 > DLT > AB GENCON 0.035MG; 1MG N72696 001
 > DLT > FEB 28, 1992
GENCEPT 10/11-28
 > ADD > AB BARR 0.035MG, 0.035MG; 0.5MG, 1MG N72697 001
 > ADD > FEB 28, 1992
 > DLT > AB GENCON 0.035MG, 0.035MG; 0.5MG, 1MG N72697 001
 > DLT > FEB 28, 1992

ETODOLAC

CAPSULE; ORAL
ETODOLAC
 > ADD > AB ENDO PHARMS 200MG N74842 001
 > ADD > JUL 17, 1997
 > ADD > AB 300MG N74842 002
 > ADD > JUL 17, 1997
 > ADD > AB GENEVA PHARMS 200MG N74840 001
 > ADD > AUG 29, 1997
 > ADD > AB 300MG N74840 002
 > ADD > AUG 29, 1997
 > ADD > AB INVAMED 200MG N74942 001
 > ADD > SEP 30, 1997
 > ADD > AB 300MG N74942 002
 > ADD > SEP 30, 1997
 > ADD > AB MYLAN 200MG N74932 001
 > ADD > MAY 16, 1997
 > ADD > AB 300MG N74932 002
 > ADD > MAY 16, 1997
 > ADD > AB WATSON LABS 200MG N74844 001
 > ADD > DEC 23, 1997
 > ADD > AB 300MG N74844 002
 > ADD > DEC 23, 1997
 > ADD > AB ZENITH GOLDLINE 200MG N74899 001
 > ADD > JUL 08, 1997
 > ADD > AB 300MG N74899 002
 > ADD > JUL 08, 1997
LODINE
 > ADD > AB WYETH AYERST 200MG N18922 002
 > ADD > JAN 31, 1991
 > ADD > AB + 300MG N18922 003
 > ADD > JAN 31, 1991

TABLET; ORAL
ETODOLAC
 > ADD > AB AESGEN 400MG N74927 001
 > ADD > OCT 30, 1997
 > ADD > AB 400MG N74841 001
 > ADD > JUN 27, 1997
 > ADD > AB ENDO PHARMS 400MG N74903 001
 > ADD > APR 11, 1997
 > ADD > AB EON 400MG N74839 001
 > ADD > JUL 11, 1997
 > ADD > AB GENEVA PHARMS 400MG N74846 001
 > ADD > FEB 28, 1997
 > ADD > AB INVAMED 400MG N74819 001
 > ADD > FEB 28, 1997
 > ADD > AB PUREPAC PHARM 400MG

ETODOLAC

TABLET; ORAL

ETODOLACAB ROYCE LABS 400MGAB TEVA 400MGAB ZENITH GOLDLINE 400MGLODINEAB WYETH AYERST 400MGETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE> DLT > AP GENSLA 20MG/ML

> DLT > @ 20MG/ML

> ADD >

> ADD > AP IMMUNEX 20MG/MLAP PIERRE FABRE 20MG/MLAP SUPERGEN 20MG/MLFAMOTIDINE

INJECTABLE; INJECTION

PEPCID IN PLASTIC CONTAINER

* MERCK 0.4MG/ML

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

+ MERCK 0.4MG/ML

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

+ NEUREX EQ 10MG BASE/ML

N74892 001

APR 16, 1997

N75009 001

NOV 26, 1997

N74883 001

FEB 28, 1997

N18922 004

JUL 29, 1993

N74510 001

JUN 29, 1995

N74510 001

JUN 29, 1995

N74513 001

MAR 14, 1996

N74813 001

JUL 09, 1997

N74513 001

MAR 14, 1996

N20249 001

FEB 18, 1994

N20249 001

FEB 18, 1994

N19922 001

SEP 23, 1997

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATEAP ABBOTT EQ 0.05MG BASE/MLAP STERLING WINTHROP EQ 0.05MG BASE/ML

N72786 001

SEP 24, 1991

N72786 001

SEP 24, 1991

> ADD > FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

> ADD > TABLET, EXTENDED RELEASE; ORAL

> ADD > ALLEGRA-D

> ADD > + HOECHST MARION RSSL 60MG;120MG

> ADD > N20786 001

> ADD > DEC 24, 1997

FINASTERIDE

TABLET; ORAL

PROPECIA

+ MERCK 1MG

N20788 001

DEC 19, 1997

FLECAINIDE ACETATE

TABLET; ORAL

TAMBOCOR

@ 3M 50MG

N18830 004

AUG 23, 1988

@ 100MG

N18830 001

OCT 31, 1985

@ 150MG

N18830 003

JUN 03, 1988

50MG

N18830 004

AUG 23, 1988

100MG

N18830 001

OCT 31, 1985

150MG

N18830 003

JUN 03, 1988

FLUCONAZOLE

INJECTABLE; INJECTION

DIFLUCAN

* PFIZER 200MG/100ML

N19950 001

JAN 29, 1990

FLUCONAZOLE

INJECTABLE; INJECTION
 DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
 + PFIZER 200MG/100ML N19950 003
 SEP 29, 1992
 @ 2MG/ML N19950 005
 JUL 08, 1994
 DIFLUCAN IN SODIUM CHLORIDE 0.9%
 + PFIZER 200MG/100ML N19950 001
 JAN 29, 1990
 DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 + PFIZER 200MG/100ML N19950 002
 JAN 29, 1990
 @ 2MG/ML N19950 004
 JUL 08, 1994

FLUCYTOSINE

CAPSULE; ORAL
 ANCOBON
 ICN 250MG N17001 001
 + 500MG N17001 002
 * ROCHE 250MG N17001 001
 500MG N17001 002

FLUNISOLIDE

SPRAY, METERED; NASAL
 NASALIDE
 BX + DURA 0.025MG/SPRAY N18148 001
 BX * SYNTEX 0.025MG/SPRAY N18148 001
 NASAREL
 BX + DURA 0.025MG/SPRAY N20409 001
 MAR 08, 1995
 BX * SYNTEX 0.025MG/SPRAY N20409 001
 MAR 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
 FLUCET
 @ ALPHARMA 0.025% N88360 001
 JAN 16, 1984
 AT NMC 0.025% N88360 001
 JAN 16, 1984

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
 FLUOCINOLONE ACETONIDE
 @ ALPHARMA 0.01% N88361 001
 JAN 16, 1984
 AT NMC 0.01% N88361 001
 JAN 16, 1984
 SYNALAR
 AT + MEDICIS 0.01% N12787 004
 AT + 0.025% N12787 002
 AT + 0.025% N12787 005
 AT + SYNTEX 0.01% N12787 004
 AT + 0.025% N12787 002
 AT + 0.025% N12787 005
 SYNALAR-HP
 + MEDICIS 0.2% N16161 002
 * SYNTEX 0.2% N16161 002

ointment; TOPICAL

SYNALAR
 AT + MEDICIS 0.025% N13960 001
 AT + SYNTEX 0.025% N13960 001

SOLUTION; TOPICAL

SYNALAR
 AT + MEDICIS 0.01% N15296 001
 AT + SYNTEX 0.01% N15296 001

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
 NEO-SYNALAR
 + MEDICIS 0.025%; EQ 3.5MG BASE/GM N60700 001
 * SYNTEX 0.025%; EQ 3.5MG BASE/GM N60700 001

FLUOCINONIDE

CREAM; TOPICAL
 LIDEX
 AB + MEDICIS 0.05% N16908 002
 AB * SYNTEX 0.05% N16908 002
 LIDEX-E
 AB MEDICIS 0.05% N16908 003
 AB SYNTEX 0.05% N16908 003

FLUOCINONIDEGEL; TOPICAL
FLUOCINONIDEAB TARO 0.05%N74935 001
JUL 29, 1997LIDEXAB + MEDICIS 0.05%

N17373 001

AB * SYNTEX 0.05%

N17373 001

OINTMENT; TOPICAL

FLUOCINONIDEAB ALTANA 0.05%N74905 001
AUG 26, 1997LIDEXAB + MEDICIS 0.05%

N16909 002

AB * SYNTEX 0.05%

N16909 002

SOLUTION; TOPICAL

LIDEXAT + MEDICIS 0.05%N18849 001
APR 06, 1984AT * SYNTEX 0.05%N18849 001
APR 06, 1984FLUOROURACIL

CREAM; TOPICAL

EFUDEX

> ADD > + ICN 5%

N16831 003

> DLT > * ROCHE 5%

N16831 003

SOLUTION; TOPICAL

EFUDEX

> ADD > + ICN 2%

N16831 001

> ADD > + 5%

N16831 002

> DLT > * ROCHE 2%

N16831 001

> DLT > * 5%

N16831 002

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

* LILLY 0.025%

N12806 003

* 0.05%

N12806 002

+ OCLASSEN 0.025%

N12806 003

+ 0.05%

N12806 002

FLURANDRENOLIDE

LOTION; TOPICAL

CORDRANAT * LILLY 0.05%

N13790 001

AT + OCLASSEN 0.05%

N13790 001

OINTMENT; TOPICAL

CORDRAN

* LILLY 0.025%

N12806 004

* 0.05%

N12806 001

+ OCLASSEN 0.025%

N12806 004

+ 0.05%

N12806 001

TAPE; TOPICAL

CORDRAN

* LILLY 0.004MG/SQ CM

N16455 001

+ OCLASSEN 0.004MG/SQ CM

N16455 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HCLAB HALSEY 15MG

N71808 001

AB 30MG

JAN 07, 1988

@ 15MG

N71809 001

@ 30MG

JAN 07, 1988

@ 15MG

N71808 001

@ 30MG

JAN 07, 1988

@ 30MG

N71809 001

@ 30MG

JAN 07, 1988

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFENAB SIDMAK LABS NJ 50MG

N74647 001

AB 100MG

APR 01, 1997

AB 100MG

N74647 002

AB 100MG

APR 01, 1997

AB WARNER CHILCOTT 100MG

N74560 002

MAY 16, 1997

FLUTICASONE PROPIONATEPOWDER; INHALATION
FLOVENT
+ GLAXO WELLCOME

0.044MG/INH

N20549 001
NOV 07, 1997

+ 0.088MG/INH

N20549 002
NOV 07, 1997

+ 0.22MG/INH

N20549 003
NOV 07, 1997FOLIC ACIDTABLET; ORAL
FOLIC ACID

AA DANBURY PHARMA

1MG

N80680 001

AA +

1MG

N80680 001

AA FOLVITE

1MG

N05897 004

AA * LEDERLE

@

1MG

N05897 004

FOLLITROPIN ALFA/BETAINJECTABLE; INJECTION
FOLLISTIM

BX ORGANON 75 IU/VIAL

N20582 001
SEP 29, 1997

BX 150 IU/VIAL

N20582 002
SEP 29, 1997

GONAL-F

BX SERONO 75 IU/VIAL

N20378 001
SEP 29, 1997

BX 150 IU/VIAL

N20378 002
SEP 29, 1997> ADD > FOMEPIZOLE> ADD > INJECTABLE; INJECTION
> ADD > ANTIZOL
> ADD > + ORPHAN MEDCL

1GM/ML

N20696 001
DEC 04, 1997FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP ABBOTT

10MG/ML

N70578 001

AP 10MG/ML

JUL 08, 1987

AP 10MG/ML

N72080 001

AP SANGPI WINTHROP 10MG/ML

AUG 13, 1991

AP STERLING WINTHROP 10MG/ML

N74337 001

AP 10MG/ML

OCT 31, 1994

N74337 001

OCT 31, 1994

N70578 001

JUL 08, 1987

N72080 001

AUG 13, 1991

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION

NEOSCAN

BS MEDI PHYSICS

2mCi/ML

N17655 001

BS NYCOMED AMERSHAM

2mCi/ML

N17655 001

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

* SYNTAX

250MG

N20460 001

DEC 22, 1994

N20460 001

DEC 22, 1994

N20460 002

DEC 12, 1997

+ 500MG

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

@ ALPHARMA

EQ 0.1% BASE

N62471 001

SEP 27, 1983

N62471 001

SEP 27, 1983

AT NMC

EQ 0.1% BASE

OINTMENT; TOPICAL

GENTAMICIN SULFATE

@ ALPHARMA

EQ 0.1% BASE

N62496 001

MAR 14, 1984

GENTAMICIN SULFATE

OINTMENT; TOPICAL

GENTAMICIN SULFATEAT NMC EQ 0.1% BASEN62495 001
MAR 14, 1984> ADD >
> ADD >
> ADD >
> ADD >GLIPIZIDE

TABLET; ORAL

GLIPIZIDEAB DURAMED 5MGN74550 001
SEP 11, 1997AB 10MGN74550 002
SEP 11, 1997AB ENDO LABS 5MGN74378 001
NOV 28, 1994AB 10MGN74378 002
NOV 28, 1994AB ENDO PHARMS 5MGN74378 001
NOV 28, 1994AB 10MGN74378 002
NOV 28, 1994AB SIDMAK LABS NJ 5MGN74619 001
APR 04, 1997AB 10MGN74619 002
APR 04, 1997GLUTETHIMIDE

TABLET; ORAL

GLUTETHIMIDEAA HALSEY 500MGN89459 001
OCT 10, 1986@ 500MGN89459 001
OCT 10, 1986GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)> ADD > AB MOVA 1.5MGN74591 001
DEC 22, 1997> ADD > AB 3MGN74591 002
DEC 22, 1997GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)AB MOVA 6MG
4.5MGN74591 004
DEC 22, 1997
N74591 003
DEC 22, 1997GLYNASEAB + PHARMACIA AND UPJOHN 6MGN20051 004
SEP 24, 1993GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

RAXAR+ GLAXO WELLCOME EQ 200MG BASEN20695 001
NOV 06, 1997GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V+ J AND J 125MG/5ML
125MG/5MLN50448 001
N62483 001
JAN 26, 1984* JOHNSON RW 125MG/5ML
125MG/5MLN50448 001
N62483 001
JAN 26, 1984

TABLET; ORAL

GRIFULVIN VAB J AND J 250MG
AB 250MG
AB 500MG
AB 500MG
125MG
125MGN60618 002
N62279 002
N60618 003
N62279 003
N60618 001
N62279 001AB JOHNSON RW 250MG
AB 250MG
AB 500MG
AB 500MG
500MG
125MG
125MGN62279 002
N60618 002
N62279 002
N60618 003
N62279 003
N60618 001
N62279 001

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HCL
AMIDE PHARM

<u>AB</u>		<u>EQ 1MG BASE</u>	N74673 001
			FEB 28, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	N74673 002
			FEB 28, 1997
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	N74796 001
			JAN 27, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	N74796 002
			JAN 27, 1997
<u>AB</u>	ROYCE LABS	<u>EQ 1MG BASE</u>	N74762 001
			JUN 25, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	N74762 002
			JUN 25, 1997

HALCINONIDE

CREAM; TOPICAL

HALOG

WESTWOOD SQUARE
@

0.025%
0.025%
N17818 001
N17818 001

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

> <u>ADD</u> >	<u>AO</u>	+	JOHNSON RW	<u>EQ 50MG BASE/ML</u>	N18701 001	> <u>DLT</u> >
> <u>ADD</u> >					JAN 14, 1986	> <u>DLT</u> >
> <u>ADD</u> >	<u>AO</u>	+		<u>EQ 100MG BASE/ML</u>	N18701 002	> <u>ADD</u> >
> <u>ADD</u> >					JAN 31, 1997	
> <u>ADD</u> >			<u>HALOPERIDOL DECANOATE</u>			
> <u>ADD</u> >	<u>AO</u>		FUJISAWA	<u>EQ 50MG BASE/ML</u>	N74893 001	
> <u>ADD</u> >					DEC 19, 1997	
> <u>ADD</u> >	<u>AO</u>			<u>EQ 100MG BASE/ML</u>	N74893 002	
> <u>ADD</u> >					DEC 19, 1997	

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

> <u>DLT</u> >	<u>AP</u>		SOLOPAK	<u>EQ 5MG BASE/ML</u>	N70800 001
> <u>DLT</u> >					DEC 14, 1987
> <u>ADD</u> >			@	<u>EQ 5MG BASE/ML</u>	N70800 001
> <u>ADD</u> >					DEC 14, 1987

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER

<u>AP</u>	FUJISAWA	<u>10 UNITS/ML</u>	N17029 017
			DEC 05, 1985
<u>AP</u>		<u>100 UNITS/ML</u>	N17029 018
			DEC 05, 1985
	@	10 UNITS/ML	N17029 017
	@	100 UNITS/ML	DEC 05, 1985
			N17029 018
			DEC 05, 1985
<u>AP</u>	<u>HEPARIN LOCK FLUSH</u>	<u>10 UNITS/ML</u>	N40082 001
	ABBOTT		FEB 28, 1995
<u>AP</u>		<u>10 UNITS/ML</u>	N88097 001
			APR 28, 1983
<u>AP</u>		<u>10 UNITS/ML</u>	N88346 001
			MAY 18, 1983
<u>AP</u>		<u>100 UNITS/ML</u>	N40082 002
			FEB 28, 1995
<u>AP</u>		<u>100 UNITS/ML</u>	N88098 001
			APR 28, 1983
<u>AP</u>		<u>100 UNITS/ML</u>	N88347 001
			MAY 18, 1983
<u>AP</u>	<u>SANOPI WINTHROP</u>	<u>10 UNITS/ML</u>	N40082 001
			FEB 28, 1995
<u>AP</u>		<u>100 UNITS/ML</u>	N40082 002
			FEB 28, 1995
<u>AP</u>	<u>SOLOPAK</u>	<u>10 UNITS/ML</u>	N87903 001
			APR 20, 1983
	@	10 UNITS/ML	N87903 001
			APR 20, 1983
<u>AP</u>	<u>STERLING WINTHROP</u>	<u>10 UNITS/ML</u>	N88097 001
			APR 28, 1983
<u>AP</u>		<u>10 UNITS/ML</u>	N88346 001
			MAY 18, 1983
<u>AP</u>		<u>100 UNITS/ML</u>	N88098 001
			APR 28, 1983
<u>AP</u>		<u>100 UNITS/ML</u>	N88347 001
			MAY 18, 1983
<u>AP</u>	<u>HEPARIN SODIUM</u>	<u>2,500 UNITS/ML</u>	N88099 001
	ABBOTT		APR 28, 1983
<u>AP</u>		<u>5,000 UNITS/ML</u>	N88100 001
			APR 28, 1983
<u>AP</u>		<u>10,000 UNITS/ML</u>	N40095 001
			JUL 26, 1996
<u>AP</u>	FUJISAWA	<u>20,000 UNITS/ML</u>	N17029 004

HEPARIN SODIUMINJECTABLE; INJECTIONHEPARIN SODIUM> DLT >
> ADD >

AP	SANOFI WINTHROP	10,000 UNITS/ML	N40095 001 JUL 26, 1986
AP	SOLOPAK	10,000 UNITS/0.5ML	N87363 001
AP	@	10,000 UNITS/0.5ML	N87363 001
AP	STERIS	1,000 UNITS/ML	N17064 002
AP	@	1,000 UNITS/ML	N17064 002
AP	STERLING WINTHROP	2,500 UNITS/ML	N88099 001 APR 28, 1983
AP		5,000 UNITS/ML	N88100 001 APR 28, 1983
<u>HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
AP	ABBOTT	10,000 UNITS/100ML	N19339 003 MAR 27, 1985
AP	@	10,000 UNITS/100ML	N19339 003 MAR 27, 1985
<u>HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
AP	ABBOTT	5,000 UNITS/100ML	N19339 001 MAR 27, 1985
AP	@	5,000 UNITS/100ML	N19339 001 MAR 27, 1985
<u>HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
AP	ABBOTT	5,000 UNITS/100ML	N19339 004 MAR 27, 1985
AP		10,000 UNITS/100ML	N19339 002 MAR 27, 1985
AP	@	5,000 UNITS/100ML	N19339 004 MAR 27, 1985
AP	@	10,000 UNITS/100ML	N19339 002 MAR 27, 1985
<u>HEPARIN SODIUM PRESERVATIVE FREE</u>			
AP	+ ABBOTT	10,000 UNITS/ML	N89522 001 MAY 04, 1987
AP	* STERLING WINTHROP	10,000 UNITS/ML	N89522 001 MAY 04, 1987

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATESYRUP; ORALHYCODAN

AA	* DUPONT MERCK	1.5MG/5ML; 5MG/5ML	N05213 002 JUL 26, 1988
----	----------------	--------------------	----------------------------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATESYRUP; ORALHYCODAN

AA	+ ENDO PHARMS	1.5MG/5ML; 5MG/5ML	N05213 002 JUL 26, 1988
AA	<u>HYDROFANE</u>	1.5MG/5ML; 5MG/5ML	N88066 001 JUN 28, 1985
AA	HALSEY	1.5MG/5ML; 5MG/5ML	N88066 001 JUN 28, 1985
AA	@	1.5MG/5ML; 5MG/5ML	N88066 001 JUN 28, 1985

TABLET; ORALHYCODAN

AA	* DUPONT MERCK	1.5MG; 5MG	N05213 001 JUL 26, 1988
AA	+ ENDO PHARMS	1.5MG; 5MG	N05213 001 JUL 26, 1988

HYDRALAZINE HYDROCHLORIDEINJECTABLE; INJECTIONHYDRALAZINE HCL

AP	LUITPOLD	20MG/ML	N40136 001 JUN 30, 1997
----	----------	---------	----------------------------

TABLET; ORALHYDRALAZINE HCL

AA	HALSEY	25MG	N89130 001 JAN 15, 1986
AA		100MG	N89178 001 JAN 15, 1986
AA	@	25MG	N89130 001 JAN 15, 1986
AA	@	100MG	N89178 001 JAN 15, 1986
AA	PUREPAC PHARM	25MG	N88177 001 JUL 29, 1983
AA	@	25MG	N88177 001 JUL 29, 1983
AA	@ ZENITH GOLDLINE	10MG	N84443 001
AA	@	25MG	N84437 001
AA	@	50MG	N84469 002
AA	@	100MG	N84581 001
AA	ZENITH LABS	10MG	N84443 001
AA		25MG	N84437 001
AA		50MG	N84469 002
AA		100MG	N84581 001

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50

@ ZENITH GOLDLINE 100MG;50MG N88358 001

APR 10, 1984

@ ZENITH LABS 100MG;50MG N88358 001

APR 10, 1984

HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25

@ ZENITH GOLDLINE 25MG;25MG N88356 001

APR 10, 1984

AB ZENITH LABS 25MG;25MG N88356 001

APR 10, 1984

HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50

@ ZENITH GOLDLINE 50MG;50MG N88357 001

APR 10, 1984

AB ZENITH LABS 50MG;50MG N88357 001

APR 10, 1984

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE

BP @ ZENITH GOLDLINE 25MG;15MG;0.1MG N84291 001

N84291 001

@ ZENITH LABS 25MG;15MG;0.1MG N84291 001

HYDROSERPINE PLUS (R-H-H)

BP @ ZENITH GOLDLINE 25MG;15MG;0.1MG N83877 001

N83877 001

@ ZENITH LABS 25MG;15MG;0.1MG N83877 001

UNIPRES

BP SOLVAY 25MG;15MG;0.1MG N86298 001

N86298 001

@ 25MG;15MG;0.1MG N86298 001

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@ ZENITH GOLDLINE 50MG N84658 001

N84658 001

@ ZENITH LABS 50MG N84658 001

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN-HYDROCHLOROTHIAZIDE

@ SANOFI 12.5MG;75MG N20758 001

SEP 30, 1997

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN-HYDROCHLOROTHIAZIDE

+ SANOFI 12.5MG;150MG

N20758 002

SEP 30, 1997

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

AB PUREPAC PHARM 15MG;250MG N70853 001

OCT 08, 1986

AB 25MG;250MG N70688 001

APR 24, 1986

AB 30MG;500MG N70854 001

OCT 08, 1986

@ 15MG;250MG N70853 001

OCT 08, 1986

@ 25MG;250MG N70688 001

APR 24, 1986

@ 30MG;500MG N70854 001

OCT 08, 1986

@ ZENITH GOLDLINE 15MG;250MG N71458 001

MAR 08, 1988

@ 25MG;250MG N71459 001

MAR 08, 1988

@ 30MG;500MG N71460 001

MAR 08, 1988

@ 50MG;500MG N71461 001

MAR 08, 1988

@ ZENITH LABS 15MG;250MG N71458 001

MAR 08, 1988

@ 25MG;250MG N71459 001

MAR 08, 1988

@ 30MG;500MG N71460 001

MAR 08, 1988

@ 50MG;500MG N71461 001

MAR 08, 1988

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIRETIC

SCHWARZ PHARMA 12.5MG;7.5MG

N20729 001

JUN 27, 1997

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
UNIRETIC
+ SCHWARZ PHARMA 25MG;15MG N20729 002
JUN 27, 1997

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE
@ ZENITH GOLDLINE 25MG;40MG N71552 001
DEC 01, 1988
@ 25MG;80MG N71553 001
DEC 01, 1988
@ 25MG;40MG N71552 001
DEC 01, 1988
@ 25MG;80MG N71553 001
DEC 01, 1988

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
HYDROCHLOROTHIAZIDE W/ RESERPINE
@ ZENITH GOLDLINE 25MG;0.1MG N83572 001
@ 25MG;0.125MG N83571 001
@ 50MG;0.1MG N83568 001
@ 50MG;0.125MG N83573 001
BP ZENITH LABS 25MG;0.125MG N83571 001
BP 50MG;0.125MG N83573 001
25MG;0.1MG N83572 001
50MG;0.1MG N83568 001

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
@ PUREPAC PHARM 25MG;25MG N87999 001
NOV 06, 1985
@ 25MG;25MG N87999 001
NOV 06, 1985
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
@ ZENITH GOLDLINE 25MG;25MG N87004 002
MAY 24, 1982
@ 25MG;25MG N87004 002
MAY 24, 1982

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
AB GENEVA PHARMS 25MG;37.5MG N74821 001
JUN 05, 1997
AB NOVARTIS 25MG;37.5MG N74857 001
SEP 09, 1997

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
B* PAR PHARM 50MG;75MG N72337 001
MAY 11, 1988

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL
VICOPROFEN
+ KNOLL PHARM 7.5MG;200MG N20716 001
SEP 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL
HYCOMINE
* DUPONT MERCK 5MG/5ML;25MG/5ML N19410 001
AUG 17, 1990
+ ENDO PHARMS 5MG/5ML;25MG/5ML N19410 001
AUG 17, 1990
HYCOMINE PEDIATRIC
DUPONT MERCK 2.5MG/5ML;12.5MG/5ML N19411 001
AUG 17, 1990
ENDO PHARMS 2.5MG/5ML;12.5MG/5ML N19411 001
AUG 17, 1990

HYDROCORTISONE

CREAM; TOPICAL
DERMACORT
AT MONARCH PHARMS 1% N83011 002
AT SOLVAY 1% N83011 002
HYDROCORTISONE
@ ALPHARMA 2.5% N89754 001
FEB 01, 1989
AT NMC 2.5% N89754 001
FEB 01, 1989

HYDROCORTISONE

CREAM; TOPICAL

PROCTOCORT

AT	MONARCH PHARMS	1%	N83011 001
AT	SOLVAY	1%	N83011 001
AT	<u>SYNACORT</u>	1%	N87458 001
AT	MEDICIS	2.5%	N87457 001
		0.5%	N87459 001
AT	@ SYNTEX	1%	N87458 001
AT		2.5%	N87457 001
		0.5%	N87459 001

TABLET; ORAL

HYDROCORTISONE

BP	PUREPAC PHARM	10MG	N84247 003
			AUG 31, 1982
BP		20MG	N84247 002
	@	10MG	N84247 003
			AUG 31, 1982
	@	20MG	N84247 002

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

CORTISPORIN

AT	* GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50479 001
AT	+ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50479 001
AT	<u>OTOCORT</u>	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60730 002
	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60730 002
	@		

SUSPENSION/DROPS; OTIC

CORTISPORIN

> DLT >	AT	* GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60613 001
> DLT >		@	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60613 001
> DLT >				
> ADD >				
> ADD >				
	AT	<u>OTOCORT</u>	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62521 001
		STERIS		JUL 11, 1985

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

OTOCORT

	@ STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62521 001
			JUL 11, 1985
	<u>PEDIOTIC</u>	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62822 001
AT	GLAXO WELLCOME		SEP 29, 1987
AT	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62822 001
			SEP 29, 1987

HYDROCORTISONE; UREA

CREAM; TOPICAL

ALPHADERM

	@ BIOGLAN	1%;10%	N86008 001
	@ VIVAN	1%;10%	N86008 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HEMSOL-HC

AT	ABLE	1%	N81274 001
			JUN 19, 1992
	+	1%	N81274 001
			JUN 19, 1992
AT	<u>HYDROCORTISONE ACETATE</u>	1%	N86052 001
	* PUREPAC PHARM	0.5%	N86050 001
	@	0.5%	N86050 001
	@	1%	N86052 001

INJECTABLE; INJECTION

HYDROCORTISONE ACETATE

BP	AKORN	25MG/ML	N09637 001
BP		50MG/ML	N09637 002
	@	25MG/ML	N09637 001
	@	50MG/ML	N09637 002
BP	STERIS	25MG/ML	N83759 001
BP		50MG/ML	N83759 002
	@	25MG/ML	N83759 001
	@	50MG/ML	N83759 002
BP	* MERCK SHARP DOHME	50MG/ML	N08228 004

HYDROCORTISONE ACETATEINJECTABLE; INJECTION
HYDROCORTONE

+ MERCK SHARP DOHME 50MG/ML N08228 004

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATECREAM; TOPICAL
CORTISPORIN+ GLAXO WELLCOME 0.5%;EQ 3.5MG BASE/GM;
10,000 UNITS/GM N50218 001
AUG 09, 1985+ MONARCH PHARMS 0.5%;EQ 3.5MG BASE/GM;
10,000 UNITS/GM N50218 001
AUG 09, 1985HYDROCORTISONE BUTEPRATECREAM; TOPICAL
PANDEL+ SAVAGE LABS 0.1% N20453 001
FEB 28, 1997HYDROCORTISONE BUTYRATECREAM; TOPICAL
LOCOID LIPOCREAM
YAMANOUCHI0.1% N20769 001
SEP 08, 1997HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATEAP ELKINS SINN EQ 1GM BASE/VIAL N87569 001
@ EQ 1GM BASE/VIAL N87569 001HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE AND HYDROFLUMETHIAZIDE

@ ZENITH GOLDLINE 50MG;0.125MG N88932 001
JAN 11, 1985HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE AND HYDROFLUMETHIAZIDE

BP ZENITH LABS 50MG;0.125MG N88932 001
JAN 11, 1985HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HCLAP ABBOTT 10MG/ML N74598 001
JUN 19, 1997AP SANOPI 10MG/ML N74598 001
JUN 19, 1997HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCLAP ABBOTT 25MG/ML N87416 001
AP 50MG/ML N87546 001
AP SOLOPAK 50MG/ML N87596 001
@ 50MG/ML N87596 001
AP STERLING WINTHROP 25MG/ML N87416 001
AP 50MG/ML N87546 001

TABLET; ORAL

HYDROXYZINE HCLAB HALSEY 25MG N89117 001
MAY 02, 1988
@ 25MG N89117 001
MAY 02, 1988
AB KV PHARM 10MG N87819 001
JUN 23, 1982
AB 25MG N87820 001
JUN 23, 1982
AB 50MG N87821 001
JUN 23, 1982
AB 100MG N87822 001
JUN 23, 1982
@ 10MG N87819 001
JUN 23, 1982
@ 25MG N87820 001
JUN 23, 1982
@ 50MG N87821 001
JUN 23, 1982

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HCL

@ KV PHARM

100MG

AB PUREPAC PHARM10MGAB 25MGAB 50MG

@ 10MG

@ 25MG

@ 50MG

@ ZENITH GOLDLINE 10MG

@ 25MG

@ 50MG

AB ZENITH LABSAB 10MGAB 25MGAB 50MGHYDROXYZINE PAMOATE

CAPSULE; ORAL

HY-PAM

EON

AB HYDROXYZINE PAMOATE

EON

EQ 25MG HCLEQ 25MG HCL

N87822 001

JUN 23, 1982

N88120 001

SEP 25, 1984

N88121 001

SEP 25, 1984

N88122 001

SEP 25, 1984

N88120 001

SEP 25, 1984

N88121 001

SEP 25, 1984

N88122 001

SEP 25, 1984

N87216 001

N87410 001

N87411 001

N87216 001

N87410 001

N87411 001

> ADD >> ADD >> ADD >> ADD >> ADD >> ADD >> DLT >IBUPROFEN

TABLET; ORAL

IBU

BASF

600MGAB

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

BASF

IBUPROFEN

TABLET; ORAL
RUFEN
> DLT > @ KNOLL PHARM 600MG N18197 002
> DLT > MAR 05, 1984

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDAMYCIN PFS
+ PHARMACIA AND UPJOHN 1MG/ML N50734 001
FEB 17, 1997

IFOSFAMIDE

INJECTABLE; INJECTION
IFEX
* BRISTOL MYERS SQUIBB 1GM/VIAL N19763 001
DEC 30, 1988
* 3GM/VIAL N19763 002
DEC 30, 1988
@ 1GM/VIAL N19763 001
DEC 30, 1988
@ 3GM/VIAL N19763 002
DEC 30, 1988

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION
IFEX/MESNEX KIT
+ BRISTOL MYERS SQUIBB 1GM/VIAL;100MG/ML N19763 003
OCT 10, 1992
+ 3GM/VIAL;100MG/ML N19763 004
OCT 10, 1992

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
JANIMINE
> DLT > AB ABBOTT 10MG N17895 001
> DLT > AB 25MG N17895 002
> DLT > AB 50MG N17895 003
> ADD > @ 10MG N17895 001
> ADD > @ 25MG N17895 002

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
JANIMINE
> ADD > @ ABBOTT 50MG N17895 003
> ADD >

IMIQUIMOD

CREAM; TOPICAL
ALDARA
+ 3M 5% N20723 001
FEB 27, 1997

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE
AB MYLAN 1.25MG N74461 002
MAR 26, 1997
AB NOVOPHARM 1.25MG N74665 001
APR 04, 1997
AB 2.5MG N74665 002
APR 04, 1997

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION
INDIUM IN-111 OXYQUINOLINE
MEDI PHYSICS 1mCi/ML N19044 001
DEC 23, 1985
NYCOMED AMERSHAM 1mCi/ML N19044 001
DEC 23, 1985

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL
MPI INDIUM DTPA IN 111
MEDI PHYSICS 1mCi/ML N17707 001
FEB 18, 1982
NYCOMED AMERSHAM 1mCi/ML N17707 001
FEB 18, 1982

INDOCYANINE GREENINJECTABLE; INJECTION
CARDIO-GREEN

+	AKORN	25MG/VIAL
+		50MG/VIAL
+	BECKTON DICKINSON	25MG/VIAL
+		50MG/VIAL

N11525 001
N11525 002
N11525 001
N11525 002

> ADD >
> ADD >

IODIXANOLINJECTABLE; INJECTION
VISIPAQUE 270
NYCOMED

55%

N20808 001
AUG 29, 1997

VISIPAQUE 320
NYCOMED

65.2%

N20808 002
AUG 29, 1997

> ADD >
> ADD >

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION

HIPTOTOPE

BRACCO

1-2mCi/VIAL

N15419 002

@

1-2mCi/VIAL

N15419 002

IODOHIPPURATE SODIUM I 131

@ CIS

0.2mCi/ML

N17313 001

SORIN

0.2mCi/ML

N17313 001

> ADD >
> ADD >

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

ABBOTT

41%

N74898 001
DEC 30, 1997

> ADD >
> ADD >

IOPAMIDOL-200 IN PLASTIC CONTAINER

ABBOTT

41%

N74636 001
DEC 30, 1997

> ADD >
> ADD >

IOPAMIDOL-250

ABBOTT

51%

N74898 002
DEC 30, 1997

> ADD >
> ADD >

FUJISAWA

51%

N74679 001
APR 02, 1997

IOPAMIDOL-250 IN PLASTIC CONTAINER

ABBOTT

51%

N74636 002
DEC 30, 1997

> ADD >
> ADD >

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-300

ABBOTT

61%

N74638 001
APR 30, 1997
N74898 003
DEC 30, 1997
N74679 002
APR 02, 1997

AP

AP

AP

FUJISAWA

61%

IOPAMIDOL-300 IN PLASTIC CONTAINER

ABBOTT

61%

N74636 003
DEC 30, 1997
N74637 001
APR 03, 1997

AP

AP

IOPAMIDOL-370

ABBOTT

76%

N74898 004
DEC 30, 1997
N74679 003
APR 02, 1997

AP

AP

FUJISAWA

76%

IOPAMIDOL-370 IN PLASTIC CONTAINER

ABBOTT

76%

N74636 004
DEC 30, 1997

AP

AP

ISOVUE-250

+ BRACCO

51%

N18735 007
JUL 06, 1992
N20327 002
OCT 12, 1994

AP

AP

IPODATE CALCIUM

GRANULE, ORAL

ORAGRAPIN CALCIUM

BRACCO

1GM/PACKET

N12968 001

@

3GM/PACKET

N12968 001

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ATROVENT

+ BOEHRINGER INGELHEIM 0.02%

N20228 001
SEP 29, 1993

AN

IPRATROPIUM BROMIDE

DEY

0.02%

N74755 001
JAN 10, 1997

AN

IRBESARTAN

TABLET; ORAL
AVAPRO
SANOFI

75MG

N20757 001

SEP 30, 1997

150MG

N20757 002

SEP 30, 1997

+

300MG

N20757 003

SEP 30, 1997

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HCL

AN ALPHARMA

1%

N87101 001

@

1%

N87101 001

ISOFLUROPHATE

OINTMENT; OPHTHALMIC

FLOPROPYL

* MERCK SHARP DOHME

0.025%

N10656 001

@

0.025%

N10656 001

ISONIAZID

SYRUP; ORAL

ISONIAZID

AA + CAROLINA MEDCL

50MG/5ML

N88235 001

*

50MG/5ML

NOV 10, 1983

N88235 001

NOV 10, 1983

AA MIKART

50MG/5ML

N81118 001

JUL 21, 1997

LANIAZID

AA LANNETT

50MG/5ML

N89243 001

FEB 03, 1986

@

50MG/5ML

N89243 001

FEB 03, 1986

TABLET; ORAL

ISONIAZID

AA MIKART

100MG

N40090 001

JUN 26, 1997

ISONIAZID

TABLET; ORAL

ISONIAZID

AA

MIKART

300MG

N40090 002

JUN 26, 1997

@ ZENITH GOLDLINE

100MG

N80270 001

@

300MG

N83610 001

@ ZENITH LABS

100MG

N80270 001

@

300MG

N83610 001

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HCL

BN

* 3M

0.12MG/INH

N10375 004

+

0.12MG/INH

N10375 004

BN

ALPHARMA

0.12MG/INH

N85904 001

@

0.12MG/INH

N85904 001

INJECTABLE; INJECTION

ISUPREL

AP

+ ABBOTT

0.2MG/ML

N10515 001

AP

* SANOFI WINTHROP

0.2MG/ML

N10515 001

ITRACONAZOLE

SOLUTION; ORAL

SPORANOX

+ JANSSEN

10MG/ML

N20657 001

FEB 21, 1997

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HCL

AP

ABBOTT

EQ 50MG BASE/ML

N74549 001

JUN 27, 1996

AP

EQ 100MG BASE/ML

N74549 002

JUN 27, 1996

AP

SANOFI WINTHROP

EQ 50MG BASE/ML

N74549 001

JUN 27, 1996

AP

EQ 100MG BASE/ML

N74549 002

JUN 27, 1996

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

> ADD > KETOPROFEN> ADD > AB ELAN PHARM 200MG> ADD >ORUVAIL> ADD > AB + WYETH AYERST 200MG> ADD >N74879 001
DEC 10, 1997N19816 001
SEP 24, 1993KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINEAP ABBOTT 15MG/MLAP 15MG/MLAP 30MG/MLAP 30MG/MLTORADOLAP + SYNTEX 15MG/MLAP + 30MG/MLN74801 001
JUN 05, 1997
N74802 001
JUN 05, 1997
N74801 002
JUN 05, 1997
N74802 002
JUN 05, 1997N19698 001
NOV 30, 1989
N19698 002
NOV 30, 1989

SOLUTION/DROPS; OPHTHALMIC

ACULAR PRESERVATIVE FREE

+ SYNTEX 0.5%

N20811 001
NOV 03, 1997

TABLET; ORAL

KETOROLAC TROMETHAMINEAB CHELSEA LABS 10MGAB MYLAN 10MGAB ROXANE 10MGAB TEVA 10MGTORADOLAB + SYNTEX 10MGN74955 001
SEP 19, 1997
N74761 001
MAY 16, 1997
N74790 001
JUN 26, 1997
N74754 001
MAY 16, 1997N19645 001
DEC 20, 1991KRYPTON, KR-81M

GAS; INHALATION

MPI KRYPTON 81M GAS GENERATOR

MEDI PHYSICS N/A

NYCOMED AMERSHAM N/A

N18088 001
N18088 001LACTULOSE

POWDER FOR RECONSTITUTION; ORAL

LACTULOSE

INALCO 10GM/PACKET

+ 20GM/PACKET

N74712 001
DEC 10, 1997
N74712 002
DEC 10, 1997LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

+ GLAXO WELLCOME 150MG;300MG

N20857 001
SEP 26, 1997LANSOPRAZOLE

CAPSULE, DELAYED REL GRANULES; ORAL

PREVACID

TAP HOLDINGS 15MG

* 30MG

N20406 001
MAY 10, 1995
N20406 002
MAY 10, 1995

CAPSULE, DELAYED REL PELLETS; ORAL

PREVACID

TAP HOLDINGS 15MG

+ 30MG

N20406 001
MAY 10, 1995
N20406 002
MAY 10, 1995LETROZOLE

TABLET; ORAL

FEMARA

+ NOVARTIS 2.5MG

N20726 001
JUL 25, 1997

LEUCOVORIN CALCIUMINJECTABLE; INJECTION
LEUCOVORIN CALCIUM

<u>AP</u> + ABBOTT	<u>EQ 10MG BASE/ML</u>	N40147 001
		JUN 25, 1997
<u>AP</u> + BEDFORD	<u>EQ 200MG BASE/VIAL</u>	N40056 001
		MAY 23, 1995
* *	<u>EQ 200MG BASE/VIAL</u>	N40056 001
		MAY 23, 1995
<u>AP</u> GENSLIA	<u>EQ 350MG BASE/VIAL</u>	N40174 001
		JUN 12, 1997
<u>AP</u> + IMMUNEX	<u>EQ 350MG BASE/VIAL</u>	N08107 005
		APR 05, 1989
<u>AP</u> PHARMACHEMIE	<u>EQ 50MG BASE/VIAL</u>	N89628 001
		APR 17, 1997
<u>AP</u>	<u>EQ 100MG BASE/VIAL</u>	N89915 001
		APR 17, 1997

TABLET; ORAL

LEUCOVORIN CALCIUM

<u>AB</u> PAR PHARM	<u>EQ 5MG BASE</u>	N74544 001
		AUG 28, 1997
<u>AB</u>	<u>EQ 25MG BASE</u>	N74544 002
		AUG 28, 1997
<u>AB</u> PHARMACHEMIE	<u>EQ 5MG BASE</u>	N73099 001
		MAR 28, 1997
<u>AB</u>	<u>EQ 25MG BASE</u>	N73101 001
		MAR 28, 1997

LEUPROLIDE ACETATEINJECTABLE; INJECTION
LUPRON DEPOT-3

+ TAP HOLDINGS	11.25MG/VIAL	N20708 001
		MAR 07, 1997

LUPRON DEPOT-4		N20517 002
+ TAP HOLDINGS	30MG/VIAL	MAY 30, 1997

LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
LIDOCAINE HCL

<u>AP</u> ABBOTT	<u>1%</u>	N40013 001
		JUN 23, 1995

LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
LIDOCAINE HCL

<u>AP</u> ABBOTT	<u>2%</u>	N40078 001
		JUN 23, 1995
<u>AP</u> SANOFI WINTHROP	<u>1%</u>	N40013 001
		JUN 23, 1995
<u>AP</u>	<u>2%</u>	N40078 001
		JUN 23, 1995

LIOETHYRONE SODIUMTABLET; ORAL
CYTOMEL

JONES MEDCL INDS	EQ 0.005MG BASE	N10379 001
	EQ 0.025MG BASE	N10379 002
	EQ 0.05MG BASE	N10379 003
+ SMITHKLINE BEECHAM	EQ 0.005MG BASE	N10379 001
	EQ 0.025MG BASE	N10379 002
* *	EQ 0.05MG BASE	N10379 003

LITHIUM CARBONATETABLET, EXTENDED RELEASE; ORAL
LITHOBID

SOLVAY	100MG	N18027 001
+	300MG	N18027 001

LORAZEPAMINJECTABLE; INJECTION
LORAZEPAM

<u>AP</u> ABBOTT	<u>2MG/ML</u>	N74243 001
		APR 12, 1994
<u>AP</u>	<u>2MG/ML</u>	N74300 001
		APR 12, 1994
<u>AP</u>	<u>4MG/ML</u>	N74243 002
		APR 12, 1994
<u>AP</u>	<u>4MG/ML</u>	N74300 003
		MAR 19, 1997
<u>AP</u> STERLING WINTHROP	<u>2MG/ML</u>	N74243 001
		APR 12, 1994
<u>AP</u>	<u>2MG/ML</u>	N74300 001
		APR 12, 1994

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

<u>AP</u>	STERLING WINTHROP	<u>4MG/ML</u>	N74243 002
			APR 12, 1994

SOLUTION; ORAL

LORAZEPAM

+	ROXANE	0.5MG/5ML	N74648 001
			MAR 18, 1997

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

+	COCENSYS	EQ 25MG BASE/ML	N17658 001
*	LEDERLE	EQ 25MG BASE/ML	N17658 001

INJECTABLE; INJECTION

LOXITANE IM

+	COCENSYS	EQ 50MG BASE/ML	N18039 001
*	LEDERLE	EQ 50MG BASE/ML	N18039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

<u>AB</u>	COCENSYS	EQ 5MG BASE	N17525 001
<u>AB</u>		EQ 10MG BASE	N17525 002
<u>AB</u>	+	EQ 25MG BASE	N17525 003
<u>AB</u>		EQ 50MG BASE	N17525 004
<u>AB</u>	LEDERLE	EQ 5MG BASE	N17525 001
<u>AB</u>		EQ 10MG BASE	N17525 002
<u>AB</u>	*	EQ 25MG BASE	N17525 003
<u>AB</u>		EQ 50MG BASE	N17525 004

LYPRESSIN

SOLUTION; NASAL

DIAPID

*	NOVARTIS	0.185MG/ML	N16755 001
@		0.185MG/ML	N16755 001

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

	FUJISAWA	500MG/ML	N19316 001
			SEP 08, 1986

+ 500MG/ML

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	ABBOTT	1GM/100ML	N20488 001
			JUL 11, 1995

+ 1GM/100ML

MAGNESIUM SULFATE IN PLASTIC CONTAINER

	ABBOTT	4GM/100ML	N20309 001
			JUN 24, 1994

+ 80MG/ML

+ 4GM/100ML

+ 80MG/ML

MALATHION

LOTION; TOPICAL

OVIDE

*	GENDERM	0.5%	N18613 001
			AUG 02, 1982

@ 0.5%

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

+	NYCOMED	37.9MG/ML	N20652 001
			NOV 26, 1997

MANGANESE CHLORIDE TETRAHYDRATE

POWDER FOR RECONSTITUTION; ORAL

LUMENHANCE

+ BRACCO 3.49MG/GM

	N20686 001
	DEC 19, 1997

> DLT >
 > DLT >
 > DLT >
 > ADD >

> ADD >
 > ADD >
 > ADD >
 > ADD >

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HCL

AA	KV PHARM	<u>12.5MG</u>	N85524 001
AA		<u>25MG</u>	N85523 001
	@	12.5MG	N85524 001
	@	25MG	N85523 001
AA	VINTAGE PHARMS	<u>12.5MG</u>	N40179 001
			JAN 30, 1997
AA		<u>25MG</u>	N40179 002
			JAN 30, 1997
AA	ZENITH GOLDLINE	<u>12.5MG</u>	N84975 001
AA		<u>25MG</u>	N84657 001
	@	12.5MG	N83784 001
AA	ZENITH LABS	<u>12.5MG</u>	N83784 001
AA		<u>12.5MG</u>	N84975 001
AA		<u>25MG</u>	N84657 001

TABLET, CHEWABLE; ORAL

MECLIZINE HCL

AA	@ ZENITH GOLDLINE	25MG	N84976 001
	ZENITH LABS	<u>25MG</u>	N84976 001

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

HUMEGON

AB	* ORGANON	<u>75 IU/VIAL; 75 IU/VIAL</u>	N20328 001
			SEP 01, 1994
AB		<u>75 IU/VIAL; 75 IU/VIAL</u>	N20328 001
			SEP 01, 1994
AB	*	<u>150 IU/VIAL; 150 IU/VIAL</u>	N20328 002
			SEP 01, 1994
AB		<u>150 IU/VIAL; 150 IU/VIAL</u>	N20328 002
			SEP 01, 1994

REPRONAL

> DLT >			
> DLT >	AB	<u>75 IU/VIAL; 75 IU/VIAL</u>	N73598 001
> DLT >			JAN 30, 1997
> DLT >	AB	<u>150 IU/VIAL; 150 IU/VIAL</u>	N73599 001
> DLT >			JAN 30, 1997
> ADD >			
> ADD >	AB	<u>75 IU/VIAL; 75 IU/VIAL</u>	N73598 001
> ADD >			JAN 30, 1997
> ADD >	AB	<u>150 IU/VIAL; 150 IU/VIAL</u>	N73599 001
> ADD >			JAN 30, 1997

REPRONEX

FERRING

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HCL

AP	MALLINCKRODT	<u>10MG/ML</u>	N40163 001
			MAY 12, 1997

TABLET; ORAL

MEPERIDINE HCL

AA	ROXANE	<u>50MG</u>	N40110 001
			MAR 12, 1997
AA		<u>100MG</u>	N40110 002
			MAR 12, 1997
AA	ROYCE LABS	<u>50MG</u>	N40186 001
			JUN 30, 1997
AA		<u>100MG</u>	N40186 002
			JUN 30, 1997

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

AA	PUREPAC PHARM	<u>200MG</u>	N84804 001
AA		<u>400MG</u>	N84804 002
	@	200MG	N84804 001
	@	400MG	N84804 002
	@ ZENITH GOLDLINE	600MG	N84181 001
AA	ZENITH LABS	<u>600MG</u>	N84181 001

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

AA	JVL	<u>10MG/5ML</u>	N74702 001
			MAR 24, 1997
AA	MORTON GROVE	<u>10MG/5ML</u>	N71656 001
			OCT 13, 1987
AA		<u>10MG/5ML</u>	N74702 001
			MAR 24, 1997
	@	10MG/5ML	N71656 001
			OCT 13, 1987

METFORMIN HYDROCHLORIDETABLET; ORAL
GLUCOPHAGE

BRISTOL MYERS SQUIBB	500MG
	850MG
	500MG
+	850MG

N20357 001	
DEC 29, 1994	
N20357 002	
DEC 29, 1994	
N20357 001	
MAR 03, 1995	
N20357 002	
MAR 03, 1995	

> DLT >
> DLT >
> DLT >
> ADD >
> ADD >

METHOTREXATE SODIUM

INJECTABLE; INJECTION

FOLEX PFS

AP PHARMACIA AND UPJOHN EQ 25MG BASE/ML

@

EQ 25MG BASE/ML

MEXATE-AQ PRESERVED

AP BRISTOL MYERS EQ 25MG BASE/ML

@ BRISTOL MYERS SQUIBB EQ 25MG BASE/ML

N81242 001	
AUG 23, 1991	
N81242 001	
AUG 23, 1991	
N89887 001	
APR 14, 1989	
N89887 001	
APR 14, 1989	

METHACHOLINE CHLORIDEPOWDER FOR RECONSTITUTION; INHALATION
PROVOCHOLINE

METHAPHARM 100MG/VIAL

ROCHE 100MG/VIAL

N19193 001	
OCT 31, 1986	
N19193 001	
OCT 31, 1986	

METHOXSALLEN

CAPSULE; ORAL

OXSORALEN-ULTRA

+ ICN 10MG

N19600 001	
OCT 30, 1986	

CAPSULE, LIQUID FILLED; ORAL
OXSORALEN-ULTRA

* ICN 10MG

N19600 001	
OCT 30, 1986	

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB APPLIED ANAL 25MG

AB 50MG

N40011 001	
JUL 17, 1997	
N40011 002	
JUL 17, 1997	

METHYLCLOTHIAZIDE

TABLET; ORAL

METHYLCLOTHIAZIDE

AB ZENITH GOLDLINE 2.5MG

@

5MG

AB ZENITH LABS 2.5MG

AB 5MG

N87913 001	
JUN 03, 1982	
N87786 001	
MAY 18, 1982	
N87913 001	
JUN 03, 1982	
N87786 001	
MAY 18, 1982	

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA PUREPAC PHARM 500MG

AA 750MG

@

500MG

@

750MG

@ ZENITH GOLDLINE

500MG

@

750MG

AA ZENITH LABS 500MG

AA 750MG

N85718 001	
N85718 002	
N85718 001	
N85718 002	
N84648 001	
N84649 001	
N84648 001	
N84649 001	

METHYLDOPA

TABLET; ORAL

METHYLDOPA

AB HALSEY 125MG

N71751 001	
MAR 28, 1988	

METHYLDOPA

TABLET; ORAL
METHYLDOPA
AB HALSEY 250MG
 @ 125MG
 @ 250MG
AB PUREPAC PHARM 125MG
AB 250MG
AB 500MG
 @ 125MG
 @ 250MG
 @ 500MG

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
METHYLPHENIDATE HCL
AB DANBURY PHARMA 5MG
AB 10MG
AB 20MG

METHYLPREDNISOLONE

TABLET; ORAL
MEDROL
AB PHARMACIA AND UPJOHN 8MG
AB METHYLPREDNISOLONE
AB CHELSEA LABS 4MG
AB INVAMED 4MG
AB TRIGEN 4MG

N71752 001
 MAR 28, 1988
 N71751 001
 MAR 28, 1988
 N71752 001
 MAR 28, 1988
 N70749 001
 FEB 07, 1986
 N70750 001
 FEB 07, 1986
 N70452 001
 FEB 07, 1986
 N70749 001
 FEB 07, 1986
 N70750 001
 FEB 07, 1986
 N70452 001
 FEB 07, 1986

N40220 001
 AUG 29, 1997
 N40220 002
 AUG 29, 1997
 N40220 003
 AUG 29, 1997

N11153 004
 N40232 001
 OCT 16, 1997
 N40194 001
 OCT 31, 1997
 N40189 001
 OCT 31, 1997

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE
AB TRIGEN 8MG

N40189 002
 OCT 31, 1997

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL
AP ABBOTT EQ 5MG BASE/ML
AP FAULDING EQ 5MG BASE/ML
 @ EQ 5MG BASE/ML
AP SANOFI WINTHROP EQ 5MG BASE/ML

N74147 001
 AUG 02, 1996
 N71990 001
 JAN 18, 1989
 N71990 001
 JAN 18, 1989
 N74147 001
 AUG 02, 1996

SOLUTION; ORAL

METOCLOPRAMIDE
AA JVL EQ 5MG BASE/5ML
METOCLOPRAMIDE HCL
AA MORTON GROVE EQ 5MG BASE/5ML
 @ EQ 5MG BASE/5ML

N74703 001
 OCT 31, 1997
 N70949 001
 MAR 06, 1987
 N70949 001
 MAR 06, 1987

TABLET; ORAL

METOCLOPRAMIDE HCL
AB MUTUAL PHARM EQ 5MG BASE

N71536 002
 JAN 16, 1997

METOLAZONE

TABLET; ORAL
 MYKROX
 MEDEVA
 + 0.5MG
 0.5MG

N19532 001
 OCT 30, 1987
 N19532 001
 OCT 30, 1987

METOPROLOL TARTRATE

INJECTABLE; INJECTION			
<u>METOPROLOL TARTRATE</u>			
<u>AP</u>	ABBOTT	<u>1MG/ML</u>	N74133 001 DEC 21, 1993
<u>AP</u>	STERLING WINTHROP	<u>1MG/ML</u>	N74133 001 DEC 21, 1993

METRONIDAZOLE

CREAM; TOPICAL			
NORITATE			
+	DERMIK LABS	1%	N20743 001 SEP 26, 1997

GEL; VAGINAL			
METROGEL-VAGINAL			
+	3M	0.75%	N20208 001 AUG 17, 1992
*	CURATEK	0.75%	N20208 001 AUG 17, 1992

INJECTABLE; INJECTION			
<u>METRONIDAZOLE</u>			
<u>AP</u>	STERIS	<u>500MG/100ML</u>	N70042 001 DEC 20, 1984
@		500MG/100ML	N70042 001 DEC 20, 1984

TABLET, EXTENDED RELEASE; ORAL			
FLAGYL ER			
+	SEARLE	750MG	N20868 001 NOV 26, 1997

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL			
<u>MEXILETINE HCL</u>			
<u>AB</u>	WATSON LABS	<u>150MG</u>	N74711 001 FEB 26, 1997
<u>AB</u>		<u>200MG</u>	N74711 002 FEB 26, 1997
<u>AB</u>		<u>250MG</u>	N74711 003 FEB 26, 1997

MIBEFRADIL DIHYDROCHLORIDE

TABLET; ORAL			
POSICOR			
	ROCHE	EQ 50MG BASE	N20689 001 JUN 20, 1997
+		EQ 100MG BASE	N20689 002 JUN 20, 1997

MICONAZOLE

INJECTABLE; INJECTION			
MONISTAT			
*	JANSSEN	10MG/ML	N18040 001
@		10MG/ML	N18040 001

MICONAZOLE NITRATE

CREAM; TOPICAL			
MONISTAT-DERM			
+	J AND J	2%	N17494 001
*	JOHNSON RW	2%	N17494 001

LOTION; TOPICAL			
MONISTAT-DERM			
@	J AND J	2%	N17739 001
@	JOHNSON RW	2%	N17739 001

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL			
MINOCYCLINE HCL			
	LEDERLE	EQ 50MG BASE	N50451 001 AUG 10, 1982
*		EQ 100MG BASE	N50451 002 AUG 10, 1982
@		EQ 50MG BASE	N50451 003 AUG 10, 1982
@		EQ 100MG BASE	N50451 002 AUG 10, 1982

MIRTAZAPINE

TABLET; ORAL

REMERON

* ORGANON

10MG

30MG

45MG

+

N20415 002

JUN 14, 1996

N20415 002

JUN 14, 1996

N20415 003

MAR 17, 1997

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL

MOBAN

@ DUPONT MERCK

5MG

@

10MG

@

25MG

@ ENDO PHARMS

5MG

@

10MG

@

25MG

N17111 001

N17111 002

N17111 003

N17111 001

N17111 002

N17111 003

CONCENTRATE; ORAL

MOBAN

* DUPONT MERCK

20MG/ML

+ ENDO PHARMS

20MG/ML

N17938 001

N17938 001

TABLET; ORAL

MOBAN

DUPONT MERCK

5MG

*

10MG

*

25MG

*

50MG

*

100MG

ENDO PHARMS

5MG

+

10MG

+

25MG

+

50MG

+

100MG

N17111 004

N17111 005

N17111 006

N17111 007

N17111 008

N17111 004

N17111 005

N17111 006

N17111 007

N17111 008

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL

NASONEX

+ SCHERING PLOUGH

EQ 0.05MG BASE/SPRAY

N20762 001

OCT 01, 1997

> ADD >

MUPIROCIIN CALCIUM

> ADD >

CREAM, AUGMENTED; TOPICAL

> ADD >

BACTROBAN

> ADD >

+ SMITHKLINE BEECHAM 2%

> ADD >

> ADD >

N50746 001

DEC 11, 1997

MYCOPHENOLATE MOFETIL

TABLET; ORAL

CELLCEPT

+ SYNTEX

500MG

N50723 001

JUN 19, 1997

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NUBAIN

AP

* DUPONT MERCK

10MG/ML

N18024 001

AP

*

20MG/ML

N18024 002

AP

*

20MG/ML

MAY 27, 1982

AP

+ ENDO PHARMS

10MG/ML

N18024 001

AP

+

20MG/ML

N18024 002

MAY 27, 1982

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

AP

ABBOTT

0.02MG/ML

N70171 001

AP

*

0.4MG/ML

SEP 24, 1986

AP

*

0.4MG/ML

N70172 001

AP

SOLOPAK

0.02MG/ML

SEP 24, 1986

AP

*

0.4MG/ML

N71672 001

AP

*

0.4MG/ML

NOV 17, 1987

AP

*

0.4MG/ML

N71683 001

AP

*

0.4MG/ML

NOV 17, 1987

AP

*

0.4MG/ML

N71672 001

AP

*

0.4MG/ML

NOV 17, 1987

AP

*

0.4MG/ML

N71683 001

AP

*

0.4MG/ML

NOV 17, 1987

AP

*

0.4MG/ML

N70171 001

AP

*

0.4MG/ML

SEP 24, 1986

AP

*

0.4MG/ML

N70172 001

AP

*

0.4MG/ML

SEP 24, 1986

AP

*

0.4MG/ML

N70171 001

AP

*

0.4MG/ML

N70172 001

AP

*

0.4MG/ML

SEP 24, 1986

AP

*

0.4MG/ML

N70171 001

AP

*

0.4MG/ML

N70172 001

AP

*

0.4MG/ML

SEP 24, 1986

AP

*

0.4MG/ML

N70171 001

AP

*

0.4MG/ML

N70172 001

AP

*

0.4MG/ML

SEP 24, 1986

AP

*

0.4MG/ML

N70171 001

AP

*

0.4MG/ML

N70172 001

AP

*

0.4MG/ML

SEP 24, 1986

AP

*

0.4MG/ML

N70171 001

AP

*

0.4MG/ML

N70172 001

AP

*

0.4MG/ML

SEP 24, 1986

AP

*

0.4MG/ML

N70171 001

AP

*

0.4MG/ML

N70172 001

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NARCAN

<u>AP</u>	+	DUPONT MERCK	<u>0.4MG/ML</u>	N16636 001
<u>AP</u>	+		<u>1MG/ML</u>	N16636 003
				JUN 14, 1982
<u>AP</u>	+	ENDO PHARMS	<u>0.02MG/ML</u>	N16636 002
<u>AP</u>	+		<u>0.4MG/ML</u>	N16636 001
<u>AP</u>	+		<u>1MG/ML</u>	N16636 003
				JUN 14, 1982

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

PENTAZOCINE AND NALOXONE HYDROCHLORIDES

<u>AB</u>		ROYCE LABS	<u>EQ 0.5MG BASE;</u>	N74736 001
			<u>EQ 50MG BASE</u>	JAN 21, 1997
<u>AB</u>	+	<u>TALWIN NX</u>	<u>EQ 0.5MG BASE;</u>	N18733 001
		SANOPI	<u>EQ 50MG BASE</u>	DEC 16, 1982

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

<u>AO</u>		STERIS	<u>50MG/ML</u>	N87598 001
				OCT 06, 1983
<u>AO</u>			<u>100MG/ML</u>	N87599 001
				OCT 06, 1983
	@		50MG/ML	N87598 001
				OCT 06, 1983
	@		100MG/ML	N87599 001
				OCT 06, 1983

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

+	FISONS	<u>1.75MG/INH</u>	N19660 001
			DEC 30, 1992
+	RHONE POULENC RORER	<u>1.75MG/INH</u>	N19660 001
			DEC 30, 1992

NEDOCROMIL SODIUM

SOLUTION; INHALATION

TILADE

+ RHONE POULENC RORER 0.5%

N20750 001
OCT 01, 1997NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

SERZONE

@ BRISTOL MYERS SQUIBB 50MG

N20152 001
DEC 22, 1994
N20152 001
DEC 22, 1994

+ 50MG

NELFINAVIR MESYLATE

POWDER FOR RECONSTITUTION; ORAL

VIRACEPT

+ AGOURON EQ 50MG BASE/SCOOPFUL

N20778 001
MAR 14, 1997

TABLET; ORAL

VIRACEPT

+ AGOURON EQ 250MG BASE

N20779 001
MAR 14, 1997NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

AA PHARMA TEK 100%

N61579 001
N61579 001NEOMYCIN SULFATE

AA PADDock 100%

N62385 001
JUN 01, 1982NIACIN

TABLET; ORAL

NIACINAA HALSEY 500MG
@ 500MG
AA PUREPAC PHARM 500MGN83453 001
N83453 001
N83271 001

NIACIN

TABLET; ORAL

NIACIN

@ PUREPAC PHARM 500MG
 @ ZENITH GOLDLINE 500MG
 @ ZENITH LABS 500MG

N83271 001
 N83180 001
 N83180 001

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

+ KOS 375MG
 + 500MG
 + 750MG
 + 1GM

N20381 001
 JUL 28, 1997
 N20381 002
 JUL 28, 1997
 N20381 003
 JUL 28, 1997
 N20381 004
 JUL 28, 1997

NIASPAN TITRATION STARTER PACK

+ KOS 375MG;500MG;750MG

N20381 005
 JUL 28, 1997

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL

AB + NOVARTIS 7MG/24HR
AB + 14MG/24HR
AB + 21MG/24HR

N20076 001
 NOV 27, 1991
 N20076 002
 NOV 27, 1991
 N20076 003
 NOV 27, 1991

NICOTINE

AB SANO 7MG/24HR
AB 14MG/24HR
AB 21MG/24HR

N74645 001
 OCT 20, 1997
 N74611 001
 OCT 20, 1997
 N74612 001
 OCT 20, 1997

INHALANT; INHALATION

NICOTROL

+ PHARMACIA AND UPJOHN 4MG/CARTRIDGE

N20714 001
 MAY 02, 1997

NITROFURANTOIN

TABLET; ORAL

NITROFURANTOIN

@ ZENITH GOLDLINE 50MG
 @ 100MG
 @ ZENITH LABS 50MG
 @ 100MG

N80078 002
 N80078 001
 N80078 002
 N80078 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTION

AB MYLAN 100MG

N74967 002
 JUL 09, 1997

NITROFURANTOIN

AB MYLAN 50MG

N74967 001
 JUL 09, 1997

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

+ ABBOTT EQ 1MG BASE/ML
 * SANOI WINTHROP EQ 1MG BASE/ML

N07513 001
 N07513 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HCL

AB INVAMED EQ 10MG BASE
AB EQ 25MG BASE
AB EQ 50MG BASE
AB EQ 75MG BASE

N74835 001
 JUN 30, 1997
 N74835 002
 JUN 30, 1997
 N74835 003
 JUN 30, 1997
 N74835 004
 JUN 30, 1997

NYSTATIN

CREAM; TOPICAL

MYKINAC

@ ALPHARMA 100,000 UNITS/GM

N62387 001
 JUL 29, 1982

NYSTATIN

CREAM; TOPICAL

MYKINAC

<u>AT</u>	NMC	<u>100,000 UNITS/GM</u>	N62387 001
			JUL 29, 1982

OINTMENT; TOPICAL

MYCOSTATIN

<u>AT</u>	* SQUIBB	<u>100,000 UNITS/GM</u>	N60571 001
	@ WESTWOOD SQUIBB	100,000 UNITS/GM	N60571 001

MYKINAC

@ ALPHARMA

100,000 UNITS/GM

N62731 001

SEP 22, 1986

<u>AT</u>	NMC	<u>100,000 UNITS/GM</u>	N62731 001
			SEP 22, 1986

NILSTAT

LEDERLE

100,000 UNITS/GM

N61444 001

<u>AT</u>	+	<u>100,000 UNITS/GM</u>	N61444 001
-----------	---	-------------------------	------------

SUSPENSION; ORAL

NYSTATIN

ALPHARMA

100,000 UNITS/ML

N62571 001

OCT 29, 1985

@		100,000 UNITS/ML	N62571 001
			OCT 29, 1985

OFLOXACIN> ADD > SOLUTION/DROPS; OTIC> ADD > FLOXIN> ADD > + DAIICHI 0.3%> ADD >

N20799 001

DEC 16, 1997

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL

ZOFTRAN

+ GLAXO WELLCOME EQ 4MG BASE/5ML

N20605 001

JAN 24, 1997

OXACILLIN SODIUM

CAPSULE; ORAL

BACTOCILL

<u>AB</u>	SMITHKLINE BEECHAM	<u>EQ 250MG BASE</u>	N61336 001
-----------	--------------------	----------------------	------------

OXACILLIN SODIUM

CAPSULE; ORAL

BACTOCILL

<u>AB</u>	+	SMITHKLINE BEECHAM	<u>EQ 250MG BASE</u>	N61336 001
-----------	---	--------------------	----------------------	------------

OXACILLIN SODIUM

<u>AB</u>	*	APOTHECON	<u>EQ 250MG BASE</u>	N61450 002
-----------	---	-----------	----------------------	------------

<u>AB</u>	*		<u>EQ 500MG BASE</u>	N61450 001
-----------	---	--	----------------------	------------

@		EQ 250MG BASE	N61450 002
---	--	---------------	------------

@		EQ 500MG BASE	N61450 001
---	--	---------------	------------

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

* PARKE DAVIS 600MG

N86742 001

+ WARNER CHILCOTT 600MG

N86742 001

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

<u>AA</u>	MORTON GROVE	<u>5MG/5ML</u>	N74868 001
-----------	--------------	----------------	------------

FEB 12, 1997

<u>AA</u>	NU PHARM	<u>5MG/5ML</u>	N74997 001
-----------	----------	----------------	------------

OCT 15, 1997

TABLET; ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	N75079 001
-----------	----------------	------------	------------

OCT 31, 1997

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN

* PURDUE FREDERICK 10MG

N20553 001

DEC 12, 1995

* 20MG

N20553 002

DEC 12, 1995

* 40MG

N20553 003

DEC 12, 1995

+ PURDUE PHARMA 10MG

N20553 001

DEC 12, 1995

+ 20MG

N20553 002

DEC 12, 1995

OXYCODONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
OXYCONTIN+ PURDUE PHARMA 40MG
+ 80MGN20553 003 > DLT >
DEC 12, 1995 > DLT >
N20553 004 > ADD >
JAN 06, 1997 > ADD >OXYMETHOLONETABLET; ORAL
ANADROL-50* SKINTEX 50MG
+ UNIMED 50MGN16848 001
N16848 001OXYMORPHONE HYDROCHLORIDEINJECTABLE; INJECTION
NUMORPHAN* DUPONT MERCK 1MG/ML
* 1.5MG/ML
+ ENDO PHARMS 1MG/ML
+ 1.5MG/MLN11707 002
N11707 001
N11707 002
N11707 001SUPPOSITORY; RECTAL
NUMORPHAN* DUPONT MERCK 5MG
+ ENDO PHARMS 5MGN11738 004
N11738 004OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

AP WYETH AYERST 10 USP UNITS/ML
@ 10 USP UNITS/MLN18243 001
N18243 001

SOLUTION, NASAL

SYNTOCINON

* NOVARTIS 40 USP UNITS/ML
@ 40 USP UNITS/MLN12285 001
N12285 001PACLITAXELINJECTABLE; INJECTION
TAXOLBRISTOL MYERS SQUIBB 6MG/ML
+ 6MG/MLN20262 001
DEC 29, 1992
N20262 001
DEC 29, 1992PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

AB + PARKE DAVIS EQ 250MG BASE
AB EQ 250MG BASEN60521 001
N62310 001AB PAROMOMYCIN SULFATE
CARACO EQ 250MG BASEN64171 001
JUN 30, 1997PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAXIL

+ SMITHKLINE BEECHAM EQ 10MG BASE/5ML

N20710 001
JUN 25, 1997PENICILLIN G POTASSIUM

TABLET; ORAL

PENICILLIN G POTASSIUM

AB @ ZENITH GOLDLINE 400,000 UNITS
ZENITH LABS 400,000 UNITSN60073 004
N60073 004PENICILLIN V POTASSIUM

TABLET; ORAL

PENICILLIN V POTASSIUM

AB @ ZENITH GOLDLINE EQ 125MG BASE
@ EQ 250MG BASE
@ EQ 500MG BASE
AB ZENITH LABS EQ 125MG BASE
AB EQ 250MG BASE
AB EQ 500MG BASEN60518 001
N60518 002
N60518 003
N60518 001
N60518 002
N60518 003AB V-CILLIN K
* ELI LILLY EQ 125MG BASE

N60003 001

PENICILLIN V POTASSIUM

TABLET; ORAL
V-CILLIN K
+ LILLY

EQ 125MG BASE

N60003 001

PENTAZOCINE LACTATE

INJECTABLE; INJECTION
TALWIN
+ ABBOTT
* SANOPI WINTHROP

EO 30MG BASE/ML
EQ 30MG BASE/ML

N16194 001
N16194 001

PENTOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM PENTOBARBITAL
@ ZENITH GOLDLINE
@

50MG
100MG
50MG
100MG

N83461 001
N83461 002
N83461 001
N83461 002

> ADD >
> ADD >
> DLT >
> DLT >

AA
AA

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB ESI LEDERLE 400MG

AB MYLAN 400MG

AB PUREPAC PHARM 400MG

TRENTAL

AB + HOECHST MARION RSSL 400MG

N74877 001
JUL 08, 1997
N74425 001
JUL 08, 1997
N74878 001
JUL 09, 1997

N18631 001
AUG 30, 1984

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

RHONE-POULENC RORER 2MG
4MG

N20184 001
DEC 30, 1993
N20184 002
DEC 30, 1993

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

* RHONE-POULENC RORER 8MG

@ 2MG

@ 4MG

@ 8MG

N20184 001
DEC 30, 1993
N20184 001
DEC 30, 1993
N20184 002
DEC 30, 1993
N20184 003
DEC 30, 1993

PERMETHRIN

CREAM; TOPICAL
ELIMITE

+ ALLERGAN 5%

* GLAXO-WELLCOME 5%

N19855 001
AUG 25, 1989
N19855 001
AUG 25, 1989

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
BONTRIL

BC MALLINCKRODT 105MG

N88021 001
SEP 21, 1982

BC PHENDIMETRAZINE TARTRATE
GRAHAM DM 105MG

BC 105MG

BC 105MG

BC 105MG

BC 105MG

BC 105MG

BC 105MG

@ 105MG

@ 105MG

N87214 001
MAY 26, 1982
N88020 001
AUG 16, 1982
N88021 001
SEP 21, 1982
N88028 001
AUG 16, 1982
N88062 001
SEP 13, 1982
N88063 001
SEP 10, 1982
N88111 001
OCT 18, 1982
N87214 001
MAY 26, 1982
N88020 001
AUG 16, 1982

PHENDIMETRAZINE TARTRATECAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE

@ GRAHAM DM	105MG
@	105MG
@	105MG
@	105MG

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

AA	INWOOD LABS	35MG
AA		35MG
AA		35MG
AA		35MG
@		35MG
@		35MG
@		35MG
@		35MG
AA	KV PHARM	35MG
AA		35MG
AA		35MG
@		35MG
@		35MG
@		35MG
@	ZENITH GOLDLINE	35MG
@		35MG
@	ZENITH LABS	35MG
@		35MG
@		35MG

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

DAPEX-37.5

> DLT >	AA	FERNDAL LABS	37.5MG
---------	----	--------------	--------

> DLT >

PHENTERMINE HCL

AA	AMIDE PHARM	30MG
AA		37.5MG

N88028 001	> ADD >	AA
AUG 16, 1982	> ADD	
N88062 001		AA
SEP 13, 1982		
N88063 001		
SEP 10, 1982		
N88111 001		
OCT 18, 1982		

N84740 001		
N84741 001		
N84742 001	> ADD >	
N84743 001	> ADD >	
N84740 001		
N84741 001		
N84742 001		
N84743 001		
N84138 001	> DLT >	
N84141 001	> DLT >	
N85525 001		
N84138 001		
N84141 001		
N85525 001		
N83682 001		
N85611 001		
N85612 001		
N83682 001		
N85511 001		
N85612 001		

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HCL

AA	EON	37.5MG
AA	KING PHARMS	30MG
@	ZENITH GOLDLINE	30MG
@	ZENITH LABS	30MG

TABLET; ORAL

PHENTERMINE HCL

AA	AMIDE PHARM	37.5MG
@	EON	8MG
@		8MG
+		30MG
@	ZENITH GOLDLINE	8MG
@	ZENITH LABS	8MG
	UMI-PEX 30	
*	FERNDAL LABS	30MG

PHENYL BUTAZONE

CAPSULE; ORAL

PHENYL BUTAZONE

@	ZENITH GOLDLINE	100MG
@	ZENITH LABS	100MG

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP	ABBOTT	50MG/ML
AP	WINTHROP	50MG/ML

N88414 001
OCT 19, 1983

N40227 001
JUN 18, 1997
N40228 001
JUN 19, 1997

N88414 001
OCT 19, 1983
N40083 001
MAR 07, 1997
N86329 001
N86329 001

N40190 001
MAY 30, 1997
N85688 001
N85689 001
N88605 001
SEP 28, 1987
N85553 001
N85553 001
N88605 001
SEP 28, 1987

N88218 001
JUN 24, 1983
N88218 001
JUN 24, 1983

N89744 001
DEC 18, 1987
N89744 001
DEC 18, 1987

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL		
DILANTIN		
PARKE DAVIS	30MG	N84349 001
+	30MG	N84349 001

PIMOZIDE

TABLET; ORAL		
ORAP		
TEVA	1MG	N17473 003
		AUG 27, 1997

PINDOLOL

TABLET; ORAL		
<u>PINDOLOL</u>		
AB LEMMON	5MG	N74123 001
		APR 17, 1997
AB	10MG	N74123 002
		APR 17, 1997
AB TEVA	5MG	N74123 001
		APR 17, 1997
AB	10MG	N74123 002
		APR 17, 1997

PIROXICAM

CAPSULE; ORAL		
<u>PIROXICAM</u>		
AB EGIS	10MG	N74808 001
		JUL 08, 1997
AB	20MG	N74808 002
		JUL 08, 1997

PODOFILOX

GEL; TOPICAL		
CONDYLOX		
+ OCLASSEN	0.5%	N20529 001
		MAR 13, 1997

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM

AT + ALLERGAN	10,000 UNITS/ML;	
	EQ 1MG BASE/ML	

N50567 001
OCT 20, 1988

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT BAUSCH AND LOMB	10,000 UNITS/ML;	
	EQ 1MG BASE/ML	

N64120 001
FEB 14, 1997

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP * ABBOTT	745MG/100ML	N20161 001
		NOV 30, 1992
AP *	14.9MG/ML	N20161 005
		NOV 30, 1992
@	745MG/100ML	N20161 001
		NOV 30, 1992
@	14.9MG/ML	N20161 005
		NOV 30, 1992
AP * BAXTER HLTHCARE	745MG/100ML	N19904 005
		DEC 17, 1990
AP *	14.9MG/ML	N19904 001
		DEC 26, 1989
+	746MG/100ML	N19904 005
		DEC 17, 1990
+	14.9MG/ML	N19904 001
		DEC 26, 1989

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP * ABBOTT	1.49GM/100ML	N20161 002
		NOV 30, 1992
@	1.49GM/100ML	N20161 002
		NOV 30, 1992
AP * BAXTER HLTHCARE	1.49GM/100ML	N19904 006
		DEC 17, 1990
+	1.49GM/100ML	N19904 006
		DEC 17, 1990

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

MISSION PHARMA	5MEQ	
----------------	------	--

N19071 001
AUG 30, 1985

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

+ MISSION PHARMA 10MEQ

UNIV TX 5MEQ

* 10MEQ

N19071 002

AUG 31, 1992

N19071 001

AUG 30, 1985

N19071 002

AUG 31, 1992

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

+ PHARMACIA AND UPJOHN 0.125MG

0.25MG

1MG

@ 1.25MG

+ 1.5MG

N20667 001

JUL 01, 1997

N20667 002

JUL 01, 1997

N20667 003

JUL 01, 1997

N20667 004

JUL 01, 1997

N20667 005

JUL 01, 1997

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

BX PUREPAC PHARM 5MG

@ 5MG

@ ZENITH GOLDLINE 5MG

BX ZENITH LABS 5MG

N80325 001

N80325 001

N80378 001

N80378 001

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

PREDNISOLONE ACETATE

STERIS 25MG/ML

@ 25MG/ML

N83654 001

N83654 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

* PISONS EQ 5MG BASE/5ML

+ MEDEVA EQ 5MG BASE/5ML

N19157 001

MAY 28, 1986

N19157 001

MAY 28, 1986

PREDNISONE

TABLET; ORAL

PREDNISONE

AB HALERY 5MG

@ 5MG

@ ZENITH GOLDLINE 5MG

@ 10MG

@ 20MG

BX ZENITH LABS 5MG

BX 10MG

@ 20MG

N80300 001

N80300 001

N80283 001

N84133 001

N84134 001

N80283 001

N84133 001

N84134 001

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

AP ABBOTT 500MG/ML

> DLT > AP SOLOPAK 500MG/ML

> DLT > @ 500MG/ML

> ADD > @ 500MG/ML

> ADD > AP WINTHROP 500MG/ML

N89537 001

AUG 25, 1987

N88532 001

MAR 04, 1985

N88532 001

MAR 04, 1985

N89537 001

AUG 25, 1987

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HCL

AB INWOOD LABS 500MG

@ 500MG

N89840 001

MAR 06, 1989

N89840 001

MAR 06, 1989

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

AP + ABBOTT 1%

N85362 003

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

AP	+	ABBOTT	2%	N85362 004
			10%	N86797 001
AP	+	STERLING WINTHROP	1%	N85362 003
AP	+		2%	N85362 004
			10%	N86797 001
		<u>PROCAINE HCL</u>		
AP		STERIS	1%	N83535 001
AP			2%	N83535 002
	@		1%	N83535 001
	@		2%	N83535 002

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

TETRACYCLIN

*	Pfizer	40MG/VIAL; 250MG/VIAL	N60285 003
@		40MG/VIAL; 250MG/VIAL	N60285 003

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP	ABBOTT	EQ 5MG BASE/ML	N89703 001
			APR 07, 1988
AP	STERIS	EQ 5MG BASE/ML	N89605 001
			JUL 08, 1987
	@	EQ 5MG BASE/ML	N89605 001
			JUL 08, 1987
AP	STERLING WINTHROP	EQ 5MG BASE/ML	N89703 001
			APR 07, 1988

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

AB	DURAMED	EQ 5MG BASE	N40207 001
			MAY 01, 1997
AB		EQ 10MG BASE	N40207 002
			MAY 01, 1997

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

> DLT >	*	GLAXO WELLCOME	5MG	N09818 003
> ADD >	+	MONARCH PHARMS	5MG	N09818 003

PROGESTERONE

GEL; VAGINAL

CRINONE

		COLUMBIA RES LABS	4%	N20701 001
				JUL 31, 1997
	+		8%	N20701 002
				JUL 31, 1997
	+		8%	N20756 001
				MAY 13, 1997

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HCL

AP	ABBOTT	50MG/ML	N83838 002
AP	STERIS	25MG/ML	N83532 001
AP		50MG/ML	N83532 002
	@	25MG/ML	N83532 001
	@	50MG/ML	N83532 002
AP	STERLING WINTHROP	50MG/ML	N83838 002

TABLET; ORAL

PROMETHAZINE HCL

	@	ZENITH GOLDLINE	12.5MG	N83604 001
	@		25MG	N83603 001
	@		50MG	N83613 001
BP		ZENITH LABS	12.5MG	N83604 001
BP			25MG	N83603 001
	@		50MG	N83613 001

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

BP		PAR PHARM	15MG	N88377 001
	@		15MG	DEC 08, 1983
				N88377 001
				DEC 08, 1983

PROPIOMAZINE HYDROCHLORIDE

> DLT >	INJECTABLE; INJECTION		
> DLT >	LARGON		
> DLT >	* WYETH AYERST	20MG/ML	N12382 002
> ADD >	@	20MG/ML	N12382 002

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	<u>PROPOXYPHENE HCL</u>		
AA	ROXANE	32MG	N83089 001
AA		65MG	N83089 002
	@	32MG	N83089 001
	@	65MG	N83089 002
	@ ZENITH GOLDLINE	32MG	N83597 001
AA	ZENITH LABS	32MG	N83597 001

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

	<u>PROPRANOLOL HCL</u>		
> DLT >	AP	SOLEPAK	1MG/ML
> DLT >			N70136 001
> ADD >	@	1MG/ML	APR 15, 1986
> ADD >			N70136 001
			APR 15, 1986

TABLET; ORAL

	<u>PROPRANOLOL HCL</u>		
AB	ROXANE	10MG	N70516 001
			JUL 07, 1986
AB		20MG	N70517 001
			JUL 07, 1986
AB		40MG	N70518 001
			JUL 07, 1986
AB		60MG	N70519 001
			SEP 24, 1986
AB		80MG	N70520 001
			JUL 07, 1986
AB		90MG	N70521 001
			SEP 24, 1986
@		10MG	N70516 001
			JUL 07, 1986
@		20MG	N70517 001
			JUL 07, 1986
@		40MG	N70518 001
			JUL 07, 1986

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	<u>PROPRANOLOL HCL</u>		
@	ROXANE	60MG	N70519 001
			SEP 24, 1986
@		80MG	N70520 001
			JUL 07, 1986
@		90MG	N70521 001
			SEP 24, 1986
@	ZENITH GOLDLINE	10MG	N72063 001
			JUL 29, 1988
@		20MG	N72066 001
			JUL 29, 1988
@		40MG	N72067 001
			JUL 29, 1988
@		60MG	N72068 001
			JUL 29, 1988
@		80MG	N72069 001
			JUL 29, 1988
AB	ZENITH LABS	10MG	N72063 001
			JUL 29, 1988
AB		20MG	N72066 001
			JUL 29, 1988
AB		40MG	N72067 001
			JUL 29, 1988
AB		60MG	N72068 001
			JUL 29, 1988
@		80MG	N72069 001
			JUL 29, 1988

PROPYLTHIOURACIL

TABLET; ORAL

	<u>PROPYLTHIOURACIL</u>		
@	ZENITH GOLDLINE	50MG	N80215 001
@	ZENITH LABS	50MG	N80215 001

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

	<u>TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL</u>		
@	ZENITH GOLDLINE	60MG; 2.5MG	N85273 001
			DEC 12, 1984
AA	ZENITH LABS	60MG; 2.5MG	N85273 001
			DEC 12, 1984

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

<u>AP</u>	+	ICN	5MG/ML	N09830 001
<u>AP</u>	*	ROCHE	5MG/ML	N09830 001

SYRUP; ORAL

MESTINON

+	ICN	60MG/5ML	N15193 001
*	ROCHE	60MG/5ML	N15193 001

TABLET; ORAL

MESTINON

+	ICN	60MG	N09829 002
*	ROCHE	60MG	N09829 002

TABLET, EXTENDED RELEASE; ORAL

MESTINON

+	ICN	180MG	N11665 001
*	ROCHE	180MG	N11665 001

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HCL

<u>AP</u>		STERIS	100MG/ML	N83760 001
	@		100MG/ML	N83760 001

QUETIAPINE FUMARATE

TABLET; ORAL

SEROQUEL

ZENECA

EQ 25MG BASE	N20639 001
	SEP 26, 1997
EQ 100MG BASE	N20639 002
	SEP 26, 1997
+	EQ 200MG BASE
	N20639 003
	SEP 26, 1997

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

SOLVAY

200MG	N85296 001
300MG	N85297 001

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

@ SOLVAY

200MG

N85296 001

@

300MG

N85297 001

TABLET; ORAL

CIN-QUIN

@ SOLVAY

100MG

N85299 001

@

200MG

N84932 001

@

300MG

N85298 001

@

100MG

N85299 001

@

200MG

N84932 001

@

300MG

N85298 001

QUINIDINE SULFATE

@ ZENITH GOLDLINE

200MG

N84549 001

AB ZENITH LABS

200MG

N84549 001

TABLET, EXTENDED RELEASE; ORAL

QUINIDEXAB * ROBIN AH

300MG

N12796 002

AB + WYETH AYERST

300MG

N12796 002

> ADD >RALOXIFENE HYDROCHLORIDE> ADD >

TABLET; ORAL

> ADD >

EVISTA

> ADD >

+ LILLY

60MG

N20815 001

> ADD >

DEC 09, 1997

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HCLAB GENEVA PHARMSEQ 150MG BASE

N74655 001

ABEQ 300MG BASE

OCT 22, 1997

ABEQ 300MG BASE

N74655 002

ABEQ 150MG BASE

OCT 22, 1997

AB ZANTAC 150EQ 150MG BASE

N20095 001

AB GLAXO WELLCOMEEQ 150MG BASE

MAR 08, 1994

AB ZANTAC 300EQ 300MG BASE

N20095 002

AB + GLAXO WELLCOMEEQ 300MG BASE

MAR 08, 1994

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HCLAB BOEHRINGER INGELHEIM EQ 150MG BASEAB EQ 300MG BASEAB CHELSEA LABS EQ 150MG BASEAB EQ 300MG BASEAB GENEVA PHARMS EQ 150MG BASEAB EQ 300MG BASEAB GENPHARM EQ 150MG BASEAB EQ 300MG BASEAB GRANUTEC PHARMS EQ 150MG BASEAB EQ 300MG BASEAB TORPHARM EQ 150MG BASEAB EQ 300MG BASEZANTAC 150AB GLAXO WELLCOME EQ 150MG BASEZANTAC 300AB + GLAXO WELLCOME EQ 300MG BASE

N74662 001

AUG 29, 1997

N74662 002

AUG 29, 1997

N74864 001

OCT 20, 1997

N74864 002

OCT 20, 1997

N74467 001

AUG 29, 1997

N74467 002

AUG 29, 1997

N74023 001

AUG 22, 1997

N74023 002

AUG 22, 1997

N74488 001

JUL 31, 1997

N74488 002

JUL 31, 1997

N74680 001

SEP 12, 1997

N74680 002

SEP 12, 1997

N18703 001

JUN 09, 1983

N18703 002

DEC 09, 1985

RAUWOLFIA SERPENTINA

TABLET; ORAL

RAUWOLFIA SERPENTINA

@ GLOBAL PHARM 50MG

@ 100MG

@ ZENITH GOLDLINE 50MG

@ 100MG

@ ZENITH LABS 50MG

@ 100MG

> ADD >

REPAGLINIDE

> ADD >

TABLET; ORAL

> ADD >

PRANDIN

> ADD >

NOVO NORDISK

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

+

RESERPINE

TABLET; ORAL

RESERPINE

BP PUREPAC PHARM 0.1MG

BP 0.25MG

@ 0.1MG

@ 0.25MG

@ TABLICAPS 0.25MG

@ 0.25MG

@ ZENITH GOLDLINE 0.1MG

@ 0.25MG

@ ZENITH LABS 0.1MG

@ 0.25MG

RIFAMPIN

CAPSULE; ORAL

RIFAMPIN

AB EON 300MG

N09273 001

N09273 002

N11521 001

N11521 002

N11521 001

N11521 002

N20741 001

DEC 22, 1997

N20741 002

DEC 22, 1997

N20741 003

DEC 22, 1997

N80753 002

N80753 001

N80753 002

N80753 001

N85207 001

N85207 001

N11185 001

N11185 002

N11185 001

N11185 002

N64150 001

MAY 28, 1997

RAUWOLFIA SERPENTINA

TABLET; ORAL

RAUVAL

BP PAL PAK 50MG

* 100MG

@ 50MG

@ 100MG

RAUWOLFIA SERPENTINA

BP DANBURY PHARMA 50MG

BP 50MG

BP GLOBAL PHARM 50MG

BP 100MG

N09108 002

N09108 004

N09108 002

N09108 004

N80907 001

N80907 001

N09273 001

N09273 002

ROPINIROLE HYDROCHLORIDETABLET; ORAL
REQUIP

+ SMITHKLINE BEECHAM	EQ 0.25MG BASE	N20658 001
		SEP 19, 1997
	EQ 0.5MG BASE	N20658 002
		SEP 19, 1997
	EQ 1MG BASE	N20658 003
		SEP 19, 1997
	EQ 2MG BASE	N20658 004
		SEP 19, 1997
+	EQ 5MG BASE	N20658 005
		SEP 19, 1997

SALMETEROL XINAFOATEPOWDER; INHALATION
SEREVENT

+ GLAXO WELLCOME	EQ 0.046MG BASE/INH	N20692 001
		SEP 19, 1997

SAMARIUM SM 153 LEXIDRONAM PENTASODIUMINJECTABLE; INJECTION
QUADRAMET
CYTOGEN

50mCi/ML	N20570 001
	MAR 28, 1997

SAQUINAVIRCAPSULE; ORAL
FORTOVASE
ROCHE

EQ 200MG BASE	N20828 001
	NOV 07, 1997

SCOPOLAMINEFILM, EXTENDED RELEASE; TRANSDERMAL
TRANSDERM SCOP

* CIBA	0.5MG/24HR	N17874 001
+ NOVARTIS	1MG/72HR	N17874 001

SECOBARBITAL SODIUMCAPSULE; ORAL
SECOBARBITAL SODIUM

@ ZENITH GOLDLINE	100MG	N85869 001
@ ZENITH LABS	100MG	N85869 001
<u>SODIUM SECOBARBITAL</u>		
<u>AA</u> HALSEY	100MG	N84676 001
@	100MG	N84676 001

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

<u>AS</u> ELDEPRYL	5MG	N20647 001
* SOMERSET		MAY 15, 1996
+	5MG	N20647 001
		MAY 15, 1996

TABLET; ORAL
SELEGILINE HCL
ALPHAPHARM

<u>AB</u>	5MG	N74866 001
		NOV 26, 1997
<u>AB</u> APOTEX	5MG	N74871 001
		JUN 06, 1997
<u>AB</u> APOTHECON	5MG	N74672 001
		APR 01, 1997
<u>AB</u> ENDO LABS	5MG	N74565 001
		AUG 02, 1996
<u>AB</u> ENDO PHARMS	5MG	N74565 001
		AUG 02, 1996
<u>AB</u> TEVA	5MG	N74744 001
		JAN 27, 1997

SELENIUM SULFIDELOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE

> ADD >	<u>AT</u>	MORTON GROVE	2.5%	N88228 001
> ADD >				SEP 01, 1983
> DLT >			2.5%	N88228 001
> DLT >				SEP 01, 1983

SERMORELIN ACETATEINJECTABLE; INJECTION
GEREF

+	SERONO	EQ 0.5MG BASE/VIAL	N20443 001
			SEP 26, 1997
+		EQ 1MG BASE/VIAL	N20443 002
			SEP 26, 1997

SIBUTRAMINE HYDROCHLORIDECAPSULE; ORAL
MERIDIA
KNOLL PHARM

	5MG	N20632 001
		NOV 22, 1997
	10MG	N20632 002
		NOV 22, 1997
+	15MG	N20632 003
		NOV 22, 1997

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	ABBOTT	<u>9MG/ML</u>	N19465 002
			JUL 15, 1985

SODIUM IODIDE, I-123CAPSULE; ORAL
SODIUM IODIDE I 123

<u>AA</u>	<u>GOLDEN PHARMS</u>	<u>100 uCi</u>	N18671 001	> DLT >
			MAY 27, 1982	> DLT >
<u>AA</u>		<u>200 uCi</u>	N18671 002	> DLT >
			MAY 27, 1982	> ADD >
	@	<u>400 uCi</u>	N18671 003	> ADD >
			MAY 27, 1982	
<u>AA</u>	<u>MEDI PHYSICS</u>	<u>100 uCi</u>	N17630 001	
<u>AA</u>	<u>NYCOMED AMERSHAM</u>	<u>100 uCi</u>	N17630 001	
<u>AA</u>	<u>SYNCOR PHARMS</u>	<u>100 uCi</u>	N18671 001	
			MAY 27, 1982	
			N18671 002	
			MAY 27, 1982	
<u>AA</u>		<u>200 uCi</u>	N18671 003	
	@	<u>400 uCi</u>	N18671 003	
			MAY 27, 1982	

SODIUM IODIDE, I-131CAPSULE; ORAL
IODOTOPE

<u>BRACCO</u>	<u>8-100 uCi</u>	N10929 001
	<u>1-50mCi</u>	N10929 002
	<u>8-100 uCi</u>	N10929 001
	<u>1-130mCi</u>	N10929 003

SODIUM NITROPRUSSIDEINJECTABLE; INJECTION
NITROPRESS

<u>AP</u>	<u>ABBOTT</u>	<u>50MG/VIAL</u>	N71555 001
			NOV 16, 1987
	@	50MG/VIAL	N71555 001
			NOV 16, 1987

SOMATROPIN, BIOSYNTHETICINJECTABLE; INJECTION
NORDITROPIN

BX	+	NOVO NORDISK	4MG/VIAL	N19721 001
				MAY 08, 1995
BX		SEROSTIM	4MG/VIAL	N20604 003
		SERONO		JUL 25, 1997

SOYBEAN OIL

INJECTABLE; INJECTION

	<u>TRAVAMULSION 10%</u>		N18660 001
<u>AP</u>	* <u>BAXTER HEALTHCARE</u>	<u>10%</u>	FEB 26, 1982
	@	10%	N18660 001
			FEB 26, 1982

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

@	ZENITH GOLDLINE	25MG	N87108 001
<u>AB</u>	<u>ZENITH LABS</u>	<u>25MG</u>	N87108 001

STRONTIUM CHLORIDE, SR-89INJECTABLE; INJECTION
METASTRON

MEDI PHYSICS 1mCi/ML

N20134 001

JUN 18, 1993

NYCOMED AMERSHAM 1mCi/ML

N20134 001

JUN 18, 1993

SULFAMETHOXAZOLESUSPENSION; ORAL
GANTANOL* ROCHE 500MG/5ML
@ 500MG/5ML

N13664 002

N13664 002

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP ABBOTT 80MG/ML; 16MG/ML

N73199 001

SEP 11, 1992

AP STERLING WINTHROP 80MG/ML; 16MG/ML

N73199 001

SEP 11, 1992

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM> ADD >
> ADD > AP HI TECH PHARMA 200MG/5ML; 40MG/5ML
> ADD >

N74650 001

DEC 29, 1997

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE> DLT > AP LEDERLE 500MG
> ADD > @ 500MG

N80197 001

N80197 001

SULFINPYRAZONE

CAPSULE; ORAL

SULFINPYRAZONE

AB ZENITH GOLDLINE 200MG

N87770 001

NOV 19, 1982

AB ZENITH LABS 200MG

N87770 001

NOV 19, 1982

SULFINPYRAZONE

TABLET; ORAL

SULFINPYRAZONE

@ ZENITH GOLDLINE 100MG

N87769 001

JUN 01, 1982

AB ZENITH LABS 100MG

N87769 001

JUN 01, 1982

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

AB PUREPAC PHARM 500MG

N80087 001

@ 500MG

N80087 001

AB + ZENITH GOLDLINE 500MG

N80142 001

AB * ZENITH LABS 500MG

N80142 001

SULFISOXAZOLE DIOLAMINE

SOLUTION/DROPS; OPHTHALMIC

GANTRISIN

* ROCHE EQ 4% BASE

N07757 002

@ EQ 4% BASE

N07757 002

SUMATRIPTAN

SPRAY; NASAL

IMITREX

+ GLAXO WELLCOME 5MG/SPRAY

N20626 001

AUG 26, 1997

+ 10MG/SPRAY

N20626 002

AUG 26, 1997

+ 20MG/SPRAY

N20626 003

AUG 26, 1997

> ADD > TALC

> ADD >

AEROSOL; INTRAPLEURAL

> ADD >

SCLEROSOL

> ADD >

+ BRYAN 400MG/SPRAY

N20587 001

> ADD >

DEC 24, 1997

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

* ZENECA

EQ 10MG BASE

N17970 001

EQ 10MG BASE

N17970 001

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

FLOMAX

+ BOEHRINGER INGELHEIM 0.4MG

N20579 001

APR 15, 1997

TAZAROTENE

GEL; TOPICAL

TAZORAC

ALLERGAN

0.05%

N20600 001

JUN 13, 1997

+

0.1%

N20600 002

JUN 13, 1997

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

AN-MAA

@ CIS

N/A

BS SORIN

N/A

N17792 001

N17792 001

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M HSA

MEDI PHYSICS

N/A

NYCOMED AMERSHAM

N/A

N17775 001

N17775 001

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION

CERETEC

AMERSHAM

N/A

N19829 001

DEC 30, 1988

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION

CERETEC

NYCOMED AMERSHAM

N/A

N19829 001

DEC 30, 1988

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

AN-MDP

CIS

N/A

N18124 001

CIS-MDP

CIS

N/A

N18124 001

MDP-BRACCO

BRACCO

N/A

N18107 001

MDP-SQUIBB

BRACCO

N/A

N18107 001

TECHNETIUM TC 99M MPI MDP

MEDI PHYSICS

N/A

N18141 001

NYCOMED AMERSHAM

N/A

N18141 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

MPI DTPA KIT - CHELATE

AP

MEDI PHYSICS

N/A

N17255 001

AP

NYCOMED AMERSHAM

N/A

N17255 001

TECHNETIUM TC-99M PENTETATE KIT

AP

MEDI PHYSICS

N/A

N17264 002

AP

NYCOMED AMERSHAM

N/A

N17264 002

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

AN-PYROTEC

@ CIS

N/A

N19039 001

JUN 30, 1987

CIS-PYRO

CIS

N/A

N19039 001

JUN 30, 1987

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
MIRALUMA
DUPONT

N/A

N19785 003
MAY 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
TECHNETIUM TC 99M GENERATOR

MEDI PHYSICS 830-16,600mCi/GENERATOR N17693 001
NYCOMED AMERSHAM 830-16,600mCi/GENERATOR N17693 001

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION
MPI DMSA KIDNEY REAGENT

MEDI PHYSICS N/A

NYCOMED AMERSHAM N/A

N17944 001
MAY 18, 1982
N17944 001
MAY 18, 1982

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION
MYOVUE

MEDI PHYSICS N/A

NYCOMED AMERSHAM N/A

N20372 001
FEB 09, 1996
N20372 001
FEB 09, 1996

TERBINAFINE HYDROCHLORIDE

SOLUTION; TOPICAL
LAMISIL
+ NOVARTIS

1%

N20749 001
OCT 17, 1997

TERFENADINE

TABLET; ORAL
SELDANE

AB + HOECHST MARION RSSL 60MG

N18949 001
MAY 08, 1985

TERFENADINE

TABLET; ORAL

TERFENADINE

AB BAKER NORTON

60MG

N74475 001
JAN 03, 1997

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

BX + THERATECH 5MG/24HR

N20489 002
MAY 02, 1997

TESTODERM

BX + ALZA 5MG/24HR

N20791 001
DEC 18, 1997

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HCL

AB WARNER CHILCOTT

250MG

N62300 001

AB 500MG

N62300 002

@ 250MG

N62300 001

@ 500MG

N62300 002

INJECTABLE; INJECTION

ACHROMYCIN

AP * LEDERLE

250MG/VIAL

N50273 002

AP 500MG/VIAL

N50273 003

+ 250MG/VIAL

N50273 002

500MG/VIAL

N50273 003

TETRACYN

AP PFIZER

250MG/VIAL

N60096 001

AP 500MG/VIAL

N60096 002

@ 250MG/VIAL

N60096 001

@ 500MG/VIAL

N60096 002

SUSPENSION; ORAL

TETRACYCLINE HCL

AB ALPHARMA

125MG/5ML

N60633 001

@ 125MG/5ML

N60633 001

AB PUREPAC PHARM 125MG/5ML

N60291 001

@ 125MG/5ML

N60291 001

TETRACYN

AB PFIPHARMECS

125MG/5ML

N60095 001

@ 125MG/5ML

N60095 001

TETRACYCLINE HYDROCHLORIDE

SUSPENSION; ORAL

TETRAMED

	@ ZENITH GOLDLINE	125MG/5ML	N61468 001
<u>AB</u>	ZENITH LABS	<u>125MG/5ML</u>	<u>N61468 001</u>

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

<u>AP</u>	DUPONT	<u>1mCi/ML</u>	<u>N17806 001</u>
<u>AP</u>	+	<u>1mCi/ML</u>	<u>N17806 001</u>
<u>AP</u>	MALLINCKRODT	<u>1mCi/ML</u>	<u>N18150 001</u>
<u>AP</u>	+	<u>1mCi/ML</u>	<u>N18150 001</u>
<u>AP</u>	* MEDI PHYSICS	<u>1mCi/ML</u>	<u>N18110 002</u>
			FEB 27, 1996
<u>AP</u>	+	<u>1mCi/ML</u>	<u>N18110 002</u>
			FEB 27, 1996

THEOPHYLLINE

CAPSULE; ORAL

BRONKODYL

<u>BP</u>	STERLING WINTHROP	100MG	N85264 001
<u>BP</u>		200MG	N85264 002
	@	100MG	N85264 001
	@	200MG	N85264 002
	<u>THEOPHYLLINE</u>		
<u>BP</u>	KV PHARM	100MG	N85263 001
<u>BP</u>		200MG	N85263 002
	@	100MG	N85263 001
	@	200MG	N85263 002

CAPSULE, EXTENDED RELEASE; ORAL

SOMOPHYLLIN-CRT

<u>BC</u>	GRAHAM DM	50MG	N87763 001
			FEB 27, 1985
<u>BC</u>		100MG	N87194 001
<u>BC</u>		200MG	N88382 001
			FEB 27, 1985
<u>BC</u>		250MG	N87193 001
<u>BC</u>		300MG	N88383 001
			FEB 27, 1985
	@	50MG	N87763 001
			FEB 27, 1985
	@	100MG	N87194 001

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

SOMOPHYLLIN-CRT

@ GRAHAM DM	200MG	N88382 001
		FEB 27, 1985
@	250MG	N87193 001
@	300MG	N88383 001
		FEB 27, 1985

THEO-24

	UCB	100MG	N87942 001
> ADD >	BC		
> ADD >			
> ADD >	BC	200MG	N87943 001
> ADD >			AUG 22, 1983
> ADD >	BC	300MG	N87944 001
> ADD >			AUG 22, 1983
> ADD >		400MG	N81034 001
> ADD >			FEB 28, 1992
> DLT >	BC	100MG	N87942 001
> DLT >			AUG 22, 1983
> DLT >	BC	200MG	N87943 001
> DLT >			AUG 22, 1983
> DLT >	BC	300MG	N87944 001
> DLT >			AUG 22, 1983
> DLT >		400MG	N81034 001
> DLT >			FEB 28, 1992

THEO-DUR

	KEY PHARMS	50MG	N88022 001
BC			SEP 10, 1985
		75MG	N88015 001
BC			SEP 10, 1985
		125MG	N88016 001
BC			SEP 10, 1985
		200MG	N87995 001
BC			SEP 10, 1985
	@ SCHERING	50MG	N88022 001
			SEP 10, 1985
	@	75MG	N88015 001
			SEP 10, 1985
	@	125MG	N88016 001
			SEP 10, 1985
	@	200MG	N87995 001
			SEP 10, 1985

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

<u>AP</u>	<u>THIAMINE HCL</u>	<u>100MG/ML</u>	N40079 001
	ABBOTT		MAY 03, 1996
<u>AP</u>	<u>SANOFI WINTHROP</u>	<u>100MG/ML</u>	N40079 001
			MAY 03, 1996
<u>AP</u>	<u>STERIS</u>	<u>100MG/ML</u>	N83534 001
		<u>200MG/ML</u>	N83534 002
	@	100MG/ML	N83534 001
	@	200MG/ML	N83534 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

<u>AA</u>	<u>THIORIDAZINE HCL</u>	<u>30MG/ML</u>	N40187 001
	PHARM ASSOC		AUG 28, 1997

THIOTHIXENE HYDROCHLORIDE

INJECTABLE; INJECTION

NAVANE

> <u>DLT</u> >	* ROERIG	EQ 2MG BASE/ML	N16904 001
> <u>DLT</u> >		EQ 10MG BASE/VIAL	N16904 002
> <u>ADD</u> >	@	EQ 2MG BASE/ML	N16904 001
> <u>ADD</u> >	+	EQ 10MG BASE/VIAL	N16904 002

THYROTROPIN

INJECTABLE; INJECTION

THYTROPAR

*	ARMOUR PHARM	10 IU/VIAL	N08682 001
@	RHONE POULENC	10 IU/VIAL	N08682 001

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

ABBOTT	4MG	N20646 001
		SEP 30, 1997
	12MG	N20646 002
		SEP 30, 1997

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

ABBOTT	16MG	N20646 003
		SEP 30, 1997
+	20MG	N20646 004
		SEP 30, 1997

TILUDRONATE DISODIUM

TABLET; ORAL

SKELID

+	SANOFI	EQ 200MG BASE	N20707 001
			MAR 07, 1997

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

* LEIRAS	EQ 0.25% BASE	N20439 001	
		MAR 31, 1995	
*	EQ 0.5% BASE	N20439 002	
		MAR 31, 1995	
+	OY STAR	EQ 0.25% BASE	N20439 001
			MAR 31, 1995
+	EQ 0.5% BASE	N20439 002	
			MAR 31, 1995

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

<u>AT</u>	ADV REMEDIES	EQ 0.25% BASE	N74465 001
			MAR 25, 1997
<u>AT</u>		EQ 0.5% BASE	N74466 001
			MAR 25, 1997
<u>AT</u>	AKORN	EQ 0.25% BASE	N74515 001
			MAR 25, 1997
<u>AT</u>		EQ 0.5% BASE	N74516 001
			MAR 25, 1997
<u>AT</u>	BAUSCH AND LOMB	EQ 0.25% BASE	N74778 001
			MAR 25, 1997
<u>AT</u>		EQ 0.5% BASE	N74776 001
			MAR 25, 1997

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AT FOUGERA EQ 0.25% BASE
 AT EQ 0.5% BASE
 AT PACIFIC PHARMA EQ 0.25% BASE
 AT EQ 0.5% BASE

N74667 001
 MAR 25, 1997
 N74668 001
 MAR 25, 1997
 N74746 001
 MAR 25, 1997
 N74747 001
 MAR 25, 1997

TIOCONAZOLEOINTMENT; VAGINAL
VAGISTAT-1

* BRISTOL MYERS 6.5%

N19345 001
 DEC 30, 1986

TIOPRONINTABLET; ORAL
TIOPRONIN

+ MISSION PHARMA 100MG

* UNIV TX 100MG

N19569 001
 AUG 11, 1988
 N19569 001
 AUG 11, 1988

TOBRAMYCIN

> ADD > SOLUTION; INHALATION
 > ADD > TOBI
 > ADD > + PATHOGENESIS 300MG/5ML
 > ADD >

N50753 001
 DEC 22, 1997

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

AB PUREPAC PHARM 500MG
 @ 500MG

N88950 001
 JUN 17, 1985
 N88950 001
 JUN 17, 1985

TOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM

AB BAKER NORTON EQ 600MG BASE
 AB LEMMON EQ 600MG BASE
 @ TEVA EQ 600MG BASE
 AB ZENITH GOLDLINE EQ 600MG BASE

N74399 001
 MAR 28, 1996
 N74729 001
 FEB 27, 1997
 N74729 001
 FEB 27, 1997
 N74399 001
 MAR 28, 1996

TOPIRAMATETABLET; ORAL
TOPAMAX

@ JOHNSON RW 400MG

N20505 006
 DEC 24, 1996

TOREMIFENE CITRATETABLET; ORAL
FARESON

+ ORION EQ 60MG BASE

N20497 001
 MAY 29, 1997

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HCL

AB TEVA 150MG

N74357 001
 APR 30, 1997

TRETINOIN

CREAM; TOPICAL

AVITA

> DLT > AB DENEDERM 0.025%
 > DLT >
 > ADD > AB + 0.025%
 > ADD >
 > DLT > RENOVA 0.05%
 > DLT > J AND J

N20404 003
 JAN 14, 1997
 N20404 003
 JAN 14, 1997
 N19963 001
 DEC 29, 1995

TRETINOIN

CREAM; TOPICAL			
RENOVA			
> ADD >	+ J AND J	0.05%	N19963 001
> ADD >			DEC 29, 1995
<u>RETIN-A</u>			
AB	+ J AND J	0.025%	N19049 001
			SEP 16, 1988
GEL; TOPICAL			
RETIN-A MICRO			
	+ ADV POLYMER	0.1%	N20475 001
			FEB 07, 1997

TRIAMCINOLONE

TABLET; ORAL			
TRIAMCINOLONE			
BP	PUREPAC PHARM	2MG	N84020 002
BP		4MG	N84020 003
	@	2MG	N84020 002
	@	4MG	N84020 003
	@ ZENITH GOLDLINE	4MG	N83750 001
BP	ZENITH LABS	4MG	N83750 001

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL			
<u>TRIAMCINOLONE ACETONIDE</u>			
AT	TARO	0.1%	N40039 001
			NOV 26, 1997
LOTION; TOPICAL			
<u>TRIAMCINOLONE ACETONIDE</u>			
AT	ALPHARMA	0.1%	N87192 001
			SEP 08, 1982
	@	0.1%	N87192 001
			SEP 08, 1982

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION			
TRIAMCINOLONE DIACETATE			
BP	STERIS	40MG/ML	N85529 001
	@	40MG/ML	N85529 001

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL			
<u>TRIFLUOPERAZINE HCL</u>			
AB	MYLAN	EQ 1MG BASE	N40209 001
			JUL 07, 1997
AB		EQ 2MG BASE	N40209 002
			JUL 07, 1997
AB		EQ 5MG BASE	N40209 003
			JUL 07, 1997
AB		EQ 10MG BASE	N40209 004
			JUL 07, 1997

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE, ORAL			
ARTANE			
	* LEDELER	5MG	N12947 001
	@	5MG	N12947 001
ELIXIR; ORAL			
<u>TRIHEXYPHENIDYL HCL</u>			
AA	PHARM ASSOC	2MG/5ML	N40177 001
			APR 17, 1997

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION			
<u>TRIMETHOBENZAMIDE HCL</u>			
AP	ABBOTT	100MG/ML	N88804 001
			APR 03, 1987
> DLT >	AE	SOLOPAK	100MG/ML
> DLT >			N88094 001
> ADD >	@	100MG/ML	N89094 001
> ADD >			APR 04, 1986
	AP	STERLING WINTHROP	100MG/ML
			N88804 001
			APR 03, 1987

TRIMETHOPRIM

TABLET; ORAL			
<u>PROLOPRIM</u>			
AB	GLAXO WELLCOME	200MG	N17943 003
			JUL 14, 1982
AB	+	200MG	N17943 003
			JUL 14, 1982

TRIMETHOPRIM

TABLET; ORAL
TRIMETH 200
AB * ROCHE 200MG
 @ 200MG

N17952 002
 NOV 09, 1982
 N17952 002
 NOV 09, 1982

TROGLITAZONE

TABLET; ORAL
PRELAY
AB SANKYO 200MG
AB 300MG
AB 400MG
REZULIN
AB PARKE DAVIS 200MG
AB 300MG
AB 400MG

N20719 001
 JAN 29, 1997
 N20719 003
 AUG 04, 1997
 N20719 002
 JAN 29, 1997
 N20720 001
 JAN 29, 1997
 N20720 003
 AUG 04, 1997
 N20720 002
 JAN 29, 1997

> ADD > TROVAFLOXACIN MESYLATE
 > ADD > TABLET; ORAL
 > ADD > TROVAN
 > ADD > PFIZER EQ 100MG BASE
 > ADD > + EQ 200MG BASE
 > ADD >

N20759 001
 DEC 18, 1997
 N20759 002
 DEC 18, 1997

UREA, C-14

CAPSULE; ORAL
 PYTEST
 + TRI MED SPECLTS 1 uCi
 PYTEST KIT
 + TRI MED SPECLTS 1 uCi

N20617 001
 MAY 09, 1997
 N20617 002
 MAY 09, 1997

URSODIOL

> ADD > TABLET; ORAL
 > ADD > URSO
 > ADD > + AXCAN 250MG
 > ADD >

N20675 001
 DEC 10, 1997

VANCOMYCIN HYDROCHLORIDEINJECTABLE; INJECTION

AP LYPHOCIN FUJISAWA EQ 500MG BASE/VIAL N62663 001
AP EQ 1GM BASE/VIAL MAR 17, 1987
AP EQ 5GM BASE/VIAL N62663 002
EQ 1GM BASE/VIAL JUL 31, 1987
EQ 5GM BASE/VIAL N62663 003
EQ 5GM BASE/VIAL JUN 03, 1988
 VANCOCIN HCL IN PLASTIC CONTAINER
 + BAXTER HLTHCARE EQ 500MG BASE/100ML N50671 001
 APR 29, 1993
 * LILLY EQ 500MG BASE/100ML N50671 001
 APR 29, 1993
VANCOLED
AP LEDERLE EQ 500MG BASE/VIAL N62682 001
AP + EQ 500MG BASE/VIAL JUL 22, 1986
AP EQ 1GM BASE/VIAL N62682 002
AP + EQ 1GM BASE/VIAL MAR 30, 1988
AP EQ 1GM BASE/VIAL N62682 002
AP + EQ 10GM BASE/VIAL MAR 30, 1988
AP + EQ 10GM BASE/VIAL N62682 005
AP + EQ 10GM BASE/VIAL MAY 11, 1988
VANCOMYCIN HCL
AP FUJISAWA EQ 500MG BASE/VIAL N62663 001
AP EQ 1GM BASE/VIAL MAR 17, 1987
AP EQ 5GM BASE/VIAL N62663 002
AP EQ 10GM BASE/VIAL JUL 31, 1987
AP EQ 10GM BASE/VIAL N62663 003
AP EQ 10GM BASE/VIAL JUN 03, 1988
AP EQ 10GM BASE/VIAL N62663 004
AP EQ 10GM BASE/VIAL NOV 28, 1997

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
EFFEXOR XR

+	WYETH AYERST	EQ 37.5MG BASE	N20699 001
			OCT 20, 1997
+		EQ 75MG BASE	N20699 002
			OCT 20, 1997
@		EQ 100MG BASE	N20699 003
			OCT 20, 1997
+		EQ 150MG BASE	N20699 004
			OCT 20, 1997

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HCL

AP	ABBOTT	2.5MG/ML
> DLT >	AP	SOLOPAK
> DLT >		2.5MG/ML
> ADD >	@	2.5MG/ML
> ADD >	AP	STERLING WINTHROP
		2.5MG/ML

N70577 001
FEB 02, 1987
N70695 001
JUL 31, 1987
N70695 001
JUL 31, 1987
N70577 001
FEB 02, 1987

TABLET, EXTENDED RELEASE; ORAL

ISOPTIN SR

AB	+	KNOLL PHARM	120MG
----	---	-------------	-------

N19152 003
MAR 06, 1991

VERAPAMIL HCL

AB	BAKER NORTON	180MG
----	--------------	-------

N74330 001
JAN 31, 1994

AB		240MG
----	--	-------

N73568 001
JUL 31, 1992

AB	MYLAN	120MG
----	-------	-------

N74587 002
FEB 21, 1997

AB		180MG
----	--	-------

N74587 003
SEP 09, 1997

AB	ZENITH GOLDLINE	120MG
----	-----------------	-------

N73568 002
OCT 10, 1997

AB		180MG
----	--	-------

N74330 001
JAN 31, 1994

AB		240MG
----	--	-------

N73568 001
JUL 31, 1992

VINCISTINE SULFATE

INJECTABLE; INJECTION

VINCOREX

AP	+	BRISTOL MYERS	5MG/VIAL
----	---	---------------	----------

N70867 001

JUL 12, 1988

N70867 001

JUL 12, 1988

@	BRISTOL MYERS SQUIBB	5MG/VIAL
---	----------------------	----------

VINCISTINE SULFATE

AP	PAULding	5MG/VIAL
----	----------	----------

N71561 001

APR 11, 1988

N71561 001

APR 11, 1988

+		5MG/VIAL
---	--	----------

VITAMIN A PALMITATE

CAPSULE; ORAL

VITAMIN A

@ ZENITH GOLDLINE

EQ 50,000 UNITS BASE

N83035 001

@

EQ 50,000 UNITS BASE

N83190 001

@ ZENITH LABS

EQ 50,000 UNITS BASE

N83035 001

@

EQ 50,000 UNITS BASE

N83190 001

WARFARIN SODIUM

TABLET; ORAL

COUMADIN

AB	DUPONT MERCK	1MG
----	--------------	-----

N09218 022

MAR 01, 1990

AB	+	2MG
----	---	-----

N09218 013

AB		2.5MG
----	--	-------

N09218 018

AB		4MG
----	--	-----

N09218 023

AUG 24, 1993

AB		5MG
----	--	-----

N09218 007

AB		7.5MG
----	--	-------

N09218 016

AB	+	10MG
----	---	------

N09218 005

WARFARIN SODIUM

AB	BARR	1MG
----	------	-----

N40145 001

MAR 26, 1997

AB		2MG
----	--	-----

N40145 002

AB		2.5MG
----	--	-------

MAR 26, 1997

AB		4MG
----	--	-----

N40145 003

AB		5MG
----	--	-----

MAR 26, 1997

AB		5MG
----	--	-----

N40145 004

MAR 26, 1997

AB		5MG
----	--	-----

N40145 005

MAR 26, 1997

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

<u>AB</u>	BARR	<u>7.5MG</u>	N40145 006 MAR 26, 1997
<u>AB</u>		<u>10MG</u>	N40145 007 MAR 26, 1997
<u>AB</u>	INVAMED	<u>1MG</u>	N40196 001 SEP 30, 1997
<u>AB</u>		<u>2MG</u>	N40196 002 SEP 30, 1997
<u>AB</u>		<u>2.5MG</u>	N40196 003 SEP 30, 1997
<u>AB</u>		<u>4MG</u>	N40196 004 SEP 30, 1997
<u>AB</u>		<u>5MG</u>	N40196 005 SEP 30, 1997
<u>AB</u>		<u>7.5MG</u>	N40196 006 SEP 30, 1997
<u>AB</u>		<u>10MG</u>	N40196 007 SEP 30, 1997

ZINC ACETATE

CAPSULE; ORAL

GALZIN

TEVA

+

EQ 25MG ZINC	N20458 001 JAN 28, 1997
EQ 50MG ZINC	N20458 002 JAN 28, 1997

ZOLMITRIPTAN

TABLET; ORAL

ZOMIG

ZENECA

+

2.5MG	N20768 001 NOV 25, 1997
5MG	N20768 002 NOV 25, 1997

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
DYNA-HEX
XTTRIUM

0.75%

N20111 001
SEP 11, 1997

TINCTURE; TOPICAL
HIBITANE
@ ZENECA

0.5%

N18049 001

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL
CHLORPHENIRAMINE MALEATE
GENEVA PHARMS

12MG

N70797 001
AUG 12, 1988
N70797 001
AUG 12, 1988

+

12MG

TELDRIN

* SMITHKLINE

12MG

N17369 002
N17369 002

@

12MG

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

COLD CAPSULE IV

* GRAHAM DM

12MG;75MG

N18793 001
APR 25, 1985
N18793 001
APR 25, 1985

@

12MG;75MG

COLD CAPSULE V

GRAHAM DM

8MG;75MG

N18794 001
APR 23, 1985
N18794 001
APR 23, 1985

@

8MG;75MG

TABLET, EXTENDED RELEASE; ORAL

CONTAC

NOVARTIS

12MG;75MG

N19613 001
JUN 13, 1986

PHENYLPROPANOLAMINE HCL/CHLORPHENIRAMINE
SANDOZ

12MG;75MG

N19613 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CODIMAL-L A 12

* CENT PHARMS

12MG;120MG

N18935 001
APR 15, 1985
N18935 001
APR 15, 1985

@ SCHWARZ PHARMA

12MG;120MG

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE

KV PHARM

12MG;120MG

N71455 001
MAR 01, 1989
N71455 001
MAR 01, 1989

@

12MG;120MG

CIMETIDINE

TABLET; ORAL

TAGAMET HB

SMITHKLINE BEECHAM

100MG

N20238 001
JUN 19, 1995
N20238 001
JUN 19, 1995

@

100MG

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

LEMMON

1.34MG

N73282 002
DEC 03, 1992
N73282 002
DEC 03, 1992

TEVA

1.34MG

CLOTRIMAZOLE

CREAM; TOPICAL

LOTTRIMIN AF

* SCHERING PLOUGH

1%

N17619 002
OCT 27, 1989
N20888 001
OCT 27, 1989

+

1%

CREAM, SUPPOSITORY, TOPICAL, VAGINAL

GYNE-LOTTRIMIN 3 COMBINATION PACK

* SCHERING PLOUGH

1%,200MG

N20526 002
JUL 29, 1996

CLOTRIMAZOLE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

GYNE-LOTTRIMIN COMBINATION PACK

* SCHERING PLOUGH 1%, 100MG

N20289 002

APR 26, 1993

MYCELEX-7 COMBINATION PACK

BAYER 1%, 100MG

N20389 002

JUN 23, 1994

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTTRIMIN 3 COMBINATION PACK

+ SCHERING PLOUGH 1%, 200MG

N20526 002

JUL 29, 1996

GYNE-LOTTRIMIN COMBINATION PACK

+ SCHERING PLOUGH 1%, 100MG

N20289 002

APR 26, 1993

MYCELEX-7 COMBINATION PACK

BAYER 1%, 100MG

N20389 002

JUN 23, 1994

LOTION; TOPICAL

LOTTRIMIN AF

* SCHERING 1%

N18813 002

OCT 27, 1989

+ SCHERING PLOUGH 1%

N20889 001

OCT 27, 1989

SOLUTION; TOPICAL

LOTTRIMIN AF

* SCHERING PLOUGH 1%

N17613 002

OCT 27, 1989

+ 1%

N20890 001

OCT 27, 1989

SUPPOSITORY; VAGINAL

GYNE-LOTTRIMIN

* SCHERING PLOUGH 100MG

N17717 002

NOV 30, 1990

GYNE-LOTTRIMIN 3

* SCHERING PLOUGH 200MG

N20525 001

JUL 29, 1996

MYCELEX-7

BAYER 100MG

N18182 002

DEC 26, 1991

TABLET; VAGINAL

GYNE-LOTTRIMIN

+ SCHERING PLOUGH 100MG

N17717 002

NOV 30, 1990

CLOTRIMAZOLE

TABLET; VAGINAL

GYNE-LOTTRIMIN 3

+ SCHERING PLOUGH 200MG

N20525 001

JUL 29, 1996

MYCELEX-7

BAYER 100MG

N18182 002

DEC 26, 1991

CROMOLYN SODIUM

SPRAY, METERED; NASAL

NASALCROM

+ PHARMACIA AND UPJOHN 5.2MG/SPRAY

N20463 001

JAN 03, 1997

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

BENYLIN

* PARKE DAVIS 12.5MG/5ML; 30MG/5ML

N19014 001

JUN 11, 1985

@ 12.5MG/5ML; 30MG/5ML

N19014 001

JUN 11, 1985

IBUPROFEN

CAPSULE; ORAL

PROVEL

@ SANDOZ 200MG

N20402 001

APR 20, 1995

SUSPENSION; ORAL

CHILDREN'S ADVIL-FLAVORED

+ WHITEHALL ROBINS 100MG/5ML

N20589 002

NOV 07, 1997

TABLET; ORAL

IBUPROFEN

PUREPAC PHARM 200MG

N71122 001

OCT 03, 1986

200MG

N71564 001

FEB 03, 1987

@ 200MG

N71122 001

OCT 03, 1986

IBUPROFENTABLET; ORAL
IBUPROFEN

@ PUREPAC PHARM 200MG

N71664 001

FEB 03, 1987

@ ZENITH GOLDLINE 200MG

N71154 001

OCT 27, 1987

@ 200MG

N72040 001

APR 29, 1988

@ ZENITH LABS 200MG

N71154 001

OCT 27, 1987

@ 200MG

N72040 001

APR 29, 1988

JUNIOR STRENGTH MOTRIN

MCNEIL 100MG

N20602 001

JUN 10, 1996

+ 100MG

N20602 001

JUN 10, 1996

NUPRIN

@ MCNEIL 200MG

N19012 001

MAY 18, 1984

@ 200MG

N19012 003

JUL 29, 1987

@ PHARMACIA AND UPJOHN 200MG

N19012 001

MAY 18, 1984

@ 200MG

N19012 003

JUL 29, 1987

IBUPROFEN POTASSIUMCAPSULE; ORAL
PROVEL

@ NOVARTIS 200MG

N20402 001

APR 20, 1995

INSULIN SEMISYNTHETIC PURIFIED HUMANINJECTABLE; INJECTION
VELOSULIN BR HUMAN

+ NOVO NORDISK 100 UNITS/ML

N19450 001

MAY 30, 1986

VELOSULIN HUMAN

+ NOVO NORDISK 100 UNITS/ML

N19450 001

MAY 30, 1986

KETOCONAZOLESHAMPOO; TOPICAL
NIZORAL A-D

J AND J 1%

N20310 001

OCT 10, 1997

LOPERAMIDE HYDROCHLORIDESOLUTION; ORAL
LOPERAMIDE HCL

DURAMED 1MG/5ML

N74991 001

DEC 29, 1997

MORTON GROVE 1MG/5ML

N74730 001

AUG 28, 1997

TABLET, CHEWABLE; ORAL
IMODIUM A-D

+ MCNEIL 2MG

N20448 001

JUL 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONETABLET, CHEWABLE; ORAL
IMODIUM ADVANCED

+ MCNEIL 2MG;125MG

N20606 001

JUN 26, 1996

MICONAZOLE NITRATECREAM; VAGINAL
MICONAZOLE NITRATE

PERRIGO 2%

N74760 001

MAY 15, 1997

TARO 2%

N74444 001

JAN 13, 1997

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
M-ZOLE 7 DUAL PACK

ALPHARMA 2%,100MG

N74586 001

JUL 17, 1997

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

G AND W LABS 100MG

N74414 001

APR 30, 1997

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE
+ PERRIGO

100MG

N74395 001
MAR 20, 1997

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)
MORTON GROVE

2%

N74767 001
FEB 28, 1997

ROGAINE EXTRA STRENGTH (FOR MEN)
+ PHARMACIA AND UPJOHN 5%

N20834 001
NOV 14, 1997

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM
GRANUTEC

EQ 200MG BASE

N74635 001
JAN 13, 1997

INVAMED

EQ 200MG BASE

N74646 001
JAN 13, 1997

~~NOVOPHARM~~~~EQ 200MG BASE~~

~~N74635 001~~
~~JAN 13, 1997~~

PERRIGO

EQ 200MG BASE

N74661 001
JAN 13, 1997

PVT FORM

EQ 200MG BASE

N74789 001
FEB 27, 1997

PERMETHRIN

LOTION; TOPICAL
NIX

+ WARNER LAMBERT

1%

N19918 001
MAY 02, 1990

~~* WARNER WELLCOME~~~~1%~~

~~N19918 001~~
~~MAY 02, 1990~~

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE, ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM

120MG;5MG

N71798 001

@

120MG;5MG

MAR 15, 1989

N71798 001

MAR 16, 1989

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL
COLGATE TOTAL

+ COLGATE PALMOLIVE 0.24%;0.3%

N20231 001
JUL 11, 1997

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1

+ BRISTOL MYERS SQUIBB 6.5%

N20676 001
FEB 11, 1997

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12/ DECEMBER '97

NO DECEMBER 1997 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

**Orphan Product Designations and Approvals List
January 1997 through December 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
15AU81 TN=	Treatment of primary pulmonary hypertension.	Lung Rx, Inc. 2 Davis Drive P.O. Box 13169 Research Triangle Park, NC 27709 DD=06/04/1997
8 Cyclopentyl 1,3-dipropylxanthine TN=	Treatment of cystic fibrosis.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Boulevard Suite 315 San Mateo, CA 94404 DD=03/24/1997
9-cis-retinoic acid TN=	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92623 DD=01/02/1997
Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture TN= CYTOIMPLANT	Treatment of pancreatic cancer.	Applied Immunotherapeutics, LLC 14132 E. Firestone Boulevard Santa Fe Springs, CA 90670 DD=06/13/1997
Alpha-melanocyte stimulating hormone TN=	Prevention and treatment of intrinsic acute renal failure due to ischemia.	Star, Robert A., M.D. UT-Southwestern Medical School 5323 Harry Hines Dallas, TX 75235 DD=08/19/1997

Orphan Product Designations and Approvals List

January 1997 through December 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Anagrelide TN= Agrylin	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown, NJ 07724 DD=01/27/1988 MA=03/14/1997
Ancrod TN=	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceuticals 30 North Jefferson Road Whippany, NJ 07981 DD=11/12/1997
Apomorphine TN= Zydis	For use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.	Scherer DDS Frankland Road Swindon SN5 8RU Wiltshire UK DD=10/20/1997
B2036-PEG TN= Trovert	Treatment of acromegaly.	Sensus Corporation Suite 430, 98 San Jacinto Boulevard Austin, TX 78701 DD=06/24/1997
Basiliximab TN= Simulect	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=12/12/1997
Beta alethine TN= Betathine	Treatment of multiple myeloma.	Dovetail Technologies, Inc. Bldg. 337, Paint Branch Drive College Park, MD 20742 DD=03/24/1997

Orphan Product Designations and Approvals List

January 1997 through December 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Beta alethine TN= Betathine	Treatment of metastatic melanoma.	Dovetail Technologies, Inc. Bldg. 337, Paint Branch Drive College Park, MD 20742 DD=03/24/1997
Busulfan TN= Spartaject	Treatment of primary brain malignancies.	Sparta Pharmaceuticals, Inc. 111 Rock Road Horsham, PA 19044 DD=07/07/1997
CAMPATH-1H TN=	Treatment of chronic lymphocytic leukemia.	L&I Partners, LP 11550 IH 10 West, Suite 300 San Antonio, TX 78230 DD=10/20/1997
CDP571 TN=	Treatment of Crohn's disease.	Celltech Therapeutics Ltd. 216 Bath Road Slough SL1 4EN Berkshire UK DD=12/11/1997
CY-1503 TN= Cylexin	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation 3525 John Hopkins Court San Diego, CA 92121 DD=07/18/1997
Calcium gluconate TN= Calgonate	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp. 190 Commerce Drive Warwick, RI 02886 DD=11/20/1997
Chondrocyte-almi nate gel suspension TN=	For use in correcting vesicoureteral reflux in the pediatric population.	Reprogenesis, Inc. 800 Huntington Ave. Boston, MA 02115 DD=12/01/1997

Orphan Product Designations and Approvals List

January 1997 through December 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Coagulation Factor IX (recombinant) TN= BeneFix	Treatment of hemophilia B.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 DD=10/03/1994 MA=02/11/1997
Cysteamine hydrochloride TN=	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg, MD 20877 DD=08/19/1997
Daclizumab TN= Zenapax	Prevention of acute renal allograft rejection.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley, NJ 07110 DD=03/05/1993 MA=12/10/1997
Dehydroepiandrosterone sulfate sodium TN=	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/28/1997
Dehydroepiandrosterone sulfate sodium TN=	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc., 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/29/1997
Diazepam viscous solution for rectal administration TN=	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Athena Neurosciences, Inc. 800f Gateway Boulevard South San Francisco, CA 94080 DD=02/25/1992 MA=07/29/1997

Orphan Product Designations and Approvals List

January 1997 through December 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Dimethylsulfoxide TN=	Topical treatment for the prevention of soft tissue injury following extravasation of cytotoxic drugs.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/15/1997
Duramycin TN=	Treatment of cystic fibrosis.	MoliChem Medicines Inc. 2135 North Lakeshore Drive Chapel Hill, NC 27514 DD=12/11/1997
Enadoline hydrochloride TN=	Treatment of severe head injury.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=01/28/1997
Fampridine TN=	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc. 145 West 58th Street Suite 8J New York, NY 10019 DD=06/02/1997
Fomepizole TN= Antizole	Treatment of methanol or ethylene glycol poisoning.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=12/22/1988 MA=12/04/1997
Gp100 adenoviral gene therapy TN=	Treatment of metastatic melanoma.	Genzyme Corporation P.O. Box 9322 One Mountain Road Framingham, MA 01701 DD=03/25/1997

Orphan Product Designations and Approvals List January 1997 through December 1997

Name	Indication Designated	Sponsor & Address
Generic Name		DD= Date Designated
TN=Trade Name		MA=Marketing Approval
Human retinal pigmented epithelial cells on collagen microcarriers TN= Spheramine	Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.	Theracell, Inc. 50 Division Street, Suite 503 Somerville, NJ 08876 DD=07/18/1997
Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution TN= Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis Solutio	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation Renal Division 1620 Waukegan Road Waukegan, IL 60085 DD=07/18/1997
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia Type II.	Behringwerke AG P.O. Box 1140 D-35001 Marburg Germany, DD=02/13/1997
Levocarnitine TN= Carnitor	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 S. Frederick Avenue, Suite 300 Gaithersburg, MD 20877 DD=04/07/1997
Liposomal amphotericin B TN= AmBisome	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=12/10/1996 MA=08/11/1997
Liposomal amphotericin B TN= AmBisome	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=12/06/1996 MA=08/11/1997

Orphan Product Designations and Approvals List

January 1997 through December 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Liposomal amphotericin B TN= AmBisome	Treatment of histoplasmosis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=12/10/1996
MART-1 adenoviral gene therapy for malignant melanoma TN=	Treatment of metastatic melanoma.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=03/28/1997
Oprelvekin TN= Neumega	Prevention of severe chemotherapy-induced thrombocytopenia.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 DD=12/17/1996 MA=11/25/1997
Oxandrolone TN= Oxandrin	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Bio-Technology General Corp. 70 Wood Avenue South Iselin, NJ 08830 DD=04/22/1997
Paclitaxel TN= Taxol	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=03/25/1997 MA=08/04/1997
Paclitaxel TN= Paxene	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc. 4400 Biscayne Boulevard Miami, FL 33137 DD=04/15/1997

Orphan Product Designations and Approvals List January 1997 through December 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Patul-end TN=	Treatment of patulous eustachian tube.	Ear Foundation 24209 Castillo Street, Suite 100 Santa Barbara, CA 93105 DD=02/18/1997
Pegylated recombinant human megakaryocyte growth and development factor TN= MEGAGEN	For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=10/20/1997
Pergolide TN= Permax	Treatment of Tourette's syndrome.	Sallee, Floyd R. M.D., Ph.D. Medical University of South Carolina 171 Ashley Avenue, Room PH246 Charleston, SC 29425 DD=11/20/1997
Poloxamer 188 TN=	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation 154 Technology Parkway Norcross, GA 30092 DD=08/05/1997
Poly-ICLC TN=	Treatment of primary brain tumors.	Salazar, Andres M. M.D. and Levy, Hilton B. Ph.D. 3202 Cleveland Avenue N.W. Washington, DC 20008 DD=03/17/1997
Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue TN= N-Graft	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Theracell, Inc. 50 Division Street Suite 503 Somerville, NJ 08876 DD=06/24/1997

Orphan Product Designations and Approvals List

January 1997 through December 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Porfiromycin TN= Promycin	Treatment of cervical cancer.	Vion Pharmaceuticals, Inc. Four Science Park New Haven, CT 06511 DD=03/13/1997
Purified extract of Pseudomonas aeruginosa TN= ImmuDyn	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	DynaGen, Inc. 99 Erie Street Cambridge, MA 02139 DD=09/22/1997
RGG0853, E1A lipid complex TN=	Treatment of ovarian cancer.	Targeted Genetics Corporation 1100 Olive way, Suite 100 Seattle, WA 98101 DD=10/27/1997
Recombinant human acid alpha-glucosidas e TN=	Treatment of glycogen storage disease type II.	Chen, Y.T., M.D., Ph.D. Department of Pediatrics Duke University Medical Center Durham, NC 27710 DD=08/19/1997
Recombinant human alpha-L-iduronid ase TN=	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceuticals, Inc. 11 Pimental Court Novato, CA 94949 DD=09/24/1997
Recombinant human interleukin-12 TN=	Treatment of renal cell carcinoma.	Genetics Institute 87 CambridgePark Drive Cambridge, MA 02140 DD=10/20/1997
Recombinant human thrombopoietin TN=	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=09/29/1997

Orphan Product Designations and Approvals List

January 1997 through December 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Retroviral vector, R-GC and GC gene 1750 TN=	Treatment of Gaucher disease.	Genzyme Corporation One Kendall Square.. Cambridge, MA 02139 DD=05/06/1997
Rituximab TN= Rituxan	Treatment of non-Hodgkin's B-cell lymphoma.	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego, CA 92121 DD=06/13/1994 MA=11/26/1997
Sermorelin acetate TN= Geref	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=09/14/1988 MA=09/26/1997
Short chain fatty acid enema TN= Colomed	Treatment of chronic radiation proctitis.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=08/19/1997
Sodium dichloroacetate TN=	Treatment of congenital lactic acidosis.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=12/31/1997
Somatropin TN= Genotropin	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn 7000 Portage Road Kalamazoo, MI 49001 DD=09/06/1994 MA=10/31/1997
Somatropin for injection TN= Nutropin	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco, CA 94080 DD=11/18/1996 MA=12/15/1997

Orphan Product Designations and Approvals List

January 1997 through December 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Sterile aerosol talc TN=	Treatment of malignant pleural effusion.	Bryan Corporation 4 Plympton Street Woburn, MA 01801 DD=09/18/1995 MA=12/24/1997
Sterile talc TN= Steritalc	Treatment of malignant pleural effusion.	Novatech SA Avenue du Vent des Dames - Z.I. les Paluds 13685 Aubagne France, DD=12/08/1997
Sterile talc TN= Steritalc	Treatment of pneumothorax.	Novatech SA Avenue du Vent des Dames - Z.I. les Paluds 13685 Aubagne France, DD=12/08/1997
Suramin TN=	Treatment of hormone-refractory prostate cancer.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=05/06/1997
Testosterone TN= TheraDerm Testosterone Transdermal System	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	TheraTech, Inc. 417 Wakara Way Salt Lake City, UT 84108 DD=09/22/1997
Tetrabenazine TN=	Treatment of Huntington's disease.	Lifehealth Limited Richmond House, Old Brewery Court, Sandyford Road Newcastle upon Tyne NE2 1XG England, UK DD=12/11/1997

Orphan Product Designations and Approvals List

January 1997 through December 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Tobramycin for inhalation TN= TOBI	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Pathogenesis Corporation 201 Elliott Avenue West, Suite 150 Seattle, WA 98119 DD=10/13/1994 MA=12/22/1997
Toremifene TN= Fareston	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation P.O. Box 65 02101 ESPOO Finland, DD=09/19/1991 MA=05/29/1997
Urofollitropin TN= Fertinex	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=12/05/1997
Ursodiol TN= URSO	Treatment of patients with primary biliary cirrhosis.	Axcan Pharma Inc. 3881, Industriel boulevard Laval, Quebec H7L 4S3 Canada, DD=06/20/1991 MA=12/10/1997
Zinc acetate TN= Galzin	Treatment of Wilson's disease.	Lemmon Company 1510 Delp Drive Kulpsville, PA 19443 DD=11/06/1985 MA=01/28/1997

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 1997 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 17TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

- D-33 ONCE DAILY DOSING FOR PLAQUE PSORIASIS
- D-34 EVERY FOUR MONTHS DOSAGE REGIMEN
- D-35 FOR A ONE WEEK DOSING PERIOD FOR INTERDIGITAL TINEA PEDIS
- D-36 FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
- D-37 DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)

NEW INDICATION

- I-177 TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
- I-178 TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
- I-179 NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
- I-180 TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
- I-181 TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
- I-182 TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
- I-183 MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
- I-184 TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG)
- I-185 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-186 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
- I-187 PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- I-188 TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
- I-189 TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
- I-190 PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
- I-191 ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
- I-192 THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
- I-193 TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
- I-194 CONGESTIVE HEART FAILURE
- I-195 USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER

PATENT AND EXCLUSIVITY TERMS
NEW INDICATION

I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OF A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN THE PEDIATRIC POPULATION

PATENT USE CODE

U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN- DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS
U-177	FUNGICIDE

PATENT AND EXCLUSIVITY TERMS
PATENT USE CODE

U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197	USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198	TREATMENT METASTIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
U-199	METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
U-200	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202	METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203	TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204	USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205	METHOD OF TREATING HEARTBURN
U-206	METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENOUS LH, IN IN VITRO FERTILIZATION
U-207	USE AS NASAL SPRAY
U-208	VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209	VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION

PATENT AND EXCLUSIVITY TERMS
PATENT USE CODE

U-210	METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211	USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212	METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214	USE AS A BLOOD GLUCOSE-LOWERING AGENT

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020059 001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
020760 001	ALATROFLOXACIN MESYLATE;TROVAN				NCE	DEC 18, 2002
>ADD> 020899 001	ALBUMIN HUMAN;OPTISON				NP	DEC 31, 2000
020291 001	ALBUTEROL SULFATE;COMBIVENT	5603918	JUN 09, 2015		NC	OCT 24, 1999
020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	5225183	JUL 06, 2010		NP	AUG 15, 1999
		5439670	JUL 06, 2010			
		5605674	FEB 25, 2014			
020560 001	ALENDRONATE SODIUM;FOSAMAX	4621077	AUG 06, 2007	U-114	I-185	APR 25, 2000
		5681590	DEC 02, 2012		I-187	APR 25, 2000
020560 002	ALENDRONATE SODIUM;FOSAMAX	4621077	AUG 06, 2007	U-114	I-185	APR 25, 2000
		5681590	DEC 02, 2012		I-187	APR 25, 2000
020560 003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		NS	APR 25, 2000
		4621077	AUG 06, 2007	U-114	I-185	APR 25, 2000
		5681590	DEC 02, 2012		I-187	APR 25, 2000
					NCE	SEP 29, 2000
020649 001	ALPROSTADIL;EDEX				NP	JUL 06, 1998
020649 002	ALPROSTADIL;EDEX				NP	JUL 06, 1988
020649 003	ALPROSTADIL;EDEX				NP	JUL 06, 1998
020649 004	ALPROSTADIL;EDEX				NP	JUL 06, 1998
020221 001	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012			
		5591731	JUL 31, 2012			
020333 001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
					NCE	MAR 14, 2002
020333 002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
					NCE	MAR 14, 2002
020541 001	ANASTROZOLE;ARIMIDEX	4935437	DEC 27, 2009			
020420 001	ARBUTAMINE HYDROCHLORIDE;GENESA				NCE	SEP 12, 2002
020227 002	ARDEPARIN SODIUM;NORMIFLO				NCE	MAY 23, 2002
020702 001	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
		5273995	DEC 28, 2010	U-162		
		5385929	MAY 04, 2014	U-59		
		5686104	NOV 11, 2014	U-213		
020702 002	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
		5273995	DEC 28, 2010	U-162		
		5385929	MAY 04, 2014	U-59		
		5686104	NOV 11, 2014	U-213		
020702 003	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
		5273995	DEC 28, 2010	U-162		
		5385929	MAY 04, 2014	U-59		
		5686104	NOV 11, 2014	U-213		
020114 001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 17, 2009	U-207		
020486 001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH				NP	DEC 24, 1999
020032 001	BERACTANT;SURVANTA	4397839	JUL 01, 2005			
020619 001	BETAXOLOL HYDROCHLORIDE;BETOPTIC PILO	5635172	JUN 03, 2014	U-191	NC	APR 17, 2000
020498 001	BICALUTAMIDE;CASODEX	4636505	OCT 01, 2008			
		4472382	SEP 18, 2001	U-197		
		5389613	SEP 18, 2001	U-197		
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NP	MAR 13, 2000
					NCE	SEP 06, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
<u>>ADD></u> 020535 002	BROMFENAC SODIUM;DURACT	4907583	MAR 13, 2007		NCE	JUL 15, 2002
020441 002	BUDESONIDE;PULMICORT	4524769	JUN 25, 2002		NCE	FEB 14, 1999
		4668218	APR 11, 2006			
<u>>ADD></u> 020441 003	BUDESONIDE;PULMICORT	4907583	MAR 13, 2007		NCE	FEB 14, 1999
		4524769	JUN 25, 2002			
		4668218	APR 11, 2006			
018644 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
018644 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
018644 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		NP	MAY 14, 2000
		5427798	AUG 12, 2013			
		RE33994	AUG 18, 2004			
020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		NP	MAY 14, 2000
		5427798	AUG 12, 2013			
		RE33994	AUG 18, 2004			
018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	4215104	MAR 26, 1999			
		4258027	MAR 26, 1999			
018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	4215104	MAR 26, 1999			
		4258027	MAR 26, 1999			
020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	JUN 04, 2008	U-177	D-35	NOV 25, 2000
019881 001	BUTOCONAZOLE NITRATE;FEMSTAT ONE	4078071	MAR 07, 1997		NP	FEB 07, 2000
020664 001	CABERGOLINE;DOSTINEX	4526892	JUL 02, 2002		NCE	DEC 23, 2001
020273 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007		D-33	MAR 20, 2000
020554 001	CALCIPOTRIENE;DOVONEX				NCE	DEC 29, 1998
020611 001	CALCIPOTRIENE;DOVONEX	4866048	SEP 12, 2006		NCE	DEC 29, 1998
					NDF	MAR 03, 2000
019880 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
019880 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
019880 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
020297 001	CARVEDILOL;COREG				I-194	MAY 29, 2000
020297 002	CARVEDILOL;COREG				I-194	MAY 29, 2000
020297 003	CARVEDILOL;COREG				I-194	MAY 29, 2000
020297 004	CARVEDILOL;COREG	4503067	MAR 05, 2002	U-3	I-194	MAY 29, 2000
					NCE	SEP 14, 2000
020740 001	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NCE	JUN 26, 2002
		5177080	NOV 26, 2011			
020740 002	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NCE	JUN 26, 2002
		5177080	NOV 26, 2011			
020740 003	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NCE	JUN 26, 2002
		5177080	NOV 26, 2011			
020740 004	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NCE	JUN 26, 2002
		5177080	NOV 26, 2011			
019835 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
019835 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
020346 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
<u>>ADD></u> 020111 001	CHLORHEXIDINE GLUCONATE;DYNA-HEX				NP	SEP 11, 2000
020519 001	CICLOPIROX;LOPROX				NDF	JUL 21, 2000
019537 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754	FEB 15, 2011		I-188	JUN 03, 2000
		4670444	DEC 09, 2003	U-36		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				1-188	JUN 03, 2000
019537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				1-188	JUN 03, 2000
019537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				1-188	JUN 03, 2000
019847 001	CIPROFLOXACIN; CIPRO	4705789	NOV 10, 2004		1-179	OCT 21, 1999
					1-201	AUG 07, 2000
020780 001	CIPROFLOXACIN; CIPRO	5695784	DEC 09, 2014			
020780 002	CIPROFLOXACIN; CIPRO	5695784	DEC 09, 2014			
019857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	4808583	FEB 28, 2006		1-179	OCT 21, 1999
					1-201	AUG 07, 2000
019858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLORIDE 0.9%	4705789	NOV 10, 2004		1-179	OCT 21, 1999
					1-201	AUG 07, 2000
020767 001	CISAPRIDE MONOHYDRATE; PROPULSID QUICKSOLV	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
017533 001	CLONAZEPAM; KLONOPIN				1-184	APR 09, 2000
017533 002	CLONAZEPAM; KLONOPIN				1-184	APR 09, 2000
017533 003	CLONAZEPAM; KLONOPIN				1-184	APR 09, 2000
017533 005	CLONAZEPAM; KLONOPIN				1-184	APR 09, 2000
017533 006	CLONAZEPAM; KLONOPIN				1-184	APR 09, 2000
020813 001	CLONAZEPAM; KLONOPIN	4305502	DEC 15, 1998			
		4371516	FEB 01, 2000			
		4758598	DEC 15, 1998			
020813 002	CLONAZEPAM; KLONOPIN	4305502	DEC 15, 1998			
		4371516	FEB 01, 2000			
		4758598	DEC 15, 1998			
020813 003	CLONAZEPAM; KLONOPIN	4305502	DEC 15, 1998			
		4371516	FEB 01, 2000			
		4758598	DEC 15, 1998			
020813 004	CLONAZEPAM; KLONOPIN	4305502	DEC 15, 1998			
		4371516	FEB 01, 2000			
		4758598	DEC 15, 1998			
020813 005	CLONAZEPAM; KLONOPIN	4758598	DEC 15, 1998			
		4305502	DEC 15, 1998			
		4371516	FEB 01, 2000			
020839 001	CLOPIDOGREL BISULFATE; PLAVIX				NCE	NOV 17, 2002
020463 001	CROMOLYN SODIUM; NASALCROM				NP	JAN 03, 2000
020430 001	DANAPAROID SODIUM; ORGARAN	5164377	OCT 03, 2010			
020705 001	DELAVIRDINE MESYLATE; RESCRIPTOR	5563142	OCT 08, 2013		NCE	APR 04, 2002
017922 001	DESMOPRESSIN ACETATE; DDAVP	5500413	JUN 29, 2013			
		5482931	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5498598	JUN 29, 2013			
017922 002	DESMOPRESSIN ACETATE; DDAVP	5500413	JUN 29, 2013			
		5482931	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5498598	JUN 29, 2013			
017922 003	DESMOPRESSIN ACETATE; DDAVP	5674850	DEC 23, 2013			
		5498598	JUN 29, 2013			
		5500413	JUN 29, 2013			
		5482931	JUN 29, 2013			
018938 001	DESMOPRESSIN ACETATE; DDAVP	5500413	JUN 29, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018938 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
019955 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
019955 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
020648 001	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
					ODE	JUL 29, 2004
020648 002	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
					ODE	JUL 29, 2004
020648 003	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
					ODE	JUL 29, 2004
020648 004	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
					ODE	JUL 29, 2004
020648 005	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
					ODE	JUL 29, 2004
>ADD>	020607 001	DICLOFENAC SODIUM;ARTHROTEC	4301146	JUL 29, 2000		
>ADD>			5601843	FEB 11, 2014		
>ADD>	020607 002	DICLOFENAC SODIUM;ARTHROTEC	4301146	JUL 29, 2000		
>ADD>			5601843	FEB 11, 2014		
	020037 001	DICLOFENAC SODIUM;VOLTAREN	4960799	OCT 03, 2007		
			4829088	APR 14, 2007		
020154 002	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020154 003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020154 004	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
020154 005	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020155 003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020155 004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
020155 005	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
020156 001	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
>ADD>	020405 001	DIGOXIN;LANOXIN			I-194	SEP 30, 2000
>ADD>	020405 002	DIGOXIN;LANOXIN			I-194	SEP 30, 2000
>ADD>	020405 003	DIGOXIN;LANOXIN			I-194	SEP 30, 2000
>ADD>	020405 004	DIGOXIN;LANOXIN			I-194	SEP 30, 2000
>ADD>	020405 005	DIGOXIN;LANOXIN			I-194	SEP 30, 2000
>ADD>	020405 006	DIGOXIN;LANOXIN			I-194	SEP 30, 2000
020148 001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL				NDF	DEC 08, 2000
018723 001	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
018723 002	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
018723 003	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
019680 001	DIVALPROEX SODIUM;DEPAKOTE	4988731	JAN 29, 2008		I-181	JUN 20, 1999
020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET				NCE	SEP 11, 2002
020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET				NCE	SEP 11, 2002
020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET				NCE	SEP 11, 2002
020624 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET				NCE	SEP 11, 2002
020706 001	EMEDASTINE DIFUMARATE;EMADINE				NCE	DEC 29, 2002
020668 001	ENALAPRIL MALEATE;LEXSEL	4472380	SEP 18, 2001			
		4374829	DEC 30, 2001	U-3		
		4703038	OCT 07, 2005	U-3		
020164 001	ENOXAPARIN SODIUM;LOVENOX				I-192	MAY 06, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020444 001	EPOPROSTENOL SODIUM; FLOLAN	4335139 4539333 4883812	JUN 15, 1999 SEP 03, 2002 MAY 12, 2006	U-185		
020444 002	EPOPROSTENOL SODIUM; FLOLAN	4338325 4539333 4338325 4883812 4335139	JUL 06, 1999 SEP 03, 2002 JUL 06, 1999 MAY 12, 2006 JUN 15, 1999	U-185		
>ADD> >ADD> 020417 001	EPROSARTAN MESYLATE; TEVETEN EPROSARTAN MESYLATE; TEVETEN ESTRADIOL; FEMPATCH	5656650 5656650 4906463 5006342	AUG 12, 2014 AUG 12, 2014 MAR 06, 2007 APR 09, 2008	U-3 U-3	NCE NCE NP	DEC 22, 2002 DEC 22, 2002 DEC 03, 1999
020683 001	ETHINYL ESTRADIOL; ALESSE				NP	MAR 27, 2000
020683 002	ETHINYL ESTRADIOL; ALESSE				NP	MAR 27, 2000
019697 001	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
019697 002	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
018922 005	ETODOLAC; LODINE				I-24	JUN 28, 1999
020457 001	ETOPOSIDE PHOSPHATE; ETOPOPHOS	RE35524	AUG 04, 2007			
020363 001	FAMCICLOVIR; FAMVIR				I-207	SEP 16, 2000
020363 002	FAMCICLOVIR; FAMVIR				I-207	SEP 16, 2000
020363 003	FAMCICLOVIR; FAMVIR				I-207	SEP 16, 2000
020325 001	FAMOTIDINE; PEPCID AC	4283408 5667794	OCT 15, 2000 MAY 02, 2015	U-205		
019922 001	FENOLDOPAM MESYLATE; CORLOPAM				NCE	SEP 23, 2002
020292 001	FERRIC AMMONIUM CITRATE; FERRISELTZ				NP	OCT 14, 2000
020410 001	FERUMOXIL; GASTROMARK	5069216 5219554 4827945 4951675 5055288 4695392 4695393 4770183 5578610	MAY 09, 2006 JUN 15, 2010 MAY 09, 2006 SEP 13, 2005 OCT 08, 2008 SEP 22, 2004 SEP 22, 2004 SEP 13, 2005 NOV 26, 2013	U-171 U-170 U-169	NCE	DEC 06, 2001
020625 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA					
020786 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA-D				NC	DEC 24, 2000
>ADD> >ADD> >ADD> 020788 001	FINASTERIDE; PROPECIA	4377584 4760071 5571817 4357324	MAR 22, 2000 JUN 19, 2006 NOV 05, 2013 FEB 24, 2003	U-169 U-192	NP	DEC 19, 2000
020038 001	FLUDARABINE PHOSPHATE; FLUDARA				NDF	NOV 07, 2000
020549 001	FLUTICASONE PROPIONATE; FLOVENT				NDF	NOV 07, 2000
020549 002	FLUTICASONE PROPIONATE; FLOVENT				NDF	NOV 07, 2000
020549 003	FLUTICASONE PROPIONATE; FLOVENT				I-210	OCT 01, 2000
>ADD> >ADD> 020261 001	FLUVASTATIN SODIUM; LESCOL				I-210	OCT 01, 2000
020261 002	FLUVASTATIN SODIUM; LESCOL				I-210	OCT 01, 2000
020582 001	FOLLITROPIN ALFA/BETA; FOLLISTIM	5270057 4589402	MAR 20, 2011 JUL 26, 2004	U-206	NP	SEP 29, 2000
020582 002	FOLLITROPIN ALFA/BETA; FOLLISTIM	5270057 4589402	MAR 20, 2011 JUL 26, 2004	U-206	NP	SEP 29, 2000
020378 001	FOLLITROPIN ALFA/BETA; GONAL-F				NP	SEP 29, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020378 002	FOLLITROPIN ALFA/BETA; GONAL-F				NP	SEP 29, 2000
020696 001	FOMEPIZOLE; ANTIZOL				NCE	DEC 04, 2002
					ODE	DEC 04, 2004
020235 001	GABAPENTIN; NEURONTIN	4087544	JAN 16, 2000	U-86		
020235 002	GABAPENTIN; NEURONTIN	4087544	JAN 16, 2000	U-86		
020235 003	GABAPENTIN; NEURONTIN	4894476	MAY 02, 2008			
		4087544	JAN 16, 2000	U-86		
020622 001	GLATIRAMER ACETATE; COPAXONE				ODE	DEC 20, 2003
020329 001	GLIPIZIDE; GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
020329 002	GLIPIZIDE; GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
>ADD>	074591 001				PC	JUN 01, 1998
>ADD>	074591 002				PC	JUN 01, 1998
>ADD>	074591 003				PC	JUN 01, 1998
>ADD>	074591 004				PC	JUN 01, 1998
019726 001	GOSERELIN ACETATE; ZOLADEX				I-191	JUN 27, 2000
020305 001	GRANISETRON HYDROCHLORIDE; KYTRIL				D-36	OCT 06, 2000
020695 001	GREPAFLOXACIN HYDROCHLORIDE; RAXAR				NCE	NOV 06, 2002
020758 001	HYDROCHLOROTHIAZIDE; IRBESARTAN-HYDROCHLOROTHIAZIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
020758 002	HYDROCHLOROTHIAZIDE; IRBESARTAN-HYDROCHLOROTHIAZIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
020504 001	HYDROCHLOROTHIAZIDE; MICROZIDE				NS	DEC 27, 1999
020729 001	HYDROCHLOROTHIAZIDE; UNIRETIC	4344949	OCT 03, 2000		NC	JUN 27, 2000
		4743450	FEB 24, 2007			
020729 002	HYDROCHLOROTHIAZIDE; UNIRETIC	4344949	OCT 03, 2000		NC	JUN 27, 2000
		4743450	FEB 24, 2007			
020716 001	HYDROCODONE BITARTRATE; VICOPROFEN				NC	SEP 23, 2000
>ADD>	020601 001				NP	NOV 15, 1999
>DLT>	020601 001				NP	JUN 16, 1998
	020267 002				NP	JUN 16, 1998
>ADD>	020601 003				NP	NOV 15, 1999
>DLT>	020601 003				NP	JUN 16, 1998
	020723 001				NP	JUN 16, 1998
		4689338	AUG 25, 2004	U-172	NCE	FEB 27, 2002
		5238944	AUG 24, 2010			
>ADD>	020351 001				I-211	OCT 10, 2000
	020808 001					
		5349085	SEP 20, 2011			
		4278654	JUL 03, 1999			
		4396597	JUL 03, 1999			
>ADD>	020351 002				I-211	OCT 10, 2000
	020808 002					
		5349085	SEP 20, 2011			
		4278654	JUL 03, 1999			
		4396597	JUL 03, 1999			
020757 001	IRBESARTAN; AVAPRO	5270317	MAR 20, 2011		NCE	SEP 30, 2002
020757 002	IRBESARTAN; AVAPRO	5270317	MAR 20, 2011		NCE	SEP 30, 2002
020757 003	IRBESARTAN; AVAPRO	5270317	MAR 20, 2011		NCE	SEP 30, 2002
040024 001	IRON DEXTRAN; DEXFERRUM	5624668	SEP 29, 2015			
020083 001	ITRACONAZOLE; SPORANOX				I-178	DEC 06, 1999
020657 001	ITRACONAZOLE; SPORANOX				NDF	FEB 21, 2000
019927 001	KETOCONAZOLE; NIZORAL				I-186	MAY 30, 2000
020310 001	KETOCONAZOLE; NIZORAL A-D				NP	OCT 10, 2000
020811 001	KETOROLAC TROMETHAMINE; ACULAR PRESERVATIVE FREE				NP	NOV 03, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020857 001	LAMIVUDINE; COMBIVIR	4828838 4833130 4837208 5047407 4724232 4818538	SEP 17, 2005 SEP 17, 2005 SEP 17, 2005 FEB 08, 2009 SEP 17, 2005 SEP 17, 2005		NCE	NOV 17, 2000
020406 001	LANSOPRAZOLE; PREVACID				I-195 I-196 I-197 I-198	JUN 17, 2000 MAY 08, 2000 APR 17, 2000 JUN 17, 2000
020406 002	LANSOPRAZOLE; PREVACID				I-195 I-196 I-197 I-198	JUN 17, 2000 MAY 08, 2000 APR 17, 2000 JUN 17, 2000
020726 001 019732 001	LETROZOLE; FEMARA LEUPROLIDE ACETATE; LUPRON DEPOT	4978672 5631020 5631021 4954298 5480656 5643607	DEC 18, 2007 MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 JAN 02, 2013 JUL 01, 2014	U-203	NCE	JUL 25, 2002
020011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5631020 5631021 4954298 5480656 5643607	MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 JAN 02, 2013 JUL 01, 2014			
020517 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5631020 5631021 5643607	MAY 20, 2014 MAY 20, 2014 JUL 01, 2014			
020517 002	LEUPROLIDE ACETATE; LUPRON DEPOT-4	4677191 4728721 4849228 5631020 5631021 4652411 5476663 5480656 5575987 4917893 4954298 5330767 5643607	JUL 03, 2005 MAY 01, 2006 JUL 18, 2006 MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 APR 17, 2007 JAN 02, 2013 NOV 19, 2013 NOV 01, 2004 NOV 01, 2004 NOV 01, 2004 JUL 01, 2014		NS D-34	MAY 30, 2000 MAY 30, 2000
020263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5480656 5631020 5631021 4954298 5643607	JAN 02, 2013 MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 JUL 01, 2014			
020263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5480656 5631020 5631021 4954298 5643607	JAN 02, 2013 MAY 20, 2014 MAY 20, 2014 NOV 01, 2004 JUL 01, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5643607	JUL 01, 2014			
020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5643607	JUL 01, 2014			
020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5643607	JUL 01, 2014		NP	MAR 07, 2000
		4652411	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4849228	JUL 18, 2006			
		4917893	NOV 01, 2004			
		4954298	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5476663	APR 17, 2007			
		5480656	JAN 02, 2013			
		5575987	NOV 19, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4652441	NOV 01, 2004			
		5643607	JUL 01, 2014			
020580 001	LIPASE;COTAZYM				NP	DEC 09, 1999
020448 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM A-D	5489436	FEB 06, 2013			
020606 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5248505	JUL 28, 2010		NC	JUN 26, 2000
		5612054	SEP 28, 2010			
		5489436	FEB 06, 2013			
		5679376	OCT 21, 2014			
>ADD>	019658 001	LORATADINE;CLARITIN	4863931	SEP 15, 2008		
>ADD>	020641 001	LORATADINE;CLARITIN	4863931	SEP 15, 2008		
		4659716	APR 21, 2004	U-142		
	020704 001	LORATADINE;CLARITIN REDITABS	4282233	JUN 19, 2002	U-77	APR 12, 1998
		4659716	APR 21, 2004	U-142		
		4863931	SEP 15, 2008			
>ADD>	019670 001	LORATADINE;CLARITIN-D	4863931	SEP 15, 2008		
>ADD>	020470 001	LORATADINE;CLARITIN-D 24 HOUR				
	018140 001	LORAZEPAM;ATIVAN			I-205	SEP 05, 2000
	018140 002	LORAZEPAM;ATIVAN			I-205	SEP 05, 2000
	020652 001	MANGAFODIPIR TRISODIUM;TESLASCAN			NCE	NOV 26, 2002
>ADD>	020686 001	MANGANESE CHLORIDE TETRAHYDRATE;LUMENHANCE			NP	DEC 19, 2000
	020264 001	MEGESTROL ACETATE;MEGACE	5338732	AUG 16, 2011		
	019651 001	MESALAMINE;ASACOL			I-203	AUG 18, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
020868 001	METRONIDAZOLE;FLAGYL ER				NDF	NOV 26, 2000
020743 001	METRONIDAZOLE;NORITATE				NP	SEP 26, 2000
020689 001	MIBEFRADIL DIHYDROCHLORIDE;POSICOR	4808605	NOV 10, 2007	U-194	NCE	JUN 20, 2002
020689 002	MIBEFRADIL DIHYDROCHLORIDE;POSICOR	4808605	NOV 10, 2007	U-194	NCE	JUN 20, 2002
>ADD> 020834 001	MINOXIDIL;ROGAINE EXTRA STRENGTH (FOR MEN)				NP	NOV 14, 2000
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX				NDF	OCT 01, 2000
020353 001	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020353 002	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020353 003	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
019660 001	NEDOCROMIL SODIUM;TILADE				I-183	MAR 06, 2000
020750 001	NEDOCROMIL SODIUM;TILADE				NDF	OCT 01, 2000
020778 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		NCE	MAR 14, 2002
020779 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		NCE	MAR 14, 2002
020636 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011	U-167	NCE	JUN 21, 2001
020381 001	NIACIN;NIASPAN				NDF	JUL 28, 2000
020381 002	NIACIN;NIASPAN				NDF	JUL 28, 2000
020381 003	NIACIN;NIASPAN				NDF	JUL 28, 2000
020381 004	NIACIN;NIASPAN				NDF	JUL 28, 2000
020381 005	NIACIN;NIASPAN TITRATION STARTER PACK				NDF	JUL 28, 2000
020714 001	NICOTINE;NICOTROL				NP	MAY 02, 2000
020592 001	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
020592 002	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
020592 003	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
020592 004	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	4871865	OCT 03, 2006			
		4923892	MAY 08, 2007	U-174		
		5116863	MAY 26, 2009			
		5641805	JUN 24, 2014	U-184		
019810 001	OMEPRAZOLE;PRILOSEC	4636499	MAY 30, 2005			
		5093342	FEB 02, 2010	U-166		
		5599794	FEB 04, 2014	U-166		
		5629305	FEB 04, 2014	U-188		
019810 003	OMEPRAZOLE;PRILOSEC	4636499	MAY 30, 2005			
		5093342	FEB 02, 2010	U-166		
		5599794	FEB 04, 2014	U-166		
		5629305	FEB 04, 2014	U-188		
020605 001	ONDANSETRON HYDROCHLORIDE;ZOFTRAN	4753789	JUN 24, 2006	U-44		
		4695578	JUN 25, 2005	U-183		
		5578628	JUN 24, 2006	U-44		
019828 001	OXICONAZOLE NITRATE;OXISTAT				I-200	AUG 18, 2000
020262 001	PACLITAXEL;TAXOL	5641803	AUG 03, 2012	U-198	ODE	AUG 04, 2004
		5670537	AUG 03, 2012	U-198	I-202	AUG 04, 2000
		5496804	MAR 09, 2013	U-204		
020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150 NCE	MAY 07, 1999 DEC 29, 1997
019385 001	PERGOLIDE MESYLATE;PERMAX	5114948 4180582	OCT 19, 2009 FEB 08, 1998	U-20		
019385 002	PERGOLIDE MESYLATE;PERMAX	5114948 4180582	OCT 19, 2009 FEB 08, 1998	U-20		
019385 003	PERGOLIDE MESYLATE;PERMAX	5114948 4180582	OCT 19, 2009 FEB 08, 1998	U-20		
018796 001	PILOCARPINE HYDROCHLORIDE;PILOPINE HS	4271143	MAY 09, 1999			
020529 001	PODOFILOX;CONDYLOX	4680399	JUL 14, 2004		NDF	MAR 13, 2000
		5057616	OCT 15, 2008			
020667 001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
020667 002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
020667 003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
020667 004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
019568 001	PREDNICARBATE;DERMATOP	4242334	AUG 02, 2000	U-50		
020279 001	PREDNICARBATE;DERMATOP	4242334	AUG 02, 2000	U-50		
020545 001	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
020545 002	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
020701 001	PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U-208	NP	JUL 31, 2000
		5543150	SEP 15, 2013	U-209		
020701 002	PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U-208	NP	JUL 31, 2000
		5543150	SEP 15, 2013	U-209		
020756 001	PROGESTERONE;CRINONE				NP	MAY 13, 2000
019151 001	PROPAFENONE HYDROCHLORIDE;RYTHMOL				I-209	DEC 23, 2000
019151 002	PROPAFENONE HYDROCHLORIDE;RYTHMOL				I-209	DEC 23, 2000
019151 003	PROPAFENONE HYDROCHLORIDE;RYTHMOL				I-209	DEC 23, 2000
>ADD>	019627 002	PROPOFOL;DIPRIVAN	5714520	MAR 22, 2015	NP	JUN 11, 1999
	020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007	NCE	SEP 26, 2002
	020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007	NCE	SEP 26, 2002
	020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007	NCE	SEP 26, 2002
	019885 001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210	
	019885 002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210	
	019885 003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210	
	019885 004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210	
>ADD>	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2003	NCE	DEC 09, 2002
>ADD>			5393763	JUL 28, 2012		
>ADD>			5457117	JUL 28, 2012		
>ADD>			5478847	MAR 02, 2014		
>ADD>			5641790	JUN 24, 2014		
>ADD>	020559 001	RANITIDINE BISMUTH CITRATE;TRITEC	5456925	OCT 10, 2012	U-186	
			5629297	MAY 13, 2014	U-199	
			5256684	OCT 26, 2010	U-200	
			5403830	APR 04, 2012	U-201	
			5407688	APR 04, 2012	U-201	
			5601848	FEB 11, 2014	U-202	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020741 001	REPAGLINIDE;PRANDIN	5216167	OCT 10, 2006	NCE	DEC 22, 2002
>ADD>			5312924	OCT 10, 2006		
>ADD>			4873080	OCT 10, 2006		
>ADD>	020741 002	REPAGLINIDE;PRANDIN	5216167	OCT 10, 2006	NCE	DEC 22, 2002
>ADD>			5312924	OCT 10, 2006	U-214	
>ADD>			4873080	OCT 10, 2006		
>ADD>	020741 003	REPAGLINIDE;PRANDIN	5216167	OCT 10, 2006	NCE	DEC 22, 2002
>ADD>			5312924	OCT 10, 2006	U-214	
>ADD>			4873080	OCT 10, 2006		
>ADD>	020474 001	RIMEXOLONE;VEXOL	4686214	JUL 22, 2008	U-100	
>DLT>	020474 001	RIMEXOLONE;VEXOL	4686214	JUL 23, 2008	U-100	
>ADD>	020272 001	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37 OCT 17, 2000
>ADD>	020272 002	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37 OCT 17, 2000
>ADD>	020272 003	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37 OCT 17, 2000
>ADD>	020272 004	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37 OCT 17, 2000
>ADD>	020588 001	RISPERIDONE;RISPERDAL	5453425	JUN 11, 2014		D-37 OCT 17, 2000
			5616587	JUN 11, 2014		
	020659 001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190	
			5648497	JUL 15, 2014		
	020680 001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190	
			5648497	JUL 15, 2014		
	020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002	NCE	SEP 19, 2002
			4824860	MAY 19, 2008	U-212	
	020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002	NCE	SEP 19, 2002
			4824860	MAY 19, 2008	U-212	
	020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002	NCE	SEP 19, 2002
			4824860	MAY 19, 2008	U-212	
	020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002	NCE	SEP 19, 2002
			4824860	MAY 19, 2008	U-212	
	020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2002	NCE	SEP 19, 2002
			4824860	MAY 19, 2008	U-212	
	020236 001	SALMETEROL XINAFOATE;SEREVENT	5380922	JAN 10, 2012		
			5225445	FEB 12, 2008	U-182	
	020692 001	SALMETEROL XINAFOATE;SEREVENT	4992474	FEB 12, 2008		
			5225445	FEB 19, 2012	U-211	
			5380922	MAY 14, 2013		
	020570 001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187	NCE MAR 28, 2002
	020570 002	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187	NCE MAR 28, 2002
>ADD>	020828 001	SAQUINAVIR;FORTOVASE			NP	NOV 07, 2000
	020443 001	SERMORELIN ACETATE;GEREF			NP	SEP 26, 2000
					ODE	SEP 26, 2004
	020443 002	SERMORELIN ACETATE;GEREF			NP	SEP 26, 2000
					ODE	SEP 26, 2004
	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT			I-193	JUL 08, 2000
					I-208	OCT 10, 2000
	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT			I-193	JUL 08, 2000
					I-208	OCT 10, 2000
	019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT			I-193	JUL 08, 2000
					I-208	OCT 10, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-208	OCT 10, 2000
020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		I-193	JUL 08, 2000
020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4929629	MAY 29, 2007		I-208	OCT 10, 2000
020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2002		I-208	OCT 10, 2000
020231 001	SODIUM FLUORIDE;COLGATE TOTAL	4929629	MAY 29, 2007		NCE	NOV 22, 2002
020280 006	SOMATROPIN, BIOSYNTHETIC;GENOTROPIN	4746680	JUN 11, 2002		NCE	NOV 22, 2002
020280 004	SOMATROPIN, BIOSYNTHETIC;GENOTROPIN PRESERVATIVE FREE	4929629	MAY 29, 2007		NCE	NOV 22, 2002
019640 001	SOMATROPIN, BIOSYNTHETIC;HUMATROPE	4746680	JUN 11, 2002		NCE	NOV 22, 2002
019640 004	SOMATROPIN, BIOSYNTHETIC;HUMATROPE	4929629	MAY 29, 2007		NC	JUL 11, 2000
020168 001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 31, 2004
020168 002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 31, 2004
020604 003	SOMATROPIN, BIOSYNTHETIC;SEROSTIM				I-182	DEC 30, 1999
020626 001	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72	ODE	DEC 30, 2003
020626 002	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72	I-182	DEC 30, 1999
020626 003	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U-72	ODE	DEC 30, 2003
020070 001	TACRINE HYDROCHLORIDE;COGNEX	4816456	SEP 09, 2007	U-82	ODE	DEC 30, 2003
020070 002	TACRINE HYDROCHLORIDE;COGNEX	4816456	SEP 09, 2007	U-82	I-182	DEC 30, 1999
020070 003	TACRINE HYDROCHLORIDE;COGNEX	4816456	SEP 09, 2007	U-82	ODE	DEC 30, 2003
020070 004	TACRINE HYDROCHLORIDE;COGNEX	4816456	SEP 09, 2007	U-82	ODE	DEC 30, 2003
020587 001	TALC;SCLEROSOL				I-182	DEC 30, 1999
>ADD>					NP	AUG 23, 1999
020579 001	TAMSULOSIN HYDROCHLORIDE;FLOMAX	4868216	SEP 19, 2006	U-181	NDF	AUG 26, 2000
		4731478	OCT 27, 2004		NDF	AUG 26, 2000
		4703063	OCT 27, 2004		NDF	AUG 26, 2000
		4772475	FEB 27, 2006		NDF	AUG 26, 2000
020600 001	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	NCE	DEC 24, 2002
020600 002	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	ODE	DEC 24, 2004
019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA				NCE	APR 15, 2002
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT;MYOVUE	5045302	AUG 14, 2008		I-190	JUN 13, 2002
019057 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			JUN 13, 2002
		5294615	APR 29, 2013	U-165		MAY 23, 2000
				U-3		
019057 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		
019057 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		
019057 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
		5294615	APR 29, 2013	U-165		
				U-3		


PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020347 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
020347 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-3 U-165		
020347 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-3 U-165		
020347 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-3 U-165		
020192 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U-73	I-180	JAN 21, 2000
020539 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U-73		
020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006		NDF	OCT 17, 2000
020646 001	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020646 002	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020646 004	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
		5354760	MAR 24, 2012			
020707 001	TILUDRONATE DISODIUM;SKELID	4876248	OCT 24, 2006		NCE	MAR 07, 2002
		4980171	APR 06, 2009			
020676 001	TIOCONAZOLE;VAGISTAT-1				NP	FEB 11, 2000
050753 001	TOBRAMYCIN;TOBI				ODE	DEC 22, 2004
020497 001	TOREMIFENE CITRATE;FARESTON	4696949	SEP 29, 2004	U-196	NCE	MAY 29, 2002
					ODE	MAY 29, 2004
020136 001	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020136 002	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020136 003	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020136 004	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020137 002	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020404 003	TRETINOIN;AVITA	4971800	NOV 20, 2007	U-178		
		5045317	SEP 03, 2008	U-179		
020475 001	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134	NP	FEB 07, 2000
020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ				I-204	SEP 26, 2000
074374 001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL				I-189	JUN 17, 2000
020326 001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4376858	MAY 09, 2004			
020719 001	TROGLITAZONE;PRELAY	4572912	AUG 28, 2004		NCE	JAN 29, 2002
		5104888	AUG 28, 2004		I-199	AUG 04, 2000
		5478852	SEP 15, 2013	U-163		
		5457109	SEP 15, 2013	U-164		
		5602133	SEP 15, 2013	U-173		
020719 002	TROGLITAZONE;PRELAY	4572912	AUG 28, 2004		NCE	JAN 29, 2002
		5104888	AUG 28, 2004		I-199	AUG 04, 2000
		5478852	SEP 15, 2013	U-163		
		5457109	SEP 15, 2013	U-164		
		5602133	SEP 15, 2013	U-173		
020719 003	TROGLITAZONE;PRELAY	5457109	SEP 15, 2013	U-164	I-199	AUG 04, 2000
		5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
		5478852	SEP 15, 2013	U-163		
		4572912	AUG 28, 2004			
		5104888	AUG 28, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020720 001	TROGLITAZONE;REZULIN	5457109 5602133 5478852 4572912 5104888	SEP 15, 2013 SEP 15, 2013 SEP 15, 2013 AUG 28, 2004 AUG 28, 2004	U-164 U-173 U-163	NCE I-199	JAN 29, 2002 AUG 04, 2000
020720 002	TROGLITAZONE;REZULIN	5602133 4572912 5104888 5478852 5457109	SEP 15, 2013 AUG 28, 2004 AUG 28, 2004 SEP 15, 2013 SEP 15, 2013	U-173 U-163 U-164	NCE I-199	JAN 29, 2002 AUG 04, 2000
020720 003	TROGLITAZONE;REZULIN	5457109 5602133 5478852 4572912 5104888	SEP 15, 2013 SEP 15, 2013 SEP 15, 2013 AUG 28, 2004 AUG 28, 2004	U-164 U-164 U-173 U-163	I-199 NCE	AUG 04, 2000 JAN 29, 2002
020759 001	TROVAFLOXACIN MESYLATE;TROVAN				NCE	DEC 18, 2002
020759 002	TROVAFLOXACIN MESYLATE;TROVAN				NCE	DEC 18, 2002
020617 001	UREA, C-14;PYTEST	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
020617 002	UREA, C-14;PYTEST KIT	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
020675 001	URSODIOL;URSO				NP ODE I-207 I-207	DEC 10, 2000 DEC 10, 2004 SEP 26, 2000 SEP 26, 2000
020487 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX					
020487 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX					
020665 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
020665 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2002		NCE NDF	DEC 28, 1998 OCT 20, 2000
020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2002		NCE NDF	DEC 28, 1998 OCT 20, 2000
020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2002		NCE NDF	DEC 28, 1998 OCT 20, 2000
020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2002		NCE NDF	DEC 28, 1998 OCT 20, 2000
020547 001	ZAFIRLUKAST;ACCOLATE	5612367 5583152	MAR 18, 2014 AUG 22, 2006	U-189		
020471 001	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
020471 003	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
020458 001	ZINC ACETATE;GALZIN				NP ODE NP ODE	JAN 28, 2000 JAN 28, 2004 JAN 28, 2000 JAN 28, 2004
020458 002	ZINC ACETATE;GALZIN				NCE NCE	NOV 25, 2002 NOV 25, 2002
020768 001	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012			
020768 002	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012			

New 18th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code

* 80128

*Charge your order.
It's easy!*



☐ **Yes,** enter my subscription as follows:

— subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for \$77.00 per year.

The total cost of my order is \$_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents

☐ GPO Deposit Account

--	--	--	--	--	--	--	--	--	--

 — ☐

☐ VISA or MasterCard

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

(_____) _____
Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

(Authorizing Signature)

Thank you for your order!

(11/97)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

